

HCP, INC.
Form 10-Q
November 01, 2016
Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2016.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-08895

HCP, INC.

(Exact name of registrant as specified in its charter)

| | |
|---|---|
| Maryland | 33-0091377 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

1920 Main Street, Suite 1200

Irvine, CA 92614

(Address of principal executive offices)

(949) 407-0700

(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). YES NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Edgar Filing: HCP, INC. - Form 10-Q

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer

Smaller Reporting Company

(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) YES NO

As of October 28, 2016, there were 467,971,166 shares of the registrant's \$1.00 par value common stock outstanding.

Table of Contents

HCP, INC.

INDEX

PART I. FINANCIAL INFORMATION

| | | |
|---------|--|----|
| Item 1. | Financial Statements (Unaudited): | |
| | <u>Consolidated Balance Sheets</u> | 3 |
| | <u>Consolidated Statements of Operations</u> | 4 |
| | <u>Consolidated Statements of Comprehensive Income</u> | 5 |
| | <u>Consolidated Statements of Equity</u> | 6 |
| | <u>Consolidated Statements of Cash Flows</u> | 7 |
| | <u>Notes to the Consolidated Financial Statements</u> | 8 |
| Item 2. | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> | 40 |
| Item 3. | <u>Quantitative and Qualitative Disclosures About Market Risk</u> | 69 |
| Item 4. | <u>Controls and Procedures</u> | 70 |

PART II. OTHER INFORMATION

| | | |
|----------|--|----|
| Item 1A. | <u>Risk Factors</u> | 71 |
| Item 2. | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | 72 |
| Item 6. | <u>Exhibits</u> | 72 |
| | <u>Signatures</u> | 74 |

Table of Contents

HCP, Inc.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

| | September 30, 2016 | December 31, 2015 |
|--|-----------------------|----------------------|
| ASSETS | | |
| Real estate: | | |
| Buildings and improvements | \$ 12,534,471 | \$ 12,198,704 |
| Development costs and construction in progress | 395,349 | 388,576 |
| Land | 1,971,601 | 1,948,757 |
| Accumulated depreciation and amortization | (2,799,969) | (2,541,334) |
| Net real estate | 12,101,452 | 11,994,703 |
| Net investment in direct financing leases | 5,860,401 | 5,905,009 |
| Loans receivable, net | 682,994 | 768,743 |
| Investments in and advances to unconsolidated joint ventures | 592,097 | 605,244 |
| Accounts receivable, net of allowance of \$4,704 and \$3,261, respectively | 41,371 | 48,929 |
| Cash and cash equivalents | 132,891 | 346,500 |
| Restricted cash | 71,727 | 60,616 |
| Intangible assets, net | 538,631 | 603,706 |
| Real estate and related assets held for sale, net | 372,968 | 314,126 |
| Other assets, net | 794,013 | 802,273 |
| Total assets(1) | \$ 21,188,545 | \$ 21,449,849 |
| LIABILITIES AND EQUITY | | |
| Bank line of credit | \$ 1,372,032 | \$ 397,432 |
| Term loans | 462,181 | 524,807 |
| Senior unsecured notes | 8,229,731 | 9,120,107 |
| Mortgage debt | 762,715 | 932,212 |
| Other debt | 93,876 | 94,445 |
| Intangible liabilities, net | 46,135 | 56,147 |
| Intangible and other liabilities related to assets held for sale, net | 23,002 | 19,126 |
| Accounts payable and accrued liabilities | 487,033 | 436,239 |
| Deferred revenue | 136,406 | 123,017 |
| Total liabilities(1) | 11,613,111 | 11,703,532 |
| Commitments and contingencies | | |
| Common stock, \$1.00 par value: 750,000,000 shares authorized; 467,820,181 and 465,488,492 shares issued and outstanding, respectively | 467,820 | 465,488 |
| Additional paid-in capital | 11,720,552 | 11,647,039 |
| Cumulative dividends in excess of earnings | (2,975,096) | (2,738,414) |
| Accumulated other comprehensive loss | (30,164) | (30,470) |
| Total stockholders' equity | 9,183,112 | 9,343,643 |
| Joint venture partners | 212,807 | 217,066 |

| | | |
|---------------------------------|---------------|---------------|
| Non-managing member unitholders | 179,515 | 185,608 |
| Total noncontrolling interests | 392,322 | 402,674 |
| Total equity | 9,575,434 | 9,746,317 |
| Total liabilities and equity | \$ 21,188,545 | \$ 21,449,849 |

(1) HCP, Inc.'s consolidated total assets and total liabilities at September 30, 2016 and December 31, 2015 include certain assets of variable interest entities ("VIEs") that can only be used to settle the liabilities of the related VIE. The VIE creditors do not have recourse to HCP, Inc. Total assets at September 30, 2016 include VIE assets as follows: buildings and improvements \$3.4 billion; development costs \$23 million; land \$324 million; accumulated depreciation and amortization \$629 million; investments in unconsolidated joint ventures \$14 million; accounts receivable \$19 million; cash \$59 million; restricted cash \$27 million; intangible assets, net \$177 million; and other assets, net \$68 million. Total assets at December 31, 2015 include VIE assets as follows: buildings and improvements \$3.4 billion; development costs \$54 million; land \$327 million; accumulated depreciation and amortization \$537 million; investments in unconsolidated joint ventures \$14 million; accounts receivable \$19 million; cash \$61 million; restricted cash \$21 million; intangible assets, net \$204 million; and other assets, net \$63 million. Total liabilities at September 30, 2016 include VIE liabilities as follows: mortgage debt \$568 million; intangible liabilities, net \$9 million; accounts payable and accrued liabilities \$127 million and deferred revenue \$26 million. Total liabilities at December 31, 2015 include VIE liabilities as follows: mortgage debt \$589 million; intangible liabilities, net \$10 million; accounts payable and accrued liabilities \$107 million and deferred revenue \$19 million. See Note 16 to the Consolidated Financial Statements for additional information.

See accompanying Notes to the Consolidated Financial Statements.

Table of Contents

HCP, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------|------------|-------------------|------------|
| | September 30, | | September 30, | |
| | 2016 | 2015 | 2016 | 2015 |
| Revenues: | | | | |
| Rental and related revenues | \$ 297,178 | \$ 293,566 | \$ 893,448 | \$ 845,382 |
| Tenant recoveries | 35,195 | 33,084 | 100,862 | 94,356 |
| Resident fees and services | 170,752 | 155,290 | 500,717 | 367,141 |
| Income from direct financing leases | 130,663 | 155,717 | 390,731 | 478,976 |
| Interest income | 20,482 | 19,842 | 71,298 | 89,049 |
| Total revenues | 654,270 | 657,499 | 1,957,056 | 1,874,904 |
| Costs and expenses: | | | | |
| Interest expense | 117,860 | 122,157 | 361,255 | 357,569 |
| Depreciation and amortization | 142,874 | 134,704 | 425,582 | 369,629 |
| Operating | 188,747 | 173,515 | 545,827 | 441,888 |
| General and administrative | 34,787 | 20,534 | 83,079 | 74,152 |
| Acquisition and pursuit costs | 17,568 | 1,553 | 34,570 | 23,350 |
| Impairments | — | 69,622 | — | 592,921 |
| Total costs and expenses | 501,836 | 522,085 | 1,450,313 | 1,859,509 |
| Other income (expense): | | | | |
| (Loss) gain on sales of real estate | (9) | 52 | 119,605 | 6,377 |
| Other income (expense), net | 1,454 | (572) | 5,128 | 13,125 |
| Total other income (expense), net | 1,445 | (520) | 124,733 | 19,502 |
| Income before income taxes and equity (loss) | | | | |
| income from and impairment of unconsolidated joint ventures | 153,879 | 134,894 | 631,476 | 34,897 |
| Income tax benefit (expense) | 2,213 | 1,980 | (48,822) | 6,620 |
| Equity (loss) income from unconsolidated joint ventures | (2,053) | 8,314 | (4,028) | 33,916 |
| Impairment of investments in unconsolidated joint ventures | — | (27,234) | — | (27,234) |
| Net income | 154,039 | 117,954 | 578,626 | 48,199 |
| Noncontrolling interests' share in earnings | (2,789) | (2,592) | (9,540) | (8,566) |
| Net income attributable to HCP, Inc. | 151,250 | 115,362 | 569,086 | 39,633 |
| Participating securities' share in earnings | (326) | (316) | (977) | (1,020) |
| Net income applicable to common shares | \$ 150,924 | \$ 115,046 | \$ 568,109 | \$ 38,613 |
| Earnings per common share: | | | | |
| Basic | \$ 0.32 | \$ 0.25 | \$ 1.22 | \$ 0.08 |

Edgar Filing: HCP, INC. - Form 10-Q

| | | | | |
|--|----------|----------|----------|----------|
| Diluted | \$ 0.32 | \$ 0.25 | \$ 1.22 | \$ 0.08 |
| Weighted average shares used to calculate earnings per common share: | | | | |
| Basic | 467,628 | 463,337 | 466,931 | 462,039 |
| Diluted | 467,835 | 463,586 | 467,132 | 462,302 |
| Dividends declared per common share | \$ 0.575 | \$ 0.565 | \$ 1.725 | \$ 1.695 |

See accompanying Notes to the Consolidated Financial Statements.

4

Table of Contents

HCP, Inc.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|----------------------------------|------------|---------------------------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| Net income | \$ 154,039 | \$ 117,954 | \$ 578,626 | \$ 48,199 |
| Other comprehensive income (loss): | | | | |
| Change in net unrealized gains (losses) on securities | 4 | (361) | (1) | (358) |
| Change in net unrealized gains (losses) on cash flow hedges: | | | | |
| Unrealized gains (losses) | 1,184 | (87) | 1,532 | (289) |
| Reclassification adjustment realized in net income | 154 | (367) | 494 | (19) |
| Change in Supplemental Executive Retirement Plan obligation | 70 | 70 | 211 | 208 |
| Foreign currency translation adjustment | (838) | 410 | (1,930) | (8,097) |
| Total other comprehensive income (loss) | 574 | (335) | 306 | (8,555) |
| Total comprehensive income | 154,613 | 117,619 | 578,932 | 39,644 |
| Total comprehensive income attributable to noncontrolling interests | (2,789) | (2,592) | (9,540) | (8,566) |
| Total comprehensive income attributable to HCP, Inc. | \$ 151,824 | \$ 115,027 | \$ 569,392 | \$ 31,078 |

See accompanying Notes to the Consolidated Financial Statements.

Table of Contents

HCP, Inc.

CONSOLIDATED STATEMENTS OF EQUITY

(In thousands, except per share data)

(Unaudited)

| | Common Shares | Stock Amount | Additional Paid-In Capital | Cumulative Dividends In Excess Of Earnings | Accumulated Other Comprehensive Loss | Total Stockholders' Equity | Total Noncontrolling Interests | Total Equity |
|---|------------------|-----------------|----------------------------------|---|---|----------------------------------|--------------------------------------|-----------------|
| January 1, 2016 | 465,488 | \$ 465,488 | \$ 11,647,039 | \$ (2,738,414) | \$ (30,470) | \$ 9,343,643 | \$ 402,674 | \$ 9,746,317 |
| Net income | — | — | — | 569,086 | — | 569,086 | 9,540 | 578,626 |
| Other comprehensive income | — | — | — | — | 306 | 306 | — | 306 |
| Issuance of common stock, net | 2,290 | 2,290 | 53,421 | — | — | 55,711 | — | 55,711 |
| Conversion of DownREIT units to common stock | 145 | 145 | 5,948 | — | — | 6,093 | (6,093) | — |
| Repurchase of common stock | (236) | (236) | (8,431) | — | — | (8,667) | — | (8,667) |
| Exercise of stock options | 133 | 133 | 3,340 | — | — | 3,473 | — | 3,473 |
| Amortization of deferred compensation | — | — | 19,307 | — | — | 19,307 | — | 19,307 |
| Common dividends (\$1.725 per share) | — | — | — | (806,243) | — | (806,243) | — | (806,243) |
| Distributions to noncontrolling interests | — | — | (36) | — | — | (36) | (18,651) | (18,687) |
| Issuance of noncontrolling interests | — | — | — | — | — | — | 4,785 | 4,785 |
| Deconsolidation of noncontrolling interests | — | — | (36) | 475 | — | 439 | 67 | 506 |
| | 467,820 | \$ 467,820 | \$ 11,720,552 | \$ (2,975,096) | \$ (30,164) | \$ 9,183,112 | \$ 392,322 | \$ 9,575,434 |

Edgar Filing: HCP, INC. - Form 10-Q

September 30,
2016

| | Common Stock | | Additional | Cumulative | Accumulated | Total | Total | Total |
|---|--------------|------------|---------------|----------------|-------------|---------------|----------------|---------------|
| | Shares | Amount | Paid-In | Dividends | Other | Stockholders' | Noncontrolling | Equity |
| | | | Capital | In Excess | Comprehens | Equity | Interests | Equity |
| | | | | Of Earnings | Loss | | | |
| January 1, 2015 | 459,746 | \$ 459,746 | \$ 11,431,987 | \$ (1,132,541) | \$ (23,895) | \$ 10,735,297 | \$ 261,802 | \$ 10,997,099 |
| Net income | — | — | — | 39,633 | — | 39,633 | 8,566 | 48,199 |
| Other comprehensive loss | — | — | — | — | (8,555) | (8,555) | — | (8,555) |
| Issuance of common stock, net | 4,054 | 4,054 | 140,591 | — | — | 144,645 | (2,659) | 141,986 |
| Repurchase of common stock | (178) | (178) | (7,828) | — | — | (8,006) | — | (8,006) |
| Exercise of stock options | 820 | 820 | 26,691 | — | — | 27,511 | — | 27,511 |
| Amortization of deferred compensation | — | — | 21,068 | — | — | 21,068 | — | 21,068 |
| Common dividends (\$1.695 per share) | — | — | — | (783,578) | — | (783,578) | — | (783,578) |
| Distributions to noncontrolling interests | — | — | (263) | — | — | (263) | (13,444) | (13,707) |
| Issuance of noncontrolling interests | — | — | — | — | — | — | 38,440 | 38,440 |
| September 30, 2015 | 464,442 | \$ 464,442 | \$ 11,612,246 | \$ (1,876,486) | \$ (32,450) | \$ 10,167,752 | \$ 292,705 | \$ 10,460,457 |

See accompanying Notes to the Consolidated Financial Statements.

Table of Contents

HCP, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

| | Nine Months Ended September 30, | |
|---|---------------------------------|-------------|
| | 2016 | 2015 |
| Cash flows from operating activities: | | |
| Net income | \$ 578,626 | \$ 48,199 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 425,582 | 369,629 |
| Amortization of market lease intangibles, net | (1,393) | (980) |
| Amortization of deferred compensation | 19,307 | 21,068 |
| Amortization of deferred financing costs | 15,598 | 14,950 |
| Straight-line rents | (14,412) | (24,817) |
| Loan and direct financing lease non-cash interest | 385 | (71,243) |
| Deferred rental revenues | (1,027) | (1,496) |
| Equity loss (income) from unconsolidated joint ventures | 4,028 | (33,916) |
| Distributions of earnings from unconsolidated joint ventures | 5,919 | 4,587 |
| Lease termination income, net | — | (1,103) |
| Gain on sales of real estate | (119,605) | (6,377) |
| Deferred income tax expense | 47,195 | — |
| Foreign exchange and other gains, net | (127) | (7,103) |
| Impairments | — | 620,155 |
| Changes in: | | |
| Accounts receivable, net | 7,558 | (10,634) |
| Other assets, net | (9,674) | (1,186) |
| Accounts payable and accrued liabilities | 40,672 | (52,073) |
| Net cash provided by operating activities | 998,632 | 867,660 |
| Cash flows from investing activities: | | |
| Acquisitions of real estate | (257,242) | (1,200,661) |
| Development of real estate | (304,818) | (190,082) |
| Leasing costs and tenant and capital improvements | (64,501) | (52,371) |
| Proceeds from sales of real estate, net | 211,810 | 19,555 |
| Contributions to unconsolidated joint ventures | (10,169) | (43,242) |
| Distributions in excess of earnings from unconsolidated joint ventures | 14,458 | 16,086 |
| Proceeds from the sales of marketable securities | — | 782 |
| Principal repayments on loans receivable, direct financing leases and other | 221,179 | 51,491 |
| Investments in loans receivable and other | (129,335) | (283,252) |
| Decrease (increase) in restricted cash | 4,459 | (3,891) |
| Net cash used in investing activities | (314,159) | (1,685,585) |
| Cash flows from financing activities: | | |

Edgar Filing: HCP, INC. - Form 10-Q

| | | |
|---|------------|------------|
| Net borrowings under bank line of credit | 1,157,897 | 282,099 |
| Repayments under bank line of credit | (135,000) | (102,063) |
| Borrowings under term loan | — | 333,014 |
| Issuance of senior unsecured notes | — | 1,338,555 |
| Repayments of senior unsecured notes | (900,000) | (400,000) |
| Repayments of mortgage and other debt | (249,540) | (50,187) |
| Deferred financing costs | (1,057) | (14,556) |
| Issuance of common stock and exercise of options | 59,184 | 169,497 |
| Repurchase of common stock | (8,667) | (8,006) |
| Dividends paid on common stock | (806,243) | (783,578) |
| Issuance of noncontrolling interests | 4,785 | 4,812 |
| Distributions to noncontrolling interests | (18,687) | (13,707) |
| Net cash (used in) provided by financing activities | (897,328) | 755,880 |
| Effect of foreign exchange on cash and cash equivalents | (754) | (1,267) |
| Net decrease in cash and cash equivalents | (213,609) | (63,312) |
| Cash and cash equivalents, beginning of period | 346,500 | 183,810 |
| Cash and cash equivalents, end of period | \$ 132,891 | \$ 120,498 |

See accompanying Notes to the Consolidated Financial Statements.

Table of Contents

HCP, Inc.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. Business

HCP, Inc., a Standard & Poor's ("S&P") 500 company, together with its consolidated entities (collectively, "HCP" or the "Company"), invests primarily in real estate serving the healthcare industry in the United States ("U.S."). The Company is a Maryland corporation organized in 1985 and qualifies as a self-administered real estate investment trust ("REIT"). The Company is headquartered in Irvine, California, with offices in Nashville, Los Angeles, San Francisco and London. The Company acquires, develops, leases, manages and disposes of healthcare real estate, and provides financing to healthcare providers. The Company's diverse portfolio is comprised of investments in the following reportable healthcare segments: (i) senior housing triple-net ("SH NNN"), (ii) senior housing operating portfolio ("SHOP"), (iii) life science, (iv) medical office and (v) QCP (defined below).

On October 31, 2016, the Company completed its previously announced spin-off (the "Spin-Off") of its subsidiary, Quality Care Properties, Inc. ("QCP") (NYSE:QCP). QCP's assets include 338 properties, primarily comprised of the HCR ManorCare, Inc. ("HCRMC") direct financing lease ("DFL") investments and an equity investment in HCRMC. Following the completion of the Spin-Off on October 31, 2016, QCP is an independent, publicly-traded, self-managed and self-administrated REIT.

On October 17, 2016, subsidiaries of QCP issued \$750 million in aggregate principal amount of senior secured notes due 2023 (the "QCP Notes"), the gross proceeds of which were deposited in escrow until they were released in connection with the consummation of the Spin-Off on October 31, 2016. The QCP Notes bear interest at a rate of 8.125% per annum, payable semiannually. From October 17, 2016 until the completion of the Spin-Off, QCP (a then wholly owned subsidiary of HCP) incurred \$2 million in interest expense. In addition, immediately prior to the effectiveness of the Spin-Off, subsidiaries of QCP received \$1.0 billion of proceeds from their borrowings under a senior secured term loan, bearing interest at a rate at QCP's option of either: (i) LIBOR plus 5.25%, subject to a 1% floor or (ii) a base rate specified in the first lien credit and guaranty agreement plus 4.25%, bringing the total gross proceeds raised by QCP and its subsidiaries under those financings to \$1.75 billion. In connection with the consummation of the Spin-Off, QCP and its subsidiaries transferred \$1.69 billion in cash and approximately 94 million shares of QCP common stock to HCP and certain of its other subsidiaries, and HCP and its applicable subsidiaries transferred the assets comprising the QCP portfolio to QCP and its subsidiaries. HCP then distributed substantially all of the outstanding shares of QCP common stock to its stockholders, based on the distribution ratio of one share of QCP common stock for every five shares of HCP common stock held by HCP stockholders as of the October 24, 2016 record date for the distribution. The Company will record the distribution of the assets and liabilities of QCP from its consolidated balance sheet on a historical cost basis as a dividend from stockholders' equity, and no gain or loss will be recorded. The Company will use the \$1.69 billion proceeds of the cash distribution it received from QCP upon consummation of the Spin-Off to pay down certain of the Company's existing debt obligations.

Because QCP is presented as part of the Company's continuing operations as of September 30, 2016, the consolidated financial information presented herein includes QCP for all periods presented. Beginning in the fourth quarter of 2016, the historical financial results of QCP will be reflected in the Company's consolidated financial statements as discontinued operations for all periods presented.

The Company entered into a Separation and Distribution Agreement (the "Separation and Distribution Agreement") with QCP in connection with the Spin-Off. The Separation and Distribution Agreement divides and allocates the assets and liabilities of the Company prior to the Spin-Off between QCP and HCP, governs the rights and obligations of the parties regarding the Spin-Off, and contains other key provisions relating to the separation of QCP's business from HCP.

Table of Contents

In connection with the Spin-Off, the Company has entered into a Transition Services Agreement ("TSA") with QCP. Per the terms of the TSA, the Company has agreed to provide certain administrative and support services to QCP on a transitional basis for established fees. The TSA provides that QCP generally has the right to terminate a transition service upon thirty days notice to the Company. The TSA contains provisions under which the Company will, subject to certain limitations, be obligated to indemnify QCP for losses incurred by QCP resulting from the Company's breach of the TSA.

Following completion of the Spin-Off, which occurred on October 31, 2016, HCP is the sole lender to QCP of a \$100 million unsecured revolving credit facility maturing in 2018 (the "Unsecured Revolving Credit Facility"). Commitments under the Unsecured Revolving Credit Facility will automatically and permanently decrease each calendar month by an amount equal to 50% of QCP's and its restricted subsidiaries' retained cash flow for the prior calendar month. All borrowings under the Unsecured Revolving Credit Facility will be subject to the satisfaction of certain conditions, including (i) QCP's senior secured revolving credit facility being unavailable, (ii) the failure of HCRMC to pay rent and (iii) other customary conditions, including the absence of a default and the accuracy of representations and warranties. QCP may only draw on the Unsecured Revolving Credit Facility prior to the one-year anniversary of the completion of the Spin-Off. Borrowings under the Unsecured Revolving Credit Facility bear interest at a rate equal to LIBOR, subject to a 1.00% floor, plus an applicable margin of 6.25%. In addition to paying interest on outstanding principal under the Unsecured Revolving Credit Facility, QCP will be required to pay a facility fee equal to 0.50% per annum of the unused capacity under the Unsecured Revolving Credit Facility to HCP, payable quarterly.

NOTE 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information. Management is required to make estimates and assumptions in the preparation of financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from management's estimates.

The consolidated financial statements include the accounts of HCP, Inc., its wholly-owned subsidiaries, joint ventures ("JVs") and VIEs that it controls through voting rights or other means. Intercompany transactions and balances have been eliminated upon consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary to present fairly the Company's financial position, results of operations and cash flows have been included. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The accompanying unaudited interim financial information should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2015 included in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC").

Segment Reporting

The Company reports its consolidated financial statements in accordance with Accounting Standards Codification 280, Segment Reporting (“ASC 280”). The Company’s reportable segments, based on how it evaluates its business and allocates resources in accordance with ASC 280, are as follows: (i) SH NNN, (ii) SHOP, (iii) life science, (iv) medical office and (v) QCP.

Prior to the third quarter of 2016, the Company operated through five reportable segments: (i) senior housing, (ii) post-acute/skilled nursing, (iii) life science, (iv) medical office and (v) hospital. During the third quarter of 2016, primarily as a result of the planned spin-off of QCP, the Company revised its operating analysis structure. The Company believes the change to its reportable segments is appropriate and consistent with how its chief operating decision makers review the Company’s operating results and determine resource allocations. Accordingly, all prior period segment information has been reclassified to conform to the current period presentation.

Table of Contents

Recent Accounting Pronouncements

In October 2016, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2016-16, Intra-Entity Transfers of Assets Other Than Inventory (“ASU 2016-16”). The amendments in ASU 2016-16 require an entity to recognize the income tax consequences of intra-entity transfers of assets other than inventory at the time that the transfer occurs. Current guidance does not require recognition of tax consequences until the asset is eventually sold to a third party. ASU 2016-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted as of the first interim period presented in a year. The Company is evaluating the impact of the adoption of ASU 2016-16 on January 1, 2018 to its consolidated financial position or results of operations.

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The amendments in ASU 2016-15 are intended to clarify current guidance on the classification of certain cash receipts and cash payments in the statement of cash flows. ASU 2016-15 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted. The Company is evaluating the impact of the adoption of ASU 2016-15 on January 1, 2018 to its consolidated statements of cash flows.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 is intended to improve financial reporting by requiring timelier recognition of credit losses on loans and other financial instruments held by financial institutions and other organizations. ASU 2016-13 is effective for fiscal years, and interim periods within, beginning after December 15, 2019. Early adoption is permitted for fiscal years, and interim periods within, beginning after December 15, 2018. The Company is evaluating the impact of the adoption of ASU 2016-13 on January 1, 2020 to its consolidated financial position or results of operations.

In May 2016, the FASB issued ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). The amendments in ASU 2016-12 do not change the core principles of the guidance in the new revenue standard described in ASU No. 2014-09 below. The amendments in ASU 2016-12 provide practical expedients and improvements on the previously narrow scope of the standard. ASU 2016-12 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted at the original effective date of the new revenue standard (January 1, 2017). The Company is evaluating the impact of the adoption of ASU 2016-12 on January 1, 2018 to its consolidated financial position or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”). ASU 2016-09 is intended to simplify accounting for share-based payment transactions. The areas for simplification in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities and classification on the statements of cash flows. ASU 2016-09 is effective for fiscal years, and interim periods within, beginning after December 15, 2016. Early adoption is permitted. The Company is evaluating the impact of the adoption of ASU 2016-09 on January 1, 2017 to its consolidated financial position, results of operations or cash flows.

In March 2016, the FASB issued ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”). ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-08 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted at the original effective date of the new revenue standard described in ASU No. 2014-09 below (January 1, 2017). The Company is evaluating the impact of the adoption of ASU 2016-08 on January 1, 2018 to its consolidated financial position or results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (“ASU 2016-02”). ASU 2016-02 amends the current accounting for leases to (i) require lessees to put most leases on their balance sheets, but continue recognizing expenses on their income statements in a manner similar to requirements under current accounting guidance, (ii) eliminate current real estate specific lease provisions and (iii) modify the classification criteria and accounting for sales-type leases for lessors. ASU 2016-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2018. Early adoption is permitted. The Company is evaluating the impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial position or results of operations.

Table of Contents

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”). ASU 2016-01 requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. This update also simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment at each reporting period. ASU 2016-01 is effective for fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted only for updates to certain disclosure requirements. The Company is evaluating the impact of the adoption of ASU 2016-01 on January 1, 2018 to its consolidated financial position or results of operations.

In September 2015, the FASB issued ASU No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”). ASU 2015-16 simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by requiring the acquirer to (i) recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined, (ii) record, in the same period, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date and (iii) present separately or disclose the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2015. Early adoption is permitted. The Company adopted ASU 2015-16 on January 1, 2016; the adoption of which did not have a material impact on its consolidated financial position or results of operations.

In February 2015, the FASB issued ASU No. 2015-02, Amendments to the Consolidation Analysis (“ASU 2015-02”). ASU 2015-02 requires amendments to both the VIE and voting consolidation accounting models. The amendments (i) rescind the indefinite deferral of certain aspects of accounting standards relating to consolidations and provide a permanent scope exception for registered money market funds and similar unregistered money market funds, (ii) modify (a) the identification of variable interests (fees paid to a decision maker or service provider), (b) the VIE characteristics for a limited partnership or similar entity and (c) the primary beneficiary determination under the VIE model and (iii) eliminate the presumption within the current voting model that a general partner controls a limited partnership or similar entity. ASU 2015-02 is effective for fiscal years, and interim periods within, beginning after December 15, 2015. Early adoption is permitted. A reporting entity may apply the amendments in ASU 2015-02 using either a modified retrospective or retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The Company adopted ASU 2015-02 on January 1, 2016; the adoption of which did not have a material impact to its consolidated financial position or results of operations (see Note 16).

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”). This update changes the requirements for recognizing revenue. ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date (“ASU 2015-14”). ASU 2015-14 defers the effective date of ASU 2014-09 by one year to fiscal years, and interim periods within, beginning after December 15, 2017. Early adoption is permitted for annual periods, and interim periods within, beginning after

December 15, 2016. A reporting entity may apply the amendments in ASU 2014-09 using either a modified retrospective or retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. The Company is evaluating the impact of the adoption of ASU 2014-09 on January 1, 2018 to its consolidated financial position or results of operations.

Reclassifications

Certain amounts in the Company's consolidated financial statements have been reclassified for prior periods to conform to the current period presentation. Real estate and related assets held for sale, net and intangible liabilities related to assets held for sale, net have been reclassified on the consolidated balance sheets (see Note 4). See Segment Reporting above for additional reclassifications.

Table of Contents

NOTE 3. Real Estate Property Investments

2016 Acquisitions

The following table summarizes the Company's real estate acquisitions for the nine months ended September 30, 2016 (in thousands):

| Segment | Consideration | | Assets Acquired(1) | |
|--------------|---------------|--|--------------------|-----------------|
| | Cash Paid | Mortgage and Other Liabilities Assumed | Real Estate | Intangibles Net |
| SH NNN | \$ 76,362 | \$ 1,200 | \$ 71,875 | \$ 5,687 |
| SHOP | 113,971 | 76,931 | 177,551 | 13,351 |
| Life Science | 49,000 | — | 47,400 | 1,600 |
| Other | 17,909 | — | 16,596 | 1,313 |
| | \$ 257,242 | \$ 78,131 | \$ 313,422 | \$ 21,951 |

(1) The purchase price allocations are preliminary and may be subject to change. Revenues and earnings since the acquisition dates, as well as the supplementary pro forma information, assuming these acquisitions occurred as of the beginning of the prior periods, were not material.

2015 Acquisitions

Acquisition of Private Pay Senior Housing Portfolio ("RIDEA III"). On June 30, 2015, the Company and Brookdale Senior Living, Inc. ("Brookdale") acquired a portfolio of 35 private pay senior housing communities from Chartwell Retirement Residences, including two leasehold interests, representing 5,025 units (reported within the Company's SHOP segment). The portfolio was acquired under a RIDEA structure which is permitted by the Housing and Economic Recovery Act of 2008 (commonly referred to as "RIDEA"), with Brookdale owning a 10% noncontrolling interest. Brookdale has operated these communities since 2011 and continues to manage the communities under a long-term management agreement, which is cancellable under certain conditions (subject to a fee if terminated within seven years from the acquisition date). The Company paid \$770 million in cash consideration, net of cash assumed, and assumed \$32 million of net liabilities and \$29 million of noncontrolling interests to acquire: (i) real estate with a fair value of \$776 million, (ii) lease-up intangible assets with a fair value of \$48 million and (iii) working capital of \$7 million. As a result of the acquisition, the Company recognized a net termination fee of \$8 million in rental and related revenues, which represents the termination value of the two leasehold interests. The lease-up intangible assets recognized were attributable to the value of the acquired underlying operating resident leases of the senior housing communities that were stabilized or nearly stabilized (i.e., resident occupancy above 80%).

Pro Forma Results of Operations. The following unaudited pro forma consolidated results of operations assume that the RIDEA III acquisition was completed as of January 1, 2014 (in thousands, except per share data):

| | Nine Months Ended September 30, 2015 |
|------------------------------------|---|
| Revenues | \$ 1,963,402 |
| Net income | 56,009 |
| Net income applicable to HCP, Inc. | 46,662 |
| Basic earnings per common share | 0.10 |
| Diluted earnings per common share | 0.10 |

Table of Contents

2015 Other Acquisitions. The following table summarizes the Company's real estate acquisitions for the nine months ended September 30, 2015 (in thousands):

| Segment | Consideration | | | Assets Acquired(1) | |
|----------------|----------------------------------|------------------------|----------------------------|--------------------|--------------------|
| | Cash Paid/ Debt Settled | Liabilities Assumed | Noncontrolling Interest | Real Estate | Intangibles Net |
| SH NNN | \$ 208 | \$ — | \$ — | \$ 208 | \$ — |
| SHOP | 103,296 | 1,373 | 3,885 | 102,579 | 5,975 |
| Medical office | 377,351 (2) | 12,849 | — | 349,649 | 40,551 |
| Other | 296,226 (3) | 6,854 | — | 257,960 | 45,120 |
| | \$ 777,081 | \$ 21,076 | \$ 3,885 | \$ 710,396 | \$ 91,646 |

- (1) Revenues and earnings since the acquisition dates, as well as the supplementary pro forma information, assuming these acquisitions occurred as of the beginning of the prior periods, were not material.
- (2) Includes \$225 million for a medical office building ("MOB") portfolio acquisition completed in June 2015 and placed in HCP Ventures V, of which, in October 2015, the Company issued a 49% noncontrolling interest for \$110 million (see Note 12).
- (3) Includes £174 million (\$254 million) of the Company's HC-One Facility (see Note 6) converted to fee ownership in a portfolio of 36 care homes located throughout the United Kingdom ("U.K.").

Construction, Tenant and Other Capital Improvements

The following table summarizes the Company's funding for construction, tenant and other capital improvements (in thousands):

| Segment | Nine Months Ended September 30, | |
|----------------|---------------------------------|------------|
| | 2016 | 2015 |
| SH NNN | \$ 35,687 | \$ 27,289 |
| SHOP | 55,795 | 49,351 |
| Life science | 152,739 | 80,871 |
| Medical office | 88,523 | 93,012 |
| Other | 6,840 | 3,406 |
| | \$ 339,584 | \$ 253,929 |

NOTE 4. Dispositions of Real Estate

Held for Sale

At September 30, 2016, eight life science facilities and two SHOP facilities were classified as held for sale, with an aggregate carrying value of \$373 million. At December 31, 2015, four life science facilities were classified as held for sale, with an aggregate carrying value of \$314 million.

2016 Dispositions

During the nine months ended September 30, 2016, the Company sold five post-acute/skilled nursing facilities and two SH NNN facilities for \$130 million, a life science facility for \$74 million, three medical office buildings for \$20 million and a SHOP facility for \$6 million and recognized total gain on sales of \$120 million.

2015 Dispositions

During the nine months ended September 30, 2015, the Company sold the following: (i) nine SH NNN facilities for \$60 million, resulting from Brookdale's exercise of its purchase option received as part of a transaction with Brookdale in 2014, (ii) a parcel of land in its life science segment for \$11 million and (iii) a MOB for \$400,000.

Pending Dispositions

In October 2016, the Company entered into definitive agreements to sell 64 assets, currently under triple-net leases with Brookdale, for \$1.125 billion to affiliates of Blackstone Real Estate Partners VIII L.P. The closing of this transaction is expected to occur in the first quarter of 2017 and remains subject to regulatory and third party approvals and other

Table of Contents

customary closing conditions. Additionally, in October 2016, the Company entered into definitive agreements for a multi-element transaction with Brookdale to: (i) sell or transition 25 assets currently triple-net leased to Brookdale, for which Brookdale will receive a \$10.5 million annualized rent reduction upon sale or transition, (ii) re-allocate annual rent of \$9.6 million from those 25 assets to the remaining Brookdale triple-net lease portfolio and (iii) transition eight triple-net leased assets into RIDEA structures. The closing of these transactions is expected to occur during the fourth quarter of 2016 and throughout 2017 and remain subject to regulatory and third party approvals and other customary closing conditions.

In July 2016, the Company entered into a definitive agreement to sell four life science facilities in Salt Lake City, Utah for \$76 million (classified as held for sale as of September 30, 2016). The transaction is expected to close in the first quarter of 2017.

In June 2016 and September 2016, the Company entered into a definitive agreement to sell two SHOP facilities out of RIDEA III for \$22 million (sold in October 2016) and \$13 million, respectively (both classified as held for sale as of September 30, 2016). The remaining SHOP facility is expected to close in the fourth quarter of 2016.

In May 2016, the Company entered into a master contribution agreement with Brookdale to contribute its ownership interest in RIDEA II to an unconsolidated JV owned by HCP and an investor group led by Columbia Pacific Advisors, LLC (“CPA”) (the “HCP/CPA JV”). The members have also agreed to recapitalize RIDEA II with an estimated \$630 million of debt, of which an estimated \$365 million will be provided by a third-party and an estimated \$265 million will be provided by HCP. In return, the Company will receive an estimated \$470 million in cash proceeds from the HCP/CPA JV and an estimated \$265 million in note receivables and retain an approximately 40% beneficial interest in RIDEA II (the note receivable and 40% beneficial interest are herein referred to as the “RIDEA II Investments”). The Company’s RIDEA II Investments will be recognized and accounted for as equity method investments. This transaction, upon completion, would result in the Company deconsolidating the net assets of RIDEA II because it will not direct the activities that most significantly impact the venture. The closing of these transactions is expected to occur in the fourth quarter of 2016 and remains subject to regulatory and third party approvals and other customary closing conditions.

In January 2016, the Company entered into a definitive agreement for purchase options that were exercised on eight life science facilities in South San Francisco, California, to be sold in two tranches for \$311 million (classified as held for sale as of September 30, 2016) and \$269 million, respectively. These transactions are expected to close in the fourth quarter of 2016 for the first tranche and in 2018 for the second tranche.

Subsequent Events

In October 2016, the Company sold seven SH NNN facilities for \$88 million. As part of the sale transaction the Company provided a \$10 million mezzanine loan with a five year term which accrues interest at 9%. Concurrently, the Company modified the in-place NNN master lease to transition the operations of the remaining three properties to

a new regional operator.

NOTE 5. Net Investment in Direct Financing Leases

Net investment in DFLs consisted of the following (dollars in thousands):

| | September 30, 2016 | December 31, 2015 |
|--|-----------------------|----------------------|
| Minimum lease payments receivable | \$ 25,799,416 | \$ 26,283,392 |
| Estimated residual values | 3,934,795 | 3,900,679 |
| Less unearned income | (23,056,770) | (23,462,022) |
| Net investment in direct financing leases before allowance | 6,677,441 | 6,722,049 |
| Allowance for DFL losses | (817,040) | (817,040) |
| Net investment in direct financing leases | \$ 5,860,401 | \$ 5,905,009 |
| Properties subject to direct financing leases | 340 | 348 |

Table of Contents

HCR ManorCare, Inc.

The Company acquired 334 post-acute, skilled nursing and assisted living facilities in its 2011 transaction with HCRMC and entered into a triple-net Master Lease and Security Agreement (the “Master Lease”) with a subsidiary (“Lessee”) of HCRMC. The Master Lease, as amended by the “HCRMC Lease Amendment” described below, is referred to herein as the “Amended Master Lease.”

As part of the Company’s fourth quarter 2015 review process, including its internal rating evaluation, it assessed the collectibility of all contractual rent payments under the Amended Master Lease, as discussed below. The Company’s evaluation included, but was not limited to, consideration of: (i) the continued decline in HCRMC’s operating performance and fixed charge coverage ratio during the second half of 2015, with the most significant deterioration occurring during the fourth quarter, (ii) the reduced growth outlook for the post-acute/skilled nursing business and (iii) HCRMC’s 2015 audited financial statements. The Company determined that the timing and amounts owed under the Amended Master Lease were no longer reasonably assured and assigned an internal rating of “Watch List” as of December 31, 2015. Further, the Company placed the HCRMC DFL investments on nonaccrual status and began utilizing a cash basis method of accounting in accordance with its policies.

As a result of assigning an internal rating of “Watch List” to its HCRMC DFL investments during the quarterly review process, the Company further evaluated the carrying amount of its HCRMC DFL investments. As a result of the significant decline in HCRMC’s fixed charge coverage ratio in the fourth quarter of 2015, combined with a lower growth outlook for the post-acute/skilled nursing business, the Company determined that it was probable that its HCRMC DFL investments were impaired and the amount of the loss could be reasonably estimated. In the fourth quarter of 2015, the Company recorded an allowance for DFL losses (impairment charge) of \$817 million, reducing the carrying amount of its HCRMC DFL investments from \$6.0 billion to \$5.2 billion at December 31, 2015.

In December 2015, the Company reduced the carrying amount of its equity investment in HCRMC to zero and, beginning in January 2016, income is recognized only if cash distributions are received from HCRMC. As a result, the Company no longer recharacterizes (eliminates) its proportional ownership share of income from DFLs to equity income from unconsolidated JVs (see Note 7).

During the three months ended March 31, 2015, the Company and HCRMC agreed to market for sale the real estate and operations associated with 50 non-strategic facilities under the Master Lease. HCRMC will receive an annual rent reduction under the Master Lease based on 7.75% of the net sales proceeds received by HCP. During the year ended December 31, 2015, the Company completed sales of 22 non-strategic HCRMC facilities for \$219 million. During the nine months ended September 30, 2016, the Company sold an additional 11 facilities for \$62 million, bringing the total facilities sold through October 31, 2016 to 33. Of the 17 remaining non-strategic facilities, seven are expected to close by the end of 2016 and 10 are expected to be sold in the first quarter of 2017, for an aggregate amount of \$62 million.

On March 29, 2015, certain subsidiaries of the Company entered into an amendment to the Master Lease (the “HCRMC Lease Amendment”) effective April 1, 2015. The HCRMC Lease Amendment reduced initial annual rent by a net \$68 million from \$541 million to \$473 million. Commencing on April 1, 2016, the minimum rent escalation was reset to 3.0% for each lease year through the expiration of the initial term of each applicable pool of facilities. Prior to the HCRMC Lease Amendment, rent payments would have increased 3.5% on April 1, 2015 and 2016 and 3.0% annually thereafter. The initial term was extended five years to an average of 16 years, and the extension options’ aggregate terms remained the same.

As consideration for the rent reduction, the Company received a deferred rent obligation (“DRO”) from the Lessee equal to an aggregate amount of \$525 million, which was allocated into two tranches: (i) a Tranche A DRO of \$275 million and (ii) a Tranche B DRO of \$250 million. The Lessee made rental payments equal to 6.9% of the outstanding amount (representing \$19 million) for the initial lease year until the entire Tranche A DRO was paid in full in March 2016 in connection with the nine facility purchases discussed below. Commencing on April 1, 2016, until the Tranche B DRO is paid in full, the outstanding principal balance of the Tranche B DRO will be increased annually by (i) 3.0% initially, (ii) 4.0% commencing on April 1, 2019, (iii) 5.0% commencing on April 1, 2020, and (iv) 6.0% commencing on April 1, 2021 and annually for the remainder of its term. The DRO is due and payable on the earlier of (i) certain capital or liquidity events of HCRMC, including an initial public offering or sale, or (ii) March 31, 2029, which is not subject to any

Table of Contents

extensions. The HCRMC Lease Amendment also imposes certain restrictions on the Lessee and HCRMC until the DRO is paid in full, including with respect to the payment of dividends and the transfer of interest in HCRMC.

Additionally, HCRMC agreed to sell, and HCP agreed to purchase, nine post-acute facilities for an aggregate purchase price of \$275 million. Through December 31, 2015, HCRMC and HCP completed seven of the nine facility purchases for \$183 million. Through March 31, 2016, HCRMC and HCP completed the remaining two facility purchases for \$92 million, bringing the nine facility purchases to an aggregate \$275 million, the proceeds of which were used to settle the Tranche A DRO discussed above. Following the purchase of a facility, the Lessee leases such facility from the Company pursuant to the Amended Master Lease. The nine facilities initially contribute an aggregate of \$19 million of annual rent (subject to escalation) under the Amended Master Lease.

In March 2015, the Company recorded a net impairment charge of \$478 million related to its HCRMC DFL investments. The impairment charge reduced the carrying value of the HCRMC DFL investments from \$6.6 billion to \$6.1 billion, based on the present value of the future lease payments effective April 1, 2015 under the Amended Master Lease discounted at the original DFL investments' effective lease rate.

During the three months ended September 30, 2016 and 2015, the Company recognized DFL income of \$116 million and \$141 million, respectively, and received cash payments of \$116 million and \$118 million, respectively, from the HCRMC DFL investments. During the nine months ended September 30, 2016, the Company recognized DFL income of \$346 million and \$433 million, respectively, and received cash payments of \$346 million and \$367 million, respectively, from the HCRMC DFL investments. During the three and nine months ended September 30, 2015, the Company recognized a total of \$23 million and \$66 million, respectively, of net accretion related to its HCRMC DFL investments. No accretion related to its HCRMC DFL investments has been recognized in 2016 due to the Company utilizing a cash basis method of accounting beginning January 1, 2016. The carrying value of the HCRMC DFL investments was \$5.1 billion and \$5.2 billion at September 30, 2016 and December 31, 2015, respectively.

The Company acquired the HCRMC DFL investments in 2011 through an acquisition of a C-Corporation, which was subject to federal and state built-in gain tax of up to \$2 billion, if all the assets were sold within 10 years. At the time of acquisition, the Company intended to hold the assets for at least 10 years, at which time the assets would no longer be subject to the built-in gain tax.

In December 2015, the U.S. Federal Government passed legislation which permanently reduced the holding period, for federal tax purposes, to five years. The Company satisfied the five year holding period requirement in April 2016. In June 2016, the U.S. Department of the Treasury issued proposed regulations that would change the holding period back to 10 years, but effective only for conversion transactions after August 8, 2016. As currently proposed, these regulations will not impact the properties in the HCRMC DFL as the HCRMC conversion transaction occurred on April 7, 2011. However, certain states still require a 10-year holding period and, as such, the assets are still subject to state built-in gain tax.

During the nine months ended September 30, 2016, the Company determined that it may sell assets during the next five years and, therefore, recorded a deferred tax liability of \$47 million representing its estimated exposure to state built-in gain tax.

On April 20, 2015, the U.S. Department of Justice (“DOJ”) unsealed a previously filed complaint in the U.S. District Court for the Eastern District of Virginia against HCRMC and certain of its affiliates in three consolidated cases following a civil investigation arising out of three lawsuits filed by former employees of HCRMC under the qui tam provisions of the federal False Claims Act. The DOJ’s complaint in intervention is captioned United States of America, ex rel. Ribik, Carson, and Slough v. HCR ManorCare, Inc., ManorCare Inc., HCR ManorCare Services, LLC and Heartland Employment Services, LLC (Civil Action Numbers: 1:09cv13; 1:11cv1054; 1:14cv1228 (CMH/TCB)). The complaint alleges that HCRMC submitted claims to Medicare for therapy services that were not covered by the skilled nursing facility benefit, were not medically reasonable and necessary, and were not skilled in nature, and therefore not entitled to Medicare reimbursement. The DOJ is seeking treble damages (in an unspecified amount); civil penalties (in an unspecified amount); compensation for alleged unjust enrichment; recovery of certain payments the government made to HCRMC; and costs, pre-judgment interest, and expenses. In June 2016, the court approved the parties’ joint discovery plan, which provides for discovery to be completed by February 2017. The court has not yet issued a scheduling order setting forth dates for summary judgment

Table of Contents

motions, other pre-trial motions or a trial date. While this litigation is at an early stage and HCRMC has indicated that it believes the claims are unjust and it will vigorously defend against them, the ultimate outcome is uncertain and could, among other things, cause HCRMC to: (i) incur substantial additional time and costs to respond to and defend HCRMC's actions in the litigation with the DOJ and any other third-party payors, (ii) refund or adjust amounts previously paid for services under governmental programs and to change business operations going forward in a manner that negatively impacts future revenue, (iii) pay substantial fines and penalties and incur other administrative sanctions, including having to conduct future business operations pursuant to a corporate integrity agreement, which may be with the Office of Inspector General of the Department of Health and Human Services, (iv) lose the right to participate in the Medicare or Medicaid programs, and (v) suffer damage to HCRMC's reputation. In addition, any settlement in the DOJ litigation, with or without an admission of wrongdoing, may include a substantial monetary component that could have a material adverse effect on HCRMC's liquidity and financial condition.

See Notes 1, 7, 11 and 17 for additional discussion of HCRMC.

DFL Internal Ratings

The following table summarizes the Company's internal ratings for DFLs at September 30, 2016 (dollars in thousands):

| Segment | Carrying Amount | Percentage of DFL Portfolio | Internal Ratings | | |
|---------|-----------------|-----------------------------|------------------|-----------------|--------------|
| | | | Performing DFLs | Watch List DFLs | Workout DFLs |
| SH NNN | \$ 629,330 | 11 | \$ 267,326 | \$ 362,004 | \$ — |
| QCP | 5,107,180 | 87 | — | 5,107,180 | — |
| Other | 123,891 | 2 | 123,891 | — | — |
| | \$ 5,860,401 | 100 | \$ 391,217 | \$ 5,469,184 | \$ — |

Beginning September 30, 2013, the Company placed a 14-property senior housing triple-net DFL (the "DFL Portfolio") on nonaccrual status and assigned an internal rating of "Watch List." The Company determined that the collection of all rental payments was and continues to be no longer reasonably assured; therefore, rental revenue from the DFL Portfolio is recognized when cash is received utilizing a cash basis method of accounting in accordance with its policies. During the three months ended September 30, 2016 and 2015, the Company recognized DFL income of \$4 million and \$3 million, respectively, and received cash payments of \$5 million from the DFL Portfolio. During the nine months ended September 30, 2016 and 2015, the Company recognized DFL income of \$11 million and \$12 million, respectively, and received cash payments of \$15 million and \$16 million, respectively, from the DFL Portfolio. The carrying value of the DFL Portfolio was \$362 million and \$366 million at September 30, 2016 and December 31, 2015, respectively.

NOTE 6. Loans Receivable

The following table summarizes the Company's loans receivable (in thousands):

| | September 30, 2016 | | | December 31, 2015 | | |
|--|--------------------|------------|------------------|-------------------|------------|------------------|
| | Real Estate | | Other Secured | Real Estate | | Other Secured |
| | Secured | Secured | | Secured | Secured | |
| Mezzanine(1) (2) | \$ — | \$ 622,671 | \$ 622,671 | \$ — | \$ 660,138 | \$ 660,138 |
| Other(3) | 64,057 | — | 64,057 | 114,322 | — | 114,322 |
| Unamortized discounts, fees and costs(1) | 539 | (4,273) | (3,734) | 961 | (6,678) | (5,717) |
| | \$ 64,596 | \$ 618,398 | \$ 682,994 | \$ 115,283 | \$ 653,460 | \$ 768,743 |

- (1) At September 30, 2016, included £281 million (\$365 million) outstanding and £3 million (\$3 million) of associated unamortized discounts, fees and costs. At December 31, 2015, included £273 million (\$403 million) outstanding and £4 million (\$5 million) of associated unamortized discounts, fees and costs.
- (2) At September 30, 2016, the Company had £37 million (\$49 million) remaining under its commitments to fund development projects and capital expenditures under its U.K. development projects.
- (3) At September 30, 2016, the Company had \$0.5 million remaining of commitments to fund development projects and capital expenditures under its senior housing development loan program.

Table of Contents

Loans Receivable Internal Ratings

The following table summarizes the Company's internal ratings for loans receivable at September 30, 2016 (dollars in thousands):

| Investment Type | Carrying Amount | Percentage of Loan Portfolio | Internal Ratings | | |
|---------------------|-----------------|------------------------------|------------------|------------------|---------------|
| | | | Performing Loans | Watch List Loans | Workout Loans |
| Real estate secured | \$ 64,596 | 9 | \$ 64,596 | \$ — | \$ — |
| Other secured | 618,398 | 91 | 362,041 | 256,357 | — |
| | \$ 682,994 | 100 | \$ 426,637 | \$ 256,357 | \$ — |

Real Estate Secured Loans

Four Seasons Health Care. In December 2015, the Company purchased £28 million (\$42 million) of Four Seasons Health Care's ("Four Seasons") £40 million senior secured term loan. The loan is secured by, among other things, the real estate assets of Four Seasons, and represents the most senior debt tranche. The loan bears interest at a rate of LIBOR plus 6.0% per annum and matures in December 2017.

Other Secured Loans

HC-One Facility. In November 2014, the Company was the lead investor in the financing for Formation Capital and Safanad's acquisition of NHP, a company that, at closing, owned 273 nursing and residential care homes representing over 12,500 beds in the U.K. principally operated by HC-One. The Company provided a loan facility (the "HC-One Facility"), secured by substantially all of NHP's assets, totaling £395 million, with £363 million (\$574 million) drawn at closing and has a five-year term. In February 2015, the Company increased the HC-One Facility by £108 million (\$164 million) to £502 million (\$795 million), in conjunction with HC-One's acquisition of Meridian Healthcare. In April 2015, the Company converted £174 million of the HC-One Facility into a sale-leaseback transaction for 36 nursing and residential care homes located throughout the U.K. In September 2015, the Company amended and increased its commitment under the HC-One Facility by £11 million primarily for the funding of capital expenditures and a development project. As part of the amendments, the Company shortened the non-call period by 17 months and provided consent for (i) the paydown of £34 million from disposition proceeds without a prepayment premium and (ii) the spin-off of 36 properties into a separate JV. In return, the Company retained security over the spin-off properties for a period of two years. During the year ended December 31, 2015, the Company received paydowns of £34 million (\$52 million). At September 30, 2016, the HC-One Facility had an outstanding balance of \$362 million.

Tandem Health Care Loan. On July 31, 2012, the Company closed a mezzanine loan facility to lend up to \$205 million to Tandem Health Care ("Tandem") as part of the recapitalization of a post-acute/skilled nursing portfolio. The Company funded \$100 million (the "First Tranche") at closing and funded an additional \$102 million (the "Second Tranche") in June 2013. In May 2015, the Company increased and extended the mezzanine loan facility with Tandem to: (i) fund \$50 million (the "Third Tranche") and \$5 million (the "Fourth Tranche"), which proceeds were used to repay a portion of Tandem's existing senior and mortgage debt, respectively, (ii) extend its maturity to October 2018 and (iii) extend the prepayment penalty period to January 2017. The loans bear interest at fixed rates of 12%, 14%, 6% and

6% per annum for the First, Second, Third and Fourth Tranches, respectively.

Based on the recent decline in Tandem's operating performance, as of September 30, 2016, the Company assigned an internal rating of "Watch List" to its Tandem Health Care Loan. Although Tandem continues to remain current on its contractual obligations, the collection and timing of all future amounts owed is no longer reasonably assured. During the three months ended September 30, 2016 and 2015, the Company recognized interest income and received cash payments of \$8 million from Tandem. During the nine months ended September 30, 2016 and 2015, the Company recognized interest income of \$23 million and \$22 million, respectively, and received cash payments of \$23 million and \$21 million, respectively, from Tandem. At September 30, 2016, the facility had an outstanding balance of \$256 million at an 11.5% blended interest rate and was subordinate to \$377 million of senior mortgage debt.

Table of Contents

NOTE 7. Investments in and Advances to Unconsolidated Joint Ventures

The Company owns interests in the following entities that are accounted for under the equity method at September 30, 2016 (dollars in thousands):

| Entity(1) | Segment | Carrying Amount | Ownership% |
|---|----------------|-----------------|------------|
| CCRC JV(2) | SHOP | \$ 450,188 | 49 |
| HCRMC | QCP | — | 9 |
| MBK JV(3) | SHOP | 39,876 | 50 |
| HCP Ventures III, LLC | Medical office | 9,492 | 30 |
| HCP Ventures IV, LLC | Medical office | 7,220 | 20 |
| HCP Life Science(4) | Life science | 68,251 | 50 – 63 |
| Vintage Park Development JV | SHOP | 8,088 | 85 |
| MBK Development JV(3) | SHOP | 2,464 | 50 |
| Suburban Properties, LLC | Medical office | 4,667 | 67 |
| K&Y(5) | Other | 1,324 | 80 |
| Advances to unconsolidated JVs, net and other | | 527 | |
| | | \$ 592,097 | |

-
- (1) These entities are not consolidated because the Company does not control, through voting rights or other means, the JVs.
- (2) Includes two unconsolidated JVs in a RIDEA structure (CCRC PropCo and CCRC OpCo).
- (3) Includes two unconsolidated JVs in a RIDEA structure.
- (4) Includes the following unconsolidated partnerships (and the Company's ownership percentage): (i) Torrey Pines Science Center, LP (50%); (ii) Britannia Biotech Gateway, LP (55%); and (iii) LASDK, LP (63%).
- (5) Includes three unconsolidated JVs.

The following tables summarize combined financial information for the Company's equity method investments (in thousands):

| | September 30, 2016 | December 31, 2015 |
|---|-----------------------|----------------------|
| Real estate, net | \$ 4,434,643 | \$ 4,470,249 |
| Goodwill and other assets, net | 4,945,250 | 4,935,343 |
| Assets held for sale | 67,817 | 94,866 |
| Total assets | \$ 9,447,710 | \$ 9,500,458 |
| Capital lease obligations and mortgage debt | \$ 6,419,016 | \$ 6,575,531 |
| Accounts payable | 1,314,659 | 1,111,350 |

Edgar Filing: HCP, INC. - Form 10-Q

| | | |
|---|--------------|--------------|
| Liabilities and mortgage debt held for sale | 1,593 | 6,318 |
| Other partners' capital | 1,078,758 | 1,163,501 |
| HCP's capital(1) | 633,684 | 643,758 |
| Total liabilities and partners' capital | \$ 9,447,710 | \$ 9,500,458 |

- (1) The combined basis difference of the Company's investments in these JVs of \$42 million, as of September 30, 2016, is attributable to goodwill, real estate, capital lease obligations, deferred tax assets and lease-related net intangibles.

Table of Contents

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------|--------------|-------------------|--------------|
| | September 30, | | September 30, | |
| | 2016 | 2015 | 2016 | 2015 |
| Total revenues | \$ 1,057,213 | \$ 1,106,667 | \$ 3,210,868 | \$ 3,375,747 |
| Income (loss) from discontinued operations | 904 | (1,794) | 3,476 | (15,696) |
| Net loss | (43,248) | (65,819) | (81,214) | (77,529) |
| HCP's share of earnings(1) | (2,053) | 8,314 | (4,028) | 33,916 |
| Fees earned by HCP | 76 | 454 | 248 | 1,372 |
| Distributions received by HCP | 10,754 | 16,186 | 20,377 | 20,673 |

- (1) The Company's JV interest in HCRMC is accounted for using the equity method and results in an elimination of DFL income proportional to HCP's ownership in HCRMC. The elimination of the respective proportional lease expense at the HCRMC level in substance resulted in \$14 million and \$44 million of DFL income that was recharacterized to the Company's share of earnings from HCRMC (equity income from unconsolidated JVs) for the three and nine months ended September 30, 2015. Beginning in January 2016, income will be recognized only if cash distributions are received from HCRMC; as a result, the Company no longer recharacterizes (eliminates) its proportional ownership share of income from DFLs to equity income (loss) from unconsolidated JVs.

HCRMC. The Company concluded that its equity investment in HCRMC was other-than-temporarily impaired as of December 2014, September 2015 and December 2015 and recorded impairment charges of \$36 million, \$27 million and \$19 million, respectively. Beginning in January 2016, equity income is recognized only if cash distributions are received from HCRMC (see Note 5). In determining the fair value of the Company's equity investment in HCRMC, the fair value was based on a discounted cash flow valuation model and inputs were considered to be Level 3 measurements within the fair value hierarchy. Inputs to this valuation model include earnings multiples, discount rate and industry growth rates of revenue, operating expenses and facility occupancy, some of which influence the Company's expectation of future cash flows from its investment in HCRMC and, accordingly, the fair value of its investment.

MBK JVs. On March 30, 2015, the Company and MBK Senior Living ("MBK"), a subsidiary of Mitsui & Co. Ltd., formed a new RIDEA JV ("MBK JV") that owns three senior housing facilities with the Company and MBK each owning a 50% equity interest. MBK manages these communities on behalf of the JV and receives cash payments. The Company contributed \$27 million of cash and MBK contributed the three senior housing facilities with a fair value of \$126 million, which were encumbered by \$78 million of mortgage debt at closing.

On September 25, 2015, the Company and MBK formed a new RIDEA JV ("MBK Development JV"), which acquired a \$3 million parcel of land for the purpose of developing a 74-unit class A senior housing facility in Santa Rosa, California. The parcel of land is located adjacent to the Oakmont Gardens independent living facility currently owned and operated by the MBK JV.

NOTE 8. Intangibles

At September 30, 2016 and December 31, 2015, gross intangible lease assets, comprised of lease-up intangibles, above market tenant lease intangibles and below market ground lease intangibles, were \$978 million and \$984 million, respectively. At September 30, 2016 and December 31, 2015, the accumulated amortization of intangible assets was \$439 million and \$380 million, respectively.

At September 30, 2016 and December 31, 2015, gross intangible lease liabilities, comprised of below market tenant lease intangibles and above market ground lease intangibles, were \$154 million and \$156 million, respectively. At September 30, 2016 and December 31, 2015, the accumulated amortization of intangible liabilities was \$108 million and \$100 million, respectively.

Table of Contents

NOTE 9. Other Assets

The following table summarizes the Company's other assets (in thousands):

| | September 30, 2016 | December 31, 2015 |
|---|-----------------------|----------------------|
| Straight-line rent receivables, net of allowance of \$30,776 and \$33,648, respectively | \$ 380,178 | \$ 370,296 |
| Marketable debt securities, net | 82,081 | 102,958 |
| Leasing costs and inducements, net | 155,889 | 158,708 |
| Goodwill | 50,346 | 50,346 |
| Other | 125,519 | 119,965 |
| Total other assets | \$ 794,013 | \$ 802,273 |

Four Seasons Health Care Senior Notes

Marketable debt securities, net are classified as held-to-maturity debt securities and primarily represent senior notes issued by Elli Investments Limited ("Elli"), a company beneficially owned by funds or limited partnerships managed by Terra Firma, as part of the financing for Elli's acquisition of Four Seasons Health Care (the "Four Seasons Notes"). The Four Seasons Notes mature in June 2020, were non-callable through June 2016 and bear interest on their par value at a fixed rate of 12.25% per annum. The Company purchased an aggregate par value of £138.5 million of the Four Seasons Notes at a discount for £136.8 million (\$215 million) in June 2012, representing 79% of the total £175 million issued and outstanding Four Seasons Notes. In June 2015 and September 2015, the Company determined that the Four Seasons Notes were other-than-temporarily impaired and recorded impairment charges of \$42 million and \$70 million, respectively, reducing the carrying value to \$174 million (£111 million) and \$100 million (£66 million), respectively. The fair value was based on quoted prices; however as the Four Seasons Notes are not actively traded, these prices were considered to be Level 2 measurements within the fair value hierarchy.

Elli remains obligated to repay the aggregate par value at maturity and interest payments due June 15 and December 15 each year. When the remaining semi-annual interest payments are received, the Company expects to continue to reduce the carrying value of the Four Seasons Notes during the related period. Accordingly, the Company applied the contractual interest payments received in both December 2015 (£8 million or \$13 million) and June 2016 (£8 million or \$13 million) against the principal balance. This treatment reduced the carrying value of the Four Seasons Notes to £58 million (\$85 million) and £49 million (\$64 million) at December 31, 2015 and September 30, 2016, respectively.

NOTE 10. Debt

Bank Line of Credit and Term Loans

The Company's \$2.0 billion unsecured revolving line of credit facility (the "Facility") matures on March 31, 2018 and contains a one-year extension option. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on the Company's credit ratings. The Company pays a facility fee on the entire revolving commitment that depends on its credit ratings. Based on the Company's credit ratings at September 30, 2016, the margin on the Facility was 1.05%, and the facility fee was 0.20%. The Facility also includes a feature that allows the Company to increase the borrowing capacity by an aggregate amount of up to \$500 million, subject to securing additional commitments from existing lenders or new lending institutions. At September 30, 2016, the Company had \$1.4 billion, including £275 million (\$357 million), outstanding under the Facility with a weighted average effective interest rate of 1.85%.

In July 2016, the Company exercised a one-year extension option on its £137 million (\$178 million at September 30, 2016), four-year unsecured term loan that it entered into on July 30, 2012 (the "2012 Term Loan"). Based on the Company's credit ratings at September 30, 2016, the 2012 Term Loan accrues interest at a rate of GBP LIBOR plus 1.40%. The Company also has a £220 million (\$286 million at September 30, 2016) four-year unsecured term loan that accrues interest at a rate of GBP LIBOR plus 1.15%, subject to adjustments based on the Company's credit ratings.

Table of Contents

The Facility and term loans contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements, (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%, (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%, (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60% and (iv) require a minimum Fixed Charge Coverage ratio of 1.5x. The Facility and term loans also require a Minimum Consolidated Tangible Net Worth of \$9.5 billion at September 30, 2016, which requirement was subsequently reduced, via an amendment to the Facility, to \$6.5 billion effective upon the completion of the Spin-Off of QCP on October 31, 2016. At September 30, 2016, the Company was in compliance with each of these restrictions and requirements.

Senior Unsecured Notes

At September 30, 2016, the Company had senior unsecured notes outstanding with an aggregate principal balance of \$8.3 billion. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. The Company believes it was in compliance with these covenants at September 30, 2016.

The following table summarizes the Company's senior unsecured notes issuances for the periods presented (dollars in thousands):

| Period | Issuance | | | |
|-------------------------------|------------|-------------|---------------|--------------|
| | Amount | Coupon Rate | Maturity Date | Net Proceeds |
| Year ended December 31, 2015: | | | | |
| January 21, 2015 | \$ 600,000 | 3.400 % | 2025 | \$ 591,000 |
| May 20, 2015 | \$ 750,000 | 4.000 % | 2025 | \$ 739,000 |
| December 1, 2015 | \$ 600,000 | 4.000 % | 2022 | \$ 594,000 |

The following table summarizes the Company's senior unsecured notes payoffs for the periods presented (dollars in thousands):

| Period | Amount | Coupon Rate |
|---------------------------------------|------------|-------------|
| Nine months ended September 30, 2016: | | |
| February 1, 2016 | \$ 500,000 | 3.750 % |
| September 15, 2016 | \$ 400,000 | 6.300 % |
| Year ended December 31, 2015: | | |
| March 1, 2015 | \$ 200,000 | 6.000 % |

June 8, 2015

\$ 200,000 7.072 %

Mortgage Debt

At September 30, 2016, the Company had mortgage debt outstanding with an aggregate principal balance of \$758 million, which is secured by 46 healthcare facilities (including redevelopment properties) with a carrying value of \$1.1 billion.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires maintenance of insurance on the assets and includes conditions to obtain lender consent to enter into or terminate material leases. Some of the mortgage debt is also cross-collateralized by multiple assets and may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

Table of Contents

Debt Maturities

The following table summarizes the Company's stated debt maturities and scheduled principal repayments at September 30, 2016 (in thousands):

| Year | Bank Line of Credit(1) | Term Loans(2) | Senior | | Total(5) |
|---|------------------------------|---------------|-----------------------|---------------------|---------------|
| | | | Unsecured Notes(3) | Mortgage Debt(4) | |
| 2016 (three months) | \$ — | \$ — | \$ — | \$ 30,626 | \$ 30,626 |
| 2017 | — | 177,867 | 750,000 | 583,541 | 1,511,408 |
| 2018 | 1,372,032 | — | 600,000 | 8,290 | 1,980,322 |
| 2019 | — | 285,626 | 450,000 | 3,839 | 739,465 |
| 2020 | — | — | 800,000 | 3,907 | 803,907 |
| Thereafter | — | — | 5,700,000 | 127,758 | 5,827,758 |
| | 1,372,032 | 463,493 | 8,300,000 | 757,961 | 10,893,486 |
| (Discounts), premiums and debt costs, net | — | (1,312) | (70,269) | 4,754 | (66,827) |
| | \$ 1,372,032 | \$ 462,181 | \$ 8,229,731 | \$ 762,715 | \$ 10,826,659 |

(1) Includes £275 million (\$357 million) translated into U.S. dollars ("USD").

(2) Represents £357 million translated into USD.

(3) Effective interest rates on senior unsecured notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.63% and a weighted average maturity of six years.

(4) Effective interest rates on the mortgage debt ranged from 3.05% to 8.20% with a weighted average effective interest rate of 5.79% and a weighted average maturity of five years.

(5) Excludes \$94 million of other debt that represents Life Care Bonds and Demand Notes (each as defined below) that have no scheduled maturities.

Other Debt

At September 30, 2016, the Company had \$66 million of non-interest bearing life care bonds at two of its CCRCs and non-interest bearing occupancy fee deposits at three of its senior housing facilities, all of which are payable to certain residents of the facilities (collectively, "Life Care Bonds"). The Life Care Bonds are generally refundable to the residents upon the termination of the contract or upon the successful resale of the unit.

At September 30, 2016, the Company had \$28 million of on-demand notes ("Demand Notes") from the CCRC JV. The Demand Notes bear interest at a rate of 4.5%.

NOTE 11. Commitments and Contingencies

Legal Proceedings

From time to time, the Company is a party to legal proceedings, lawsuits and other claims that arise in the ordinary course of the Company's business. Except as described below, the Company is not aware of any other legal proceedings or claims that it believes may have, individually or taken together, a material adverse effect on the Company's financial condition, results of operations or cash flows. The Company's policy is to expense legal costs as they are incurred.

On May 9, 2016, a purported stockholder of the Company filed a putative class action complaint, *Boynton Beach Firefighters' Pension Fund v. HCP, Inc., et al.*, Case No. 3:16-cv-01106-JJH, in the U.S. District Court for the Northern District of Ohio against the Company, certain of its officers, HCRMC, and certain of its officers, asserting violations of the federal securities laws. The suit asserts claims under sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and alleges that the Company made certain false or misleading statements relating to the value of and risks concerning its investment in HCRMC by allegedly failing to disclose that HCRMC had engaged in billing fraud, as alleged by the DOJ in a pending suit against HCRMC arising from the False Claims Act. The plaintiff in the suit demands compensatory damages (in an unspecified amount), costs and expenses (including attorneys' fees and expert fees), and equitable, injunctive, or other relief as the Court deems just and proper. The DOJ lawsuit against HCRMC is described in greater detail in Note 5. As the Boynton Beach action is in its early stages and a lead plaintiff has not yet been named, the defendants have not yet responded to the complaint. The Company believes the suit to be without merit and intends to vigorously defend against it.

Table of Contents

On June 16, 2016 and July 5, 2016, purported stockholders of the Company filed two derivative actions, respectively Subodh v. HCR ManorCare Inc., et al., Case No. 30-2016-00858497-CU-PT-CXC and Stearns v. HCR ManorCare, Inc., et al., Case No. 30-2016-00861646-CU-MC-CJC, in the Superior Court of California, County of Orange, against certain of the Company's current and former directors and officers and HCRMC. The Stearns action was subsequently consolidated by the Court with the Subodh action. The Company is named as a nominal defendant. The consolidated derivative action alleges that the defendants engaged in various acts of wrongdoing, including, among other things, breaching fiduciary duties by publicly making false or misleading statements of fact regarding HCRMC's finances and prospects, and failing to maintain adequate internal controls. The plaintiffs demand damages (in an unspecified amount), pre-judgment and post-judgment interest, a directive that the Company and the individual defendants improve the Company's corporate governance and internal procedures (including putting resolutions to amend the bylaws or charter to a stockholder vote), restitution from the individual defendants, costs (including attorneys' fees, experts' fees, costs, and expenses), and further relief as the Court deems just and proper. As the Subodh action is in the early stages, the defendants are in the process of evaluating the suit and have not yet responded to the complaint.

On June 9, 2016, and on August 25, 2016, the Company received letters from a private law firm, acting on behalf of its clients, purported stockholders of the Company, each asserting substantially the same allegations made in the Subodh and Stearns matters discussed above. Each letter demands that the Company's Board of Directors take action to assert the Company's rights. The Board of Directors is in the process of evaluating the demand letters.

The Company is unable to estimate the ultimate individual or aggregate amount of monetary liability or financial impact with respect to matters discussed above as of September 30, 2016.

Commitments for Capital Additions

Under the terms of the Amended Master Lease with HCRMC, the Company is required through April 1, 2019, upon the Lessee's request, to provide the Lessee an amount to fund Capital Additions Costs (as defined in the Amended Master Lease) approved by the Company, in the Company's reasonable discretion, such amount not to exceed \$100 million in the aggregate ("Capital Addition Financing"), but the Company is not obligated to advance more than \$50 million in Capital Addition Financing in any single lease year. In connection with any Capital Addition Financing, the minimum rent allocated to the applicable property will be increased by an amount equal to the product of: (i) the amount disbursed on account of the Capital Addition Financing for the applicable property times (ii) at the time of any such disbursement, the greater of (a) 7.75% and (b) 500 basis points in excess of the then current 10-year Treasury Rate. Any such Capital Addition Financing shall be structured in a REIT tax-compliant fashion. Through September 30, 2016, approximately \$1.2 million in Capital Addition Financing has been funded by the Company.

NOTE 12. Equity

Common Stock

The following table summarizes the Company's common stock cash dividends declared in 2016:

| Declaration Date | Record Date | Amount Per Share | Dividend Payable Date |
|------------------|-------------|---------------------|--------------------------|
| January 28 | February 8 | \$ 0.575 | February 23 |
| April 27 | May 9 | 0.575 | May 24 |
| July 28 | August 8 | 0.575 | August 23 |
| October 31 | November 10 | 0.370 | November 25 |

Table of Contents

The following table summarizes the Company's other common stock activities (shares in thousands):

| | Nine Months Ended September 30, | |
|---|---------------------------------|-------|
| | 2016 | 2015 |
| Dividend Reinvestment and Stock Purchase Plan | 1,763 | 2,345 |
| Conversion of DownREIT units(1) | 145 | 75 |
| Exercise of stock options | 133 | 820 |
| Vesting of restricted stock units | 527 | 382 |
| Repurchase of common stock | 236 | 178 |

(1) Non-managing member limited liability company ("LLC") units.

Accumulated Other Comprehensive Loss

The following table summarizes the Company's accumulated other comprehensive loss (in thousands):

| | September 30, | December 31, |
|--|---------------|--------------|
| | 2016 | 2015 |
| Cumulative foreign currency translation adjustment | \$ (21,415) | \$ (19,485) |
| Unrealized losses on cash flow hedges, net | (5,556) | (7,582) |
| Supplemental Executive Retirement Plan minimum liability | (3,200) | (3,411) |
| Unrealized gains on available for sale securities | 7 | 8 |
| Total accumulated other comprehensive loss | \$ (30,164) | \$ (30,470) |

Noncontrolling Interests

At September 30, 2016, non-managing members held an aggregate of 4 million units in five limited liability companies ("DownREITs"), for which the Company is the managing member. At September 30, 2016, the carrying and fair values of these DownREIT units were \$180 million and \$221 million, respectively.

On October 7, 2015, the Company issued a 49% noncontrolling interest in HCP Ventures V to an institutional capital investor for \$110 million (see Note 3).

See Note 15 for the supplemental schedule of non-cash financing activities.

NOTE 13. Segment Disclosures

The Company evaluates its business and allocates resources based on its five reportable business segments: (i) SH NNN, (ii) SHOP, (iii) life science, (iv) medical office and (v) QCP. Under the medical office segment, the Company invests through the acquisition and development of medical office buildings (“MOBs”), which generally require a greater level of property management. Otherwise, the Company primarily invests, through the acquisition and development of real estate, in single tenant and operator properties. The Company has non-reportable segments that are comprised primarily of the Company’s debt investments, hospital properties and U.K. care homes. The accounting policies of the segments are the same as those in Note 2 to the Consolidated Financial Statements in the Company’s 2015 Annual Report on Form 10-K filed with the SEC, as amended by Note 2 herein. In August 2016, six SH NNN facilities were transitioned to a RIDEA structure (reported in our SHOP segment). There were no intersegment sales or transfers during the nine months ended September 30, 2015. The Company evaluates performance based upon: (i) property net operating income from continuing operations (“NOI”) and (ii) adjusted NOI (cash NOI) of the combined consolidated and unconsolidated investments in each segment.

Non-segment assets consist primarily of corporate assets, including cash and cash equivalents, restricted cash, accounts receivable, net, marketable equity securities and, if any, real estate and related assets held for sale. Interest expense, depreciation and amortization, and non-property specific revenues and expenses are not allocated to individual segments in evaluating the Company’s segment-level performance. See Note 17 for other information regarding concentrations of credit risk.

Table of Contents

The following tables summarize information for the reportable segments (in thousands):

For the three months ended September 30, 2016:

| | SH NNN | SHOP | Life Science | Medical Office | QCP | Other Non-reportable | Corporate Non-segment | Total |
|--|------------|-----------|-----------------|-------------------|------------|-------------------------|--------------------------|------------|
| Rental revenues(1) | \$ 104,249 | \$ — | \$ 90,847 | \$ 113,653 | \$ 123,716 | \$ 30,571 | \$ — | \$ 463,036 |
| Resident fees and services | 13 | 170,739 | — | — | — | — | — | 170,752 |
| HCP share of unconsolidated JV revenues | — | 50,973 | 1,929 | 502 | — | 410 | — | 53,814 |
| Less: | | | | | | | | — |
| Operating expenses HCP share of unconsolidated JV operating expenses | (1,794) | (121,502) | (18,487) | (44,738) | (1,036) | (1,190) | — | (188,747) |
| NOI | 102,468 | 57,747 | 73,883 | 69,269 | 122,680 | 29,771 | — | 455,818 |
| Non-cash adjustments to NOI(2) | (1,003) | 4,608 | (314) | (814) | 172 | (1,140) | — | 1,509 |
| Adjusted (cash) NOI | 101,465 | 62,355 | 73,569 | 68,455 | 122,852 | 28,631 | — | 457,327 |
| Addback non-cash adjustments | 1,003 | (4,608) | 314 | 814 | (172) | 1,140 | — | (1,509) |
| Interest income | — | — | — | — | — | 20,482 | — | 20,482 |
| Interest expense | (644) | (8,130) | (634) | (1,608) | — | (2,260) | (104,584) | (117,860) |
| Depreciation and amortization | (34,030) | (26,837) | (31,967) | (41,111) | (1,467) | (7,462) | — | (142,874) |
| General and administrative expenses | — | — | — | — | — | — | (34,787) | (34,787) |
| Acquisition and pursuit costs | — | — | — | — | — | — | (17,568) | (17,568) |
| Loss on sales of real estate, net | — | — | — | (9) | — | — | — | (9) |

Edgar Filing: HCP, INC. - Form 10-Q

| | | | | | | | | |
|--|-----------|-----------|-----------|-----------|------------|-----------|--------------|------------|
| Other income, net | — | — | — | — | — | — | 1,454 | 1,454 |
| Income tax benefit | — | — | — | — | — | — | 2,213 | 2,213 |
| Less: HCP share of unconsolidated JV NOI | — | (8,510) | (1,523) | (354) | — | (390) | — | (10,777) |
| Equity (loss) income in unconsolidated JVs | — | (3,517) | 778 | 462 | — | 224 | — | (2,053) |
| Net income (loss) | \$ 67,794 | \$ 10,753 | \$ 40,537 | \$ 26,649 | \$ 121,213 | \$ 40,365 | \$ (153,272) | \$ 154,039 |

Table of Contents

For the three months ended September 30, 2015:

| | SH NNN | SHOP | Life Science | Medical Office | QCP | Other Non-reportable | Corporate Non-segment | Total |
|---|------------|-----------|-----------------|-------------------|------------|-------------------------|--------------------------|------------|
| Rental revenues(1) | \$ 105,405 | \$ 182 | \$ 86,140 | \$ 108,898 | \$ 148,599 | \$ 33,143 | \$ — | \$ 482,367 |
| Resident fees and services | — | 155,290 | — | — | — | — | — | 155,290 |
| HCP share of unconsolidated JV revenues | — | 45,891 | 1,840 | 464 | — | 400 | — | 48,595 |
| Less: | | | | | | | | — |
| Operating expenses | (871) | (110,254) | (17,785) | (43,008) | (1,008) | (589) | — | (173,515) |
| HCP share of unconsolidated JV operating expenses | — | (39,226) | (425) | (150) | — | (19) | — | (39,820) |
| NOI | 104,534 | 51,883 | 69,770 | 66,204 | 147,591 | 32,935 | — | 472,917 |
| Non-cash adjustments to NOI(2) | (2,312) | 6,984 | (2,673) | (1,342) | (23,158) | (770) | — | (23,271) |
| Adjusted (cash) NOI | 102,222 | 58,867 | 67,097 | 64,862 | 124,433 | 32,165 | — | 449,646 |
| Addback non-cash adjustments | 2,312 | (6,984) | 2,673 | 1,342 | 23,158 | 770 | — | 23,271 |
| Interest income | — | — | — | — | — | 19,842 | — | 19,842 |
| Interest expense | (4,239) | (8,026) | (701) | (2,540) | — | (2,521) | (104,130) | (122,157) |
| Depreciation and amortization | (31,527) | (24,398) | (32,013) | (37,151) | (1,470) | (8,145) | — | (134,704) |
| General and administrative expenses | — | — | — | — | — | — | (20,534) | (20,534) |
| Acquisition and pursuit costs | — | — | — | — | — | — | (1,553) | (1,553) |
| Impairments | — | — | — | — | — | (69,622) | — | (69,622) |
| Gain on sales of real estate, net | — | — | — | 52 | — | — | — | 52 |
| Other expense, net | — | — | — | — | — | — | (572) | (572) |
| Income tax benefit | — | — | — | — | — | — | 1,980 | 1,980 |
| | — | (6,665) | (1,415) | (314) | — | (381) | — | (8,775) |

| | | | | | | | | |
|--|-----------|----------|-----------|-----------|------------|-------------|--------------|------------|
| Less: HCP share of unconsolidated JV NOI Equity (loss) income in unconsolidated JVs | — | (3,291) | 706 | (586) | 11,485 | — | — | 8,314 |
| Impairment of investments in unconsolidated JVs | — | — | — | — | (27,234) | — | — | (27,234) |
| Net income (loss) | \$ 68,768 | \$ 9,503 | \$ 36,347 | \$ 25,665 | \$ 130,372 | \$ (27,892) | \$ (124,809) | \$ 117,954 |

Table of Contents

For the nine months ended September 30, 2016:

| | SH NNN | SHOP | Life Science | Medical Office | QCP | Other Non-reportable | Corporate Non-segment | Total |
|---|------------|-----------|-----------------|-------------------|------------|-------------------------|--------------------------|--------------|
| Rental revenues(1) | \$ 319,976 | \$ — | \$ 269,994 | \$ 331,881 | \$ 367,714 | \$ 95,476 | \$ — | \$ 1,385,945 |
| Resident fees and services | 13 | 500,704 | — | — | — | — | — | 500,717 |
| HCP share of unconsolidated JV revenues | — | 152,424 | 5,628 | 1,503 | — | 1,224 | — | 160,755 |
| Less: | | | | | | | | — |
| Operating expenses | (5,521) | (350,949) | (53,191) | (129,715) | (3,068) | (3,383) | — | (545,827) |
| HCP share of unconsolidated JV operating expenses | — | (125,244) | (1,173) | (452) | — | (30) | — | (126,899) |
| NOI | 314,468 | 176,935 | 221,258 | 203,217 | 364,646 | 93,287 | — | 1,373,811 |
| Non-cash adjustments to NOI(2) | (8,464) | 15,175 | (1,545) | (2,361) | 375 | (1,926) | — | 1,254 |
| Adjusted (cash) NOI | 306,004 | 192,110 | 219,713 | 200,856 | 365,021 | 91,361 | — | 1,375,045 |
| Addback non-cash adjustments | 8,464 | (15,175) | 1,545 | 2,361 | (375) | 1,926 | — | (1,254) |
| Interest income | — | — | — | — | — | 71,298 | — | 71,298 |
| Interest expense | (8,859) | (23,818) | (1,904) | (4,899) | — | (7,067) | (314,708) | (361,288) |
| Depreciation and amortization | (101,737) | (78,124) | (97,640) | (120,432) | (4,402) | (23,247) | — | (425,582) |
| General and administrative expenses | — | — | — | — | — | — | (83,079) | (83,079) |
| Acquisition and pursuit costs | — | — | — | — | — | — | (34,570) | (34,570) |
| Gain on sales of real estate, net | 23,940 | — | 29,428 | 8,333 | — | 57,904 | — | 119,605 |
| Other income, net | — | — | — | — | — | — | 5,128 | 5,128 |
| Income tax expense | — | — | — | — | — | — | (48,822) | (48,822) |
| Less: HCP share of | — | (27,180) | (4,455) | (1,051) | — | (1,194) | — | (33,880) |

| | | | | | | | | |
|---|------------|-----------|------------|-----------|------------|------------|--------------|------------|
| unconsolidated JV NOI Equity (loss) income in unconsolidated JVs | — | (8,477) | 2,263 | 1,541 | — | 645 | — | (4,028) |
| Net income (loss) | \$ 227,812 | \$ 39,336 | \$ 148,950 | \$ 86,709 | \$ 360,244 | \$ 191,626 | \$ (476,051) | \$ 578,626 |

Table of Contents

For the nine months ended September 30, 2015:

| | SH NNN | SHOP | Life Science | Medical Office | QCP | Other Non-reportable | Corporate Non-segment | Total |
|---|------------|------------|-----------------|-------------------|------------|-------------------------|--------------------------|--------------|
| Rental revenues(1) | \$ 317,520 | \$ (7,127) | \$ 255,100 | \$ 307,881 | \$ 454,740 | \$ 90,600 | \$ — | \$ 1,411,714 |
| Resident fees and services | 12 | 367,129 | — | — | — | — | — | 367,141 |
| HCP share of unconsolidated JV revenues | — | 134,047 | 5,257 | 1,395 | — | 1,193 | — | 141,892 |
| Less: | | | | | | | | |
| Operating expenses | (2,655) | (260,393) | (51,718) | (121,330) | (2,898) | (2,894) | — | (441,888) |
| HCP share of unconsolidated JV operating expenses | — | (112,395) | (1,173) | (467) | — | (54) | — | (114,089) |
| NOI | 314,877 | 121,261 | 207,466 | 187,479 | 451,842 | 88,845 | — | 1,372,770 |
| Non-cash adjustments to NOI(2) | (8,853) | 26,620 | (8,635) | (4,326) | (65,807) | (1,633) | — | (62,001) |
| Adjusted (cash) NOI | 306,024 | 147,881 | 198,831 | 183,153 | 386,035 | 87,212 | — | 1,310,769 |
| Addback non-cash adjustments | 8,853 | (26,620) | 8,635 | 4,326 | 65,807 | 1,633 | — | 62,634 |
| Interest income | — | — | — | — | — | 89,049 | — | 89,049 |
| Interest expense | (12,677) | (23,895) | (2,229) | (7,458) | — | (7,270) | (304,040) | (357,579) |
| Depreciation and amortization | (93,260) | (55,627) | (92,503) | (102,748) | (4,410) | (21,081) | — | (369,629) |
| General and administrative expenses | — | — | — | — | — | — | (74,152) | (74,152) |
| Acquisition and pursuit costs | — | — | — | — | — | — | (23,350) | (23,350) |
| Impairments | — | — | — | (2,948) | (478,464) | (111,509) | — | (592,921) |
| Gain on sales of real estate, net | 6,325 | — | — | 52 | — | — | — | 6,377 |
| Other income, net | — | — | — | — | — | — | 13,125 | 13,125 |
| Income tax benefit | — | — | — | — | — | — | 6,620 | 6,620 |
| | — | (21,652) | (4,084) | (928) | — | (1,139) | — | (27,793) |

| | | | | | | | | |
|--|---|---------|-------|---------|----------|---|---|-------|
| Less: HCP share of unconsolidated JV NOI Equity (loss) income in unconsolidated JVs | — | (5,917) | 2,123 | (1,761) | 39,471 | — | — | 33,9 |
| Impairment of investments in unconsolidated JVs | — | — | — | — | (27,234) | — | — | (27,2 |

29

Table of Contents

| | | | | | | | | |
|------------|------------|-----------|------------|-----------|-------------|-----------|--------------|-----------|
| Net income | | | | | | | | |
| (loss) | \$ 215,265 | \$ 14,170 | \$ 110,773 | \$ 71,688 | \$ (18,795) | \$ 36,895 | \$ (381,797) | \$ 48,199 |

- (1) Represents rental and related revenues, tenant recoveries and income from DFLs.
(2) Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles and lease termination fees.

The following table summarizes the Company's revenues by segment (in thousands):

| Segment | Three Months Ended | | Nine Months Ended | |
|------------------------------|--------------------|------------|-------------------|--------------|
| | September 30, | | September 30, | |
| | 2016 | 2015 | 2016 | 2015 |
| SH NNN | \$ 104,262 | \$ 105,405 | \$ 319,989 | \$ 317,532 |
| SHOP | 170,739 | 155,472 | 500,704 | 360,002 |
| Life science | 90,847 | 86,140 | 269,994 | 255,100 |
| Medical office | 113,653 | 108,898 | 331,881 | 307,881 |
| QCP | 123,716 | 148,599 | 367,714 | 454,740 |
| Other non-reportable segment | 51,053 | 52,985 | 166,774 | 179,649 |
| Total revenues | \$ 654,270 | \$ 657,499 | \$ 1,957,056 | \$ 1,874,904 |

The following table summarizes the Company's assets by segment (in thousands):

| Segment | September 30, 2016 | December 31, 2015 |
|---|-----------------------|----------------------|
| SH NNN | \$ 5,097,301 | \$ 5,092,443 |
| SHOP | 3,476,136 | 3,195,384 |
| Life science | 3,983,929 | 3,905,137 |
| Medical office | 3,481,174 | 3,436,884 |
| QCP | 5,335,708 | 5,382,843 |
| Gross reportable segment assets | 21,374,248 | 21,012,691 |
| Accumulated depreciation and amortization | (3,064,520) | (2,769,744) |
| Net reportable segment assets | 18,309,728 | 18,242,947 |
| Other non-reportable segment assets | 1,598,092 | 1,787,579 |
| Real estate and related assets held for sale, net | 372,968 | 314,126 |
| Other non-segment assets | 907,757 | 1,105,197 |
| Total assets | \$ 21,188,545 | \$ 21,449,849 |

As a result of a change in operating and reporting segments, the Company allocated goodwill to the new reporting units using a relative fair value approach. In addition, the Company completed a goodwill impairment assessment for all reporting units immediately prior to the reallocation and determined that no impairment existed. At both

September 30, 2016 and December 31, 2015, goodwill of \$50 million was reallocated to segment assets as follows: (i) SH NNN—\$21 million, (ii) SHOP—\$9 million, (iii) medical office—\$11 million, (iv) QCP—\$3 million and (v) other—\$6 million.

Subsequent Event.

The Spin-Off, completed on October 31, 2016, resulted in the Company disposing of its entire QCP segment, including its allocated goodwill (see Note 1).

Table of Contents

NOTE 14. Earnings Per Common Share

The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|----------------------------------|------------|---------------------------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| Numerator - Basic and Dilutive | | | | |
| Net income | \$ 154,039 | \$ 117,954 | \$ 578,626 | \$ 48,199 |
| Noncontrolling interests' share in earnings | (2,789) | (2,592) | (9,540) | (8,566) |
| Net income attributable to HCP, Inc. | 151,250 | 115,362 | 569,086 | 39,633 |
| Participating securities' share in earnings | (326) | (316) | (977) | (1,020) |
| Net income applicable to common shares | \$ 150,924 | \$ 115,046 | \$ 568,109 | \$ 38,613 |
| Denominator | | | | |
| Basic weighted average common shares | 467,628 | 463,337 | 466,931 | 462,039 |
| Dilutive potential common shares - equity awards | 207 | 249 | 201 | 263 |
| Diluted weighted average common shares | 467,835 | 463,586 | 467,132 | 462,302 |
| Earnings per common share | | | | |
| Basic | \$ 0.32 | \$ 0.25 | \$ 1.22 | \$ 0.08 |
| Diluted | \$ 0.32 | \$ 0.25 | \$ 1.22 | \$ 0.08 |

Restricted stock and certain of the Company's performance restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, which requires the use of the two-class method when computing basic and diluted earnings per share. Options to purchase approximately 1.0 million and 1.2 million shares of common stock that had an exercise price (including deferred compensation expense) in excess of the average closing market price of the Company's common stock during the three months ended September 30, 2016 and 2015, respectively, were not included in the Company's earnings per share calculations because they are anti-dilutive. Restricted stock and performance restricted stock units representing 0.1 million and 0.3 million shares of common stock during the three months ended September 30, 2016 and 2015 were not included because they are anti-dilutive. Additionally, during the three months ended September 30, 2016 and 2015, 6 million shares issuable upon conversion of 4 million DownREIT units were not included because they are anti-dilutive.

Table of Contents

NOTE 15. Supplemental Cash Flow Information

The following table provides supplemental cash flow information (in thousands):

| | Nine Months Ended September 30, | |
|---|---------------------------------|------------|
| | 2016 | 2015 |
| Supplemental cash flow information: | | |
| Interest paid, net of capitalized interest | \$ 401,628 | \$ 393,095 |
| Income taxes paid | 5,734 | 4,808 |
| Capitalized interest | 8,490 | 5,995 |
| Supplemental schedule of non-cash investing and financing activities: | | |
| Accrued construction costs | 60,897 | 46,104 |
| Non-cash acquisitions and dispositions settled with receivables and restricted cash held in connection with Section 1031 transactions | 15,570 | 346,745 |
| Tenant funded tenant improvements owned by HCP | 21,085 | 17,552 |
| Vesting of restricted stock units | 527 | 382 |
| Conversion of non-managing member units into common stock | 6,093 | 2,454 |
| Noncontrolling interest and other liabilities, net assumed in connection with the RIDEA III acquisition | — | 61,219 |
| Noncontrolling interest issued in connection with real estate acquisitions | — | 3,885 |
| Mortgage debt and other liabilities assumed with real estate acquisitions | 78,131 | 21,076 |
| Unrealized gains (losses) on available-for-sale securities and derivatives designated as cash flow hedges, net | 1,531 | (647) |

NOTE 16. Variable Interest Entities

On January 1, 2016, the Company adopted ASU 2015-02 using the modified retrospective method as permitted by the ASU. As a result of the adoption, the Company identified additional assets and liabilities of certain VIEs in its consolidated total assets and total liabilities at December 31, 2015 of \$543 million and \$651 million, respectively. Refer to the specific VIE descriptions below for detail on which entities were classified as consolidated VIEs subsequent to the adoption of ASU 2015-02. Additionally, the Company deconsolidated three JVs and recognized \$0.5 million as a cumulative-effect adjustment to cumulative dividends in excess of earnings.

Unconsolidated Variable Interest Entities

At September 30, 2016, the Company had investments in: (i) four unconsolidated VIE JVs, (ii) 358 properties leased to VIE tenants, (iii) marketable debt securities of a VIE and (iv) a loan to a VIE borrower. The Company has determined that it is not the primary beneficiary of and therefore does not consolidate these VIEs because it does not have the ability to control the activities that most significantly impact their economic performance. Except for the Company's equity interest in the unconsolidated JVs (HCRMC, CCRC OpCo, Vintage Park Development JV and the LLC investment discussed below), it has no formal involvement in these VIEs beyond its investments.

Until the completion of the Spin-Off of QCP on October 31, 2016, the Company leased 310 properties to, and had an approximately 9% ownership interest in, HCRMC that was identified as a VIE upon a reconsideration event in the fourth quarter of 2015. HCRMC has experienced continued operational declines and is a "thinly capitalized" entity that relies on the operating cash flows generated from its senior housing and post-acute facilities to fund operating expenses, including the rent obligations under the Amended Master Lease (see Notes 1, 5 and 7).

The Company holds a 49% ownership interest in CCRC OpCo, which operates senior housing properties in a RIDEA structure and has been identified as a VIE (see Note 7). The equity members of CCRC OpCo "lack power" because they share certain operating rights with Brookdale, as manager of the CCRCs. The assets of CCRC OpCo primarily consist of the CCRCs that it owns and leases, resident fees receivable, notes receivable, and cash and cash equivalents; its obligations primarily consist of operating lease obligations to CCRC PropCo, debt service payments and capital expenditures for the properties, and accounts payable and expense accruals associated with the cost of its CCRCs' operations. Assets generated by the CCRC operations (primarily rents from CCRC residents) of CCRC OpCo may only be used to settle its contractual

Table of Contents

obligations (primarily from debt service payments, capital expenditures, and rental costs and operating expenses incurred to manage such facilities).

The Company holds an 85% ownership interest in Vintage Park Development JV (see Note 7), which has been identified as a VIE as power is shared with a member that does not have a substantive equity investment at risk. The assets of Vintage Park Development JV primarily consist of an in-progress independent living facility development project that it owns and cash and cash equivalents; its obligations primarily consist of accounts payable and expense accruals associated with the cost of its development obligations. Any assets generated by Vintage Park Development JV may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

The Company holds a limited partner ownership interest in an unconsolidated LLC that has been identified as a VIE. The Company's involvement in the entity is limited to its equity investment as a limited partner, and it does not have any substantive participating rights or kick-out rights over the managing member. The assets and liabilities of the entity primarily consist of those associated with its senior housing real estate and development activities. Any assets generated by the entity may only be used to settle its contractual obligations (primarily development expenses and debt service payments).

In addition to the properties leased to HCRMC, the Company leases 48 properties to a total of seven tenants that have also been identified as VIEs ("VIE tenants"). These VIE tenants are "thinly capitalized" entities that rely on the operating cash flows generated from the senior housing facilities to pay operating expenses, including the rent obligations under their leases.

The Company holds commercial mortgage-backed securities ("CMBS") issued by Federal Home Loan Mortgage Corporation (commonly referred to as Freddie MAC) through a special purpose entity that has been identified as a VIE because it is "thinly capitalized." The CMBS issued by the VIE are backed by mortgage debt obligations on real estate assets.

The Company holds Four Seasons Notes (see Note 9) and a portion of Four Seasons' senior secured term loan (see Note 6). In the second quarter of 2015, upon the occurrence of a reconsideration event, it was determined that the issuer of the Four Seasons Notes is a VIE because this entity is "thinly capitalized."

The classification of the related assets and liabilities and the maximum loss exposure as a result of the Company's involvement with these VIEs at September 30, 2016 are as follows (in thousands):

| VIE Type | Maximum Loss Exposure(1) | Asset/Liability Type | Carrying Amount |
|--|--------------------------|--|-----------------|
| HCRMC(2) | \$ 5,107,180 | Net investment in DFLs and investments in unconsolidated JVs | \$ 5,107,180 |
| VIE tenants—DFLs(2) | 601,799 | Net investment in DFLs | 601,799 |
| VIE tenants—operating leases(2) | 8,403 | Lease intangibles, net and straight-line rent receivables | 8,403 |
| CCRC OpCo | 224,171 | Investments in unconsolidated JVs | 224,171 |
| Four Seasons Vintage Park Development JV | 8,088 | Investments in unconsolidated JVs | 8,088 |
| CMBS and LLC investment | 33,166 | Marketable debt and cost method investment | 33,166 |

- (1) The Company's maximum loss exposure represents the aggregate carrying amount of such investments (including accrued interest).
- (2) The Company's maximum loss exposure may be mitigated by re-leasing the underlying properties to new tenants upon an event of default.

As of September 30, 2016, the Company has not provided, and is not required to provide, financial support through a liquidity arrangement or otherwise, to its unconsolidated VIEs, including circumstances in which it could be exposed to further losses (e.g., cash shortfalls). See Notes 5, 6, 7 and 9 for additional descriptions of the nature, purpose and operating activities of the Company's unconsolidated VIEs and interests therein.

Table of Contents

Consolidated Variable Interest Entities

RIDEA I. The Company holds a 90% ownership interest in JV entities formed in September 2011 that own and operate senior housing properties in a RIDEA structure (“RIDEA I”). The Company has historically classified RIDEA I OpCo as a VIE and, as a result of the adoption of ASU 2015-02, also classifies RIDEA I PropCo as a VIE due to the non-managing member lacking substantive participation rights in the management of RIDEA I PropCo or kick-out rights over the managing member. The Company consolidates RIDEA I PropCo and RIDEA I OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of RIDEA I PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of notes payable to a non-VIE consolidated subsidiary of the Company. The assets of RIDEA I OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to RIDEA I PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA I structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs).

RIDEA II. The Company holds an 80% ownership interest in JV entities formed in August 2014 that own and operate senior housing properties in a RIDEA structure (“RIDEA II”). The Company consolidates RIDEA II (“SH PropCo” and “SH OpCo”) as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of SH PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a note payable to a non-VIE consolidated subsidiary of the Company. The assets of SH OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to SH PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA II structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs). See Note 4 for additional discussion of pending RIDEA II transactions.

RIDEA III. The Company holds a 90% ownership interest in JV entities formed in June 2015 that own and operate senior housing properties in a RIDEA structure. The Company has historically classified RIDEA III OpCo as a VIE and, as a result of the adoption of ASU 2015-02, also classifies RIDEA III PropCo as a VIE due to the non-managing member lacking substantive participation rights in the management of RIDEA III PropCo or kick-out rights over the managing member. The Company consolidates RIDEA III PropCo and RIDEA III OpCo as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of RIDEA III PropCo primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of a note payable to a non-VIE consolidated subsidiary of the Company. The assets of RIDEA III OpCo primarily consist of leasehold interests in senior housing facilities (operating leases), resident fees receivable, and cash and cash equivalents; its obligations primarily consist of lease payments to RIDEA III PropCo and operating expenses of its senior housing facilities (accounts payable and accrued expenses). Assets generated by the senior housing operations (primarily from senior housing resident rents) of the RIDEA III structure may only be used to settle its contractual obligations (primarily from the rental costs, operating expenses incurred to manage such facilities and debt costs).

HCP Ventures V, LLC. The Company holds a 51% ownership interest in and is the managing member of a JV entity formed in October 2015 that owns and leases MOBs (“HCP Ventures V, LLC”). Upon adoption of ASU 2015-02, the Company classified HCP Ventures V, LLC as a VIE due to the non-managing member lacking substantive participation rights in the management of HCP Ventures V, LLC or kick-out rights over the managing member. The Company consolidates HCP Ventures V, LLC as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of HCP Ventures V, LLC primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; its obligations primarily consist of capital expenditures for the properties. Assets generated by HCP Ventures V, LLC may only be used to settle its contractual obligations (primarily from capital expenditures).

Table of Contents

Vintage Park JV. The Company holds a 90% ownership interest in a JV entity formed in January 2015 that owns an 85% interest in an unconsolidated development VIE (“Vintage Park JV”). Upon adoption of ASU 2015-02, the Company classified Vintage Park JV as a VIE due to the non-managing member lacking substantive participation rights in the management of the Vintage Park JV or kick-out rights over the managing member. The Company consolidates Vintage Park JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIE’s economic performance. The assets of Vintage Park JV primarily consist of an investment in the Vintage Park Development JV and cash and cash equivalents; its obligations primarily consist of funding the ongoing development of the Vintage Park Development JV. Assets generated by the Vintage Park JV may only be used to settle its contractual obligations (primarily from the funding of the Vintage Park Development JV).

DownREITs. The Company holds a controlling ownership interest in and is the managing member of five DownREITs (see Note 12). Upon adoption of ASU 2015-02, the Company classified the DownREITs as VIEs due to the non-managing members lacking substantive participation rights in the management of the DownREITs or kick-out rights over the managing member. The Company consolidates the DownREITs as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the DownREITs primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the DownREITs (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other Consolidated Real Estate Partnerships. The Company holds a controlling ownership interest in and is the general partner (or managing member) of multiple partnerships that own and lease real estate assets (the “Partnerships”). Upon adoption of ASU 2015-02, the Company classified the Partnerships as VIEs due to the limited partners (non-managing members) lacking substantive participation rights in the management of the Partnerships or kick-out rights over the general partner (managing member). The Company consolidates the Partnerships as the primary beneficiary because it has the ability to control the activities that most significantly impact these VIEs’ economic performance. The assets of the Partnerships primarily consist of leased properties (net real estate), rents receivable, and cash and cash equivalents; their obligations primarily consist of debt service payments and capital expenditures for the properties. Assets generated by the Partnerships (primarily from resident rents) may only be used to settle their contractual obligations (primarily from debt service and capital expenditures).

Other consolidated VIEs. The Company made a loan to an entity that entered into a tax credit structure (“Tax Credit Subsidiary”) and a loan to an entity that made an investment in a development JV (“Development JV”) both of which are considered VIEs. The Company consolidates the Tax Credit Subsidiary and Development JV as the primary beneficiary because it has the ability to control the activities that most significantly impact the VIEs’ economic performance. The assets and liabilities of the Tax Credit Subsidiary and Development JV substantially consist of a development in progress, notes receivable, prepaid expenses, notes payable, and accounts payable and accrued liabilities generated from their operating activities. Any assets generated by the operating activities of the Tax Credit Subsidiary and Development JV may only be used to settle their contractual obligations.

NOTE 17. Concentration of Credit Risk

Concentrations of credit risk arise when one or more tenants, operators or obligors related to the Company's investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to the Company, to be similarly affected by changes in economic conditions. The Company regularly monitors various segments of its portfolio to assess potential concentrations of credit risks. The Company does not have significant foreign operations.

Table of Contents

The following tables provide information regarding the Company's concentrations with respect to certain tenants:

| Tenant | Percentage of SH NNN Gross Assets | | Percentage of SH NNN Revenues | | | | |
|-----------|--------------------------------------|----------------------|---|---|---|---|---|
| | September 30, 2016 | December 31, 2015 | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2015 |
| Brookdale | 54 | % 53 | % 60 | % 59 | % 59 | % 58 | % |

| Tenant | Percentage of QCP Gross Assets | | Percentage of QCP Revenues | | | | |
|----------|-----------------------------------|----------------------|---|---|---|---|---|
| | September 30, 2016 | December 31, 2015 | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2015 |
| HCRMC(1) | 96 | % 96 | % 94 | % 95 | % 94 | % 95 | % |

| Tenant | Percentage of Total Company Gross Assets | | Percentage of Total Company Revenues | | | | |
|--------------|---|----------------------|---|---|---|---|---|
| | September 30, 2016 | December 31, 2015 | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2016 | Three Months Ended September 30, 2015 | Three Months Ended September 30, 2015 |
| HCRMC(1) | 24 | % 24 | % 18 | % 21 | % 18 | % 23 | % |
| Brookdale(2) | 13 | % 13 | % 10 | % 9 | % 10 | % 10 | % |

- (1) Subsequent to the Spin-Off on October 31, 2016, the Company's concentration in HCRMC was reduced to less than 10 percent.
- (2) Excludes senior housing facilities operated by Brookdale in the Company's SHOP segment, as discussed below.

As of September 30, 2016 and December 31, 2015, Brookdale managed or operated approximately 13% and 13%, respectively, of the Company's real estate investments based on gross assets. Because an operator manages the Company's facilities in exchange for the receipt of a management fee, the Company is not directly exposed to the credit risk of its operators in the same manner or to the same extent as its triple-net tenants. As of September 30, 2016, Brookdale provided comprehensive facility management and accounting services with respect to 107 of the Company's senior housing facilities and 15 CCRCs owned by the CCRC JV, for which the Company or JV pay annual management fees pursuant to long-term management agreements. Most of the management agreements have terms ranging from 10 to 15 years, with three to four 5-year renewal periods. The base management fees are 4.5% to 5.0% of gross revenues (as defined) generated by the RIDEA facilities. In addition, there are incentive management fees payable to Brookdale if operating results of the RIDEA properties exceed pre-established EBITDAR (as defined) thresholds.

Brookdale is subject to the registration and reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information with the

SEC. The information related to Brookdale contained or referred to in this report has been derived from SEC filings made by Brookdale or other publicly available information, or was provided to the Company by Brookdale, and the Company has not verified this information through an independent investigation or otherwise. The Company has no reason to believe that this information is inaccurate in any material respect, but the Company cannot assure the reader of its accuracy. The Company is providing this data for informational purposes only, and encourages the reader to obtain Brookdale's publicly available filings, which can be found on the SEC's website at www.sec.gov.

To mitigate the credit risk of leasing properties to certain operators, leases with operators are often combined into portfolios that contain cross-default terms, so that if a tenant of any of the properties in a portfolio defaults on its obligations under its lease, the Company may pursue its remedies under the lease with respect to any of the properties in the portfolio. Certain portfolios also contain terms whereby the net operating profits of the properties are combined for the purpose of securing the funding of rental payments due under each lease.

Table of Contents

NOTE 18. Fair Value Measurements

Items Measured at Fair Value on a Recurring Basis

The following table illustrates the Company's financial assets and liabilities measured at fair value on a recurring basis at September 30, 2016 in the consolidated balance sheets (in thousands):

| Financial Instrument | Fair Value | Level 1 | Level 2 | Level 3 |
|--------------------------------|------------|---------|---------|---------|
| Marketable equity securities | \$ 37 | \$ 37 | \$ — | \$ — |
| Interest-rate swap liabilities | 6,558 | — | 6,558 | — |
| Currency swap asset | 2,901 | — | 2,901 | — |
| Warrants | 18 | — | — | 18 |

Recognized gains and losses are recorded in other income (loss), net on the Company's consolidated statements of operations. During the nine months ended September 30, 2016, there were no transfers of financial assets or liabilities within the fair value hierarchy.

Disclosures About Fair Value of Financial Instruments

Cash and cash equivalents, restricted cash, accounts receivable, net, and accounts payable and accrued liabilities – The carrying values are reasonable estimates of fair value because of the short-term maturities of these instruments.

Loans receivable, net and mortgage debt – The fair values are based on discounting future cash flows utilizing current market rates for loans and debt of the same type and remaining maturity.

Marketable debt securities – The fair value is based on quoted prices from inactive markets.

Marketable equity securities and senior unsecured notes – The fair values are based on quoted prices in active markets.

Warrants – The fair value is based on significant unobservable market inputs utilizing standardized derivative pricing models.

Bank line of credit, term loans and other debt – The carrying values are reasonable estimates of fair value because the borrowings are primarily based on market interest rates and the Company's current credit ratings.

Interest-rate swaps – The fair value is based on observable inputs utilizing standardized pricing models that consider forward yield curves and discount rates which are observable in active and inactive markets.

Currency swaps – The fair value is based on observable inputs utilizing standardized pricing models that consider the future value of the currency exchange rates, comprised of current spot and traded forward points, and calculating a present value of the net amount using discount rates based on observable traded interest rates.

Table of Contents

The following table summarizes the carrying values and fair values of the Company's financial instruments (in thousands):

| | September 30, 2016 | | December 31, 2015 | |
|-----------------------------------|--------------------|------------|-------------------|------------|
| | Carrying Value | Fair Value | Carrying Value | Fair Value |
| Loans receivable, net(2) | \$ 682,994 | \$ 688,804 | \$ 768,743 | \$ 770,052 |
| Marketable debt securities(2) | 82,081 | 82,081 | 102,958 | 102,958 |
| Marketable equity securities(1) | 37 | 37 | 39 | 39 |
| Warrants(3) | 18 | 18 | 55 | 55 |
| Bank line of credit(2) | 1,372,032 | 1,372,032 | 397,432 | 397,432 |
| Term loans(2) | 462,181 | 462,181 | 524,807 | 524,807 |
| Senior unsecured notes(1) | 8,229,731 | 8,737,688 | 9,120,107 | 9,390,668 |
| Mortgage debt(2) | 762,715 | 813,236 | 932,212 | 963,786 |
| Other debt(2) | 93,876 | 93,876 | 94,445 | 94,445 |
| Interest-rate swap assets(2) | — | — | 196 | 196 |
| Interest-rate swap liabilities(2) | 6,558 | 6,558 | 6,251 | 6,251 |
| Currency swap asset(2) | 2,901 | 2,901 | 1,551 | 1,551 |

- (1) Level 1: Fair value calculated based on quoted prices in active markets.
(2) Level 2: Fair value based on quoted prices for similar or identical instruments in active or inactive markets, respectively, or calculated utilizing standardized pricing models in which significant inputs or value drivers are observable in active markets.
(3) Level 3: Fair value determined based on significant unobservable market inputs using standardized derivative pricing models.

NOTE 19. Derivative Financial Instruments

The following table summarizes the Company's outstanding interest-rate and foreign currency swap contracts as of September 30, 2016 (dollars and British pound sterling ("GBP") in thousands):

| Date Entered | Maturity Date | Hedge Designation | Fixed Rate/Buy Amount | Floating/Exchange Rate Index | Notional/Sell Amount | Fair Value(1) |
|------------------|---------------|-------------------|-----------------------|------------------------------|----------------------|---------------|
| Interest rate: | | | | | | |
| July 2005(2) | July 2020 | Cash Flow | 3.82 % | BMA Swap Index | \$ 44,700 | \$ (4,643) |
| November 2008(3) | October 2016 | Cash Flow | 5.95 % | 1 Month LIBOR+1.50% | \$ 24,600 | \$ (35) |
| January 2015(4) | October 2017 | Cash Flow | 1.79 % | 1 Month GBP LIBOR+0.975% | £ 220,000 | \$ (1,880) |

Foreign currency:

| | | | | | | |
|-----------------|--------------|-----------|-----------|------------------|----------|----------|
| January 2015(5) | October 2017 | Cash Flow | \$ 20,700 | Buy USD/Sell GBP | £ 13,700 | \$ 2,901 |
|-----------------|--------------|-----------|-----------|------------------|----------|----------|

- (1) Derivative assets are recorded in other assets, net and derivative liabilities are recorded in accounts payable and accrued liabilities on the consolidated balance sheets.
- (2) Represents three interest-rate swap contracts, which hedge fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.
- (3) Represents an interest-rate swap contract, which hedges fluctuations in interest payments on variable-rate secured debt due to overall changes in hedged cash flows.
- (4) Hedges fluctuations in interest payments on variable-rate unsecured debt due to fluctuations in the underlying benchmark interest rate.
- (5) Currency swap contract (buy USD/sell GBP) hedges the foreign currency exchange risk related to the Company's forecasted GBP denominated interest receipts on its HC-One Facility. Represents a currency swap to sell approximately £1.0 million monthly at a rate of 1.5149 through October 2017.

The Company uses derivative instruments to mitigate the effects of interest rate and foreign currency fluctuations on specific forecasted transactions as well as recognized financial obligations or assets. Utilizing derivative instruments allows the Company to manage the risk of fluctuations in interest and foreign currency rates related to the potential impact these changes could have on future earnings and forecasted cash flows. The Company does not use derivative instruments for speculative or trading purposes.

The primary risks associated with derivative instruments are market and credit risk. Market risk is defined as the potential for loss in value of a derivative instrument due to adverse changes in market prices. Credit risk is the risk that one of the

Table of Contents

parties to a derivative contract fails to perform or meet its financial obligation. The Company does not obtain collateral associated with its derivative contracts, but monitors the credit standing of its counterparties on a regular basis. Should a counterparty fail to perform, the Company would incur a financial loss to the extent that the associated derivative contract was in an asset position. At September 30, 2016, the Company does not anticipate non-performance by the counterparties to its outstanding derivative contracts.

As of September 30, 2016, the Company has £268 million of its GBP-denominated borrowings under the Facility and 2012 Term Loan designated as a hedge of a portion of the Company's net investments in GBP-functional subsidiaries to mitigate its exposure to fluctuations in the GBP to USD exchange rate. For instruments that are designated and qualify as net investment hedges, the variability in the foreign currency to USD exchange rate of the instrument is recorded as part of the cumulative translation adjustment component of accumulated other comprehensive income (loss). Accordingly, the remeasurement value of the designated £268 million GBP-denominated borrowings due to fluctuations in the GBP to USD exchange rate are reported in accumulated other comprehensive income (loss) as the hedging relationship is considered to be effective. The cumulative balance of the remeasurement value will be reclassified to earnings when the hedged investment is sold or substantially liquidated.

During the three and nine months ended September 30, 2016, the Company determined a portion of a cash flow hedge was ineffective and reclassified \$0.1 million and \$0.4 million, respectively, of unrealized gains related to this interest-rate swap contract into other income (loss), net during each of the respective periods. The Company expects that the hedged forecasted transactions for each of the outstanding qualifying cash flow hedging relationships at September 30, 2016 remain probable of occurring and, as a result, no additional gains or losses recorded to accumulated other comprehensive loss are expected to be reclassified to earnings for any other outstanding hedges.

To illustrate the effect of movements in interest rates and foreign currency markets, the Company performed a market sensitivity analysis on its outstanding derivative financial instruments. The Company applied various basis point spreads to the underlying interest rate curves and foreign currency exchange rates of the derivative portfolio in order to determine the instruments' change in fair value. The following table summarizes the results of the analysis performed (dollars in thousands):

| Date Entered | Maturity Date | Effects of Change in Interest and Foreign Currency Rates | | | |
|-------------------|---------------|--|------------------|-------------------|-------------------|
| | | +50 Basis Points | -50 Basis Points | +100 Basis Points | -100 Basis Points |
| Interest rate: | | | | | |
| July 2005 | July 2020 | \$ 884 | \$ (722) | \$ 1,686 | \$ (1,524) |
| November 2008 | October 2016 | 2 | (7) | 7 | (12) |
| January 2015 | October 2017 | 1,566 | (1,524) | 3,110 | (3,069) |
| Foreign currency: | | | | | |
| January 2015 | October 2017 | (28) | 149 | (117) | 238 |

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

All references in this report to "HCP," "we," "us" or "our" mean HCP, Inc., together with its consolidated subsidiaries.

Cautionary Language Regarding Forward-Looking Statements

Statements in this Quarterly Report on Form 10-Q that are not historical factual statements are "forward-looking statements." We intend to have our forward-looking statements covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include this statement for purposes of complying with those provisions. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negative thereof. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and reasonable assumptions based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this Quarterly Report, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. As more fully set forth under Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and Part II, Item 1A. "Risk Factors" in our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016, risks and uncertainties that may cause our actual results to differ materially from the expectations contained in the forward-looking statements include, among other things:

- our reliance on a concentration of a small number of tenants and operators for a significant portion of our revenues, with our concentration in Brookdale increasing as a result of the consummation of the Spin-Off of QCP on October 31, 2016;
- the financial condition of our existing and future tenants, operators and borrowers, including potential bankruptcies and downturns in their businesses, and their legal and regulatory proceedings, which results in uncertainties regarding our ability to continue to realize the full benefit of such tenants' and operators' leases and borrowers' loans;
- the ability of our existing and future tenants, operators and borrowers to conduct their respective businesses in a manner sufficient to maintain or increase their revenues and to generate sufficient income to make rent and loan payments to us and our ability to recover investments made, if applicable, in their operations;
- competition for tenants and operators, including with respect to new leases and mortgages and the renewal or rollover of existing leases;
- competition for skilled management and other key personnel;
- availability of suitable properties to acquire at favorable prices and the competition for the acquisition and financing of those properties;
- our ability to negotiate the same or better terms with new tenants or operators if existing leases are not renewed or we exercise our right to replace an existing tenant or operator upon default;
- the risks associated with our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners' financial condition and continued cooperation;

- our ability to achieve the benefits of investments within expected time frames or at all, or within expected cost projections;
- the potential impact on us, our tenants, operators and borrowers from current and future litigation matters, including the possibility of larger than expected litigation costs, adverse results and related developments;
- the effect on our tenants and operators of legislation and other legal requirements, including licensure, certification and inspection requirements, and laws addressing entitlement programs and related services, including Medicare and Medicaid, which may result in future reductions in reimbursements;

Table of Contents

- changes in federal, state or local laws and regulations, including those affecting the healthcare industry that affect our costs of compliance or increase the costs, or otherwise affect the operations, of our tenants and operators;
- volatility or uncertainty in the capital markets, the availability and cost of capital as impacted by interest rates, changes in our credit ratings, and the value of our common stock, and other conditions that may adversely impact our ability to fund our obligations or consummate transactions, or reduce the earnings from potential transactions;
- changes in global, national and local economic conditions, and currency exchange rates;
- our ability to manage our indebtedness level and changes in the terms of such indebtedness; and
- our ability to maintain our qualification as a real estate investment trust (“REIT”).

Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

The information set forth in this Item 2 is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations. We will discuss and provide our analysis in the following order:

- Executive Summary
- 2016 Transaction Overview
- Dividends
- Results of Operations
- Liquidity and Capital Resources
- Contractual Obligations
- Off-Balance Sheet Arrangements
- Inflation
- Non-GAAP Financial Measures Reconciliations
- Critical Accounting Policies
- Recent Accounting Pronouncements

Executive Summary

HCP, Inc., a Standard & Poor’s (“S&P”) 500 company, invests primarily in real estate serving the healthcare industry in the United States. We are a Maryland corporation organized in 1985 and qualify as a self-administered REIT. We acquire, develop, lease, manage and dispose of healthcare real estate, and provide financing to healthcare providers. At September 30, 2016, our portfolio of investments, including properties in our unconsolidated joint ventures (“JVs”), consisted of interests in 1,198 properties.

We invest and manage our real estate portfolio for the long-term to maximize the benefit to our stockholders and support the growth of our dividends. The core elements of our strategy are: (i) to acquire, develop, lease, own and manage a diversified portfolio of quality healthcare properties across multiple business segments and geographic

locations (including Europe), (ii) to align ourselves with leading healthcare companies, operators and service providers, which over the long-term should result in higher relative rental rates, net operating cash flows and appreciation of property values, (iii) to allocate capital targeting a balanced portfolio between longer-term escalating triple-net leases with high-quality tenants, and operating businesses with shorter-term leases in our medical office and life science segments, (iv) to maintain adequate liquidity with long-term fixed rate debt financing with staggered maturities, which supports the longer-term nature of our investments, while reducing our exposure to interest rate volatility and refinancing risk at any point in the interest rate or credit cycles and (v) to continue to manage our balance sheet with a targeted financial leverage of 40% relative to our assets.

Table of Contents

We believe that our longer-term escalating triple-net leases with larger tenants and operators having scale enhance the quality, stability and growth of our rental income. Further, we believe many of our existing properties hold the potential for increased future cash flows as they are well maintained and in desirable locations within markets where the creation of new supply is limited by the lack of available sites and the difficulty of obtaining the necessary licensing, other approvals and/or financing. Our strategy for maximizing the benefits from these opportunities is to: (i) work with new or existing tenants and operators to address their space and capital needs, and (ii) provide high-quality property management services in order to motivate tenants to renew, expand or relocate into our properties.

The delivery of healthcare services requires real estate and, as a result, tenants and operators depend on real estate, in part, to maintain and grow their businesses. We believe that the healthcare real estate market provides investment opportunities due to the: (i) compelling long-term demographics driving the demand for healthcare services, (ii) specialized nature of healthcare real estate investing and (iii) ongoing consolidation of the fragmented healthcare real estate sector.

While we emphasize healthcare real estate ownership, we may also provide real estate secured financing to, or invest in equity or debt securities of, healthcare operators or other entities engaged in healthcare real estate ownership. We may also acquire all or substantially all of the securities or assets of other REITs, operating companies or similar entities where such investments would be consistent with our investment strategies. We may co-invest alongside institutional or development investors through partnerships or limited liability companies.

We monitor, but do not limit, our investments based on the percentage of our total assets that may be invested in any one property type, investment vehicle or geographic location, the number of properties that may be leased to a single tenant or operator, or loans that may be made to a single borrower. In allocating capital to our multiple segments, we target opportunities with the most attractive risk/reward profile for our portfolio as a whole. We may take additional measures to mitigate risk, including diversifying our investments (by sector, geography, tenant or operator), structuring transactions as master leases, requiring tenant or operator insurance and indemnifications, and obtaining credit enhancements in the form of guarantees, letters of credit or security deposits.

Our REIT qualification requires us to distribute at least 90% of our REIT taxable income (excluding net capital gains); therefore, we do not retain capital. As a result, we regularly access the public equity and debt markets to raise the funds necessary to finance acquisitions and debt investments, develop and redevelop properties, and refinance maturing debt.

We maintain a disciplined balance sheet by actively managing our debt to equity levels and maintaining multiple sources of liquidity, such as our revolving line of credit facility, access to capital markets and secured debt lenders, relationships with current and prospective institutional JV partners, and our ability to divest assets. Our debt obligations are primarily long-term fixed rate with staggered maturities, which reduces the impact of rising interest rates on our operations.

We finance our investments based on our evaluation of available sources of funding. For short-term purposes, we may utilize our revolving line of credit facility or arrange for other short-term borrowings from banks or other sources. We arrange for longer-term financing by offering debt and equity securities, placing mortgage debt and obtaining capital from institutional lenders and JV partners.

42

Table of Contents

2016 Transaction Overview

HCR ManorCare, Inc.

Spin-Off of Real Estate Portfolio

On October 31, 2016, we completed our previously announced spin-off (the “Spin-Off”) of our subsidiary, Quality Care Properties, Inc. (“QCP”) (NYSE:QCP). QCP’s assets include 338 properties, primarily comprised of the HCR ManorCare, Inc. (“HCRMC”) direct financing lease (“DFL”) investments and an equity investment in HCRMC. Following the completion of the Spin-Off on October 31, 2016, QCP is an independent, publicly-traded, self-managed and self-administrated REIT.

We entered into a Separation and Distribution Agreement (the “Separation and Distribution Agreement”) with QCP in connection with the Spin-Off. The Separation and Distribution Agreement divides and allocates the assets and liabilities of HCP prior to the Spin-Off between QCP and HCP, governs the rights and obligations of the parties regarding the Spin-Off, and contains other key provisions relating to the separation of QCP’s business from HCP.

In connection with the Spin-Off, we have entered into a Transition Services Agreement (“TSA”) with QCP. Per the terms of the TSA, we have agreed to provide certain administrative and support services to QCP on a transitional basis for established fees, which are expected to approximate the actual cost incurred by us in providing the transition services to QCP for the relevant period. The TSA provides that QCP generally has the right to terminate a transition service upon thirty days’ notice to us. The TSA contains provisions under which we will, subject to certain limitations, be obligated to indemnify QCP for losses incurred by QCP resulting from our breach of the TSA.

See Note 1 to the Consolidated Financial Statements for further information on the Spin-Off.

Third Quarter Operating Performance

For the third quarter of 2016, HCRMC reported normalized EBITDAR (defined as earnings before interest, taxes, depreciation and amortization, and rent) of \$119 million, bringing the year-to-date total to \$382 million. On a year-over-year basis, normalized EBITDAR decreased \$8 million, or 6% for the quarter, and decreased \$38 million or 9% year-to-date, primarily due to a weaker flu season, continued pressure from payor mix shift and shorter lengths of stay. HCRMC’s normalized fixed charge coverage ratio for the trailing twelve months ended September 30, 2016 was 1.02x and for the trailing three months ended September 30, 2016 was 0.98x.

HCRMC ended the quarter with \$164 million of cash and cash equivalents and continues to be current on its obligations under the amended master lease we entered into with HCRMC in March 2015.

Second Quarter Operating Performance

For the second quarter of 2016, HCRMC reported normalized EBITDAR of \$132 million, bringing the year-to-date total to \$263 million. On a year-over-year basis, normalized EBITDAR decreased \$14 million, or 10% for the quarter, and decreased \$41 million or 13% year-to-date, primarily due to a weaker flu season, continued pressure from payor mix shift and shorter lengths of stay. HCRMC's normalized fixed charge coverage ratio for the trailing twelve months ended June 30, 2016 was 1.03x and for the trailing three months ended June 30, 2016 was 1.08x.

First Quarter Operating Performance

For the first quarter of 2016, HCRMC reported normalized EBITDAR of \$131 million, which was up \$22 million, or 20% sequentially, driven by a 110 basis point increase in core post-acute/skilled nursing occupancy. On a year-over-year basis, normalized EBITDAR decreased \$27 million, or 17%, primarily due to a weaker flu season, continued pressure from payor mix shift, and shorter lengths of stay, as well as transaction costs and operational disruption from the non-strategic asset sales. HCRMC's normalized fixed charge coverage ratio for the trailing twelve months ended March 31, 2016 was 1.06x and for the trailing three months ended March 31, 2016 was 1.11x.

Table of Contents

Transaction Activity

During the nine months ended September 30, 2016, we completed 11 of our planned 50 non-strategic asset sales, generating proceeds of \$62 million, bringing total anticipated sales proceeds from all 50 assets to \$350 million, including our sales of 22 non-strategic asset in 2015. Of the 17 remaining non-strategic facilities, seven are expected to close by the end of 2016 and 10 are expected to be sold in the first quarter of 2017, for an aggregate amount of \$62 million. In addition, we completed the final transfer of the nine assets that were part of the HCRMC master lease amendment representing \$275 million of value received in the fee ownership of these recently built post-acute assets, by acquiring the remaining two assets for \$92 million during the three months ended March 31, 2016.

In February 2016, we acquired a new 64-bed memory care facility in Easton, Pennsylvania for \$15 million that opened in January 2016, which is located adjacent to our existing post-acute asset. The facility was developed by HCRMC and was added to its master lease with a term of 16 years.

Accounting and Income Tax Update

We acquired the HCRMC DFL investments in 2011 through an acquisition of a C-Corporation, which was subject to federal and state built-in gain tax, if all the assets were sold within 10 years, of up to \$2 billion. At the time of the acquisition, we intended to hold the assets for at least 10 years, at which time the assets would no longer be subject to the built-in gain tax.

In December 2015, the U.S. Federal Government passed legislation which permanently reduced the holding period, for federal tax purposes, to five years. We satisfied the five year holding period requirement in April 2016. In June 2016, the U.S. Department of the Treasury issued proposed regulations that would change the holding period back to 10 years, but effective only for conversion transactions after August 8, 2016. As currently proposed, these regulations will not impact our properties in the HCRMC DFL, as the HCRMC conversion transaction occurred on April 7, 2011. However, certain states still require a 10-year holding period and, as such, the assets are still subject to state built-in gain tax.

During the nine months ended September 30, 2016, the Company determined that it may sell assets during the next five years and, therefore, recorded a deferred tax liability of \$47 million representing its estimated exposure to state built-in gain tax.

See Notes 1, 5, 6, 7, 10, 11 and 17 to the Consolidated Financial Statements for additional discussion of HCRMC, which information is incorporated by reference herein.

Investment Transactions

In January 2016, we acquired a portfolio of five private pay senior housing communities with 364 units and one skilled nursing facility with 120 beds for \$95 million. All of the communities were developed within the past two years and are triple-net leased to four regional operators.

In July 2016, we acquired two Class A life science buildings totaling 136,000 square feet and a four-acre parcel of land in San Diego, California for \$49 million.

In September 2016, we acquired a portfolio of seven private pay senior housing communities for \$186 million, including the assumption of \$74 million of debt maturing in 2044 at a 4.0% interest rate. Consisting of 526 assisted living and memory care units, the portfolio will be managed by Senior Lifestyle Corporation in a 100% owned RIDEA structure which is permitted by the Housing and Economic Recovery Act of 2008 (commonly referred to as "RIDEA").

Developments and Redevelopments

Through November 1, 2016, we have pre-leased 73% of The Cove Phase I, which consists of two Class A buildings totaling up to 250,000 square feet, expected to be delivered in the third quarter of 2016. In response to Phase I leasing success and continued strong demand from life science users in South San Francisco, in February 2016, we commenced the \$215 million development, The Cove Phase II, which adds two Class A buildings totaling up to 230,000 square feet expected to be delivered by the third quarter of 2017. Through November 1, 2016, we have pre-leased 50% of The Cove Phase II. In response to The Cove Phase I and Phase II leasing success and continued strong demand from life science users in South

Table of Contents

San Francisco, we are commencing the \$211 million development of Phase III, which adds two Class A buildings representing up to 336,000 square feet.

In June 2016, we commenced a \$62 million multi-building development project encompassing 301,000 square feet at our Ridgeview Business Park in Poway, California, which is 50% pre-leased. The project includes a \$32 million build-to-suit totaling 152,000 square feet for an existing tenant and is expected to be completed in 2018 as part of a larger leasing transaction.

Disposition Transactions

During the nine months ended September 30, 2016, we sold five post-acute/skilled nursing and two senior housing triple-net (“SH NNN”) facilities for \$130 million, a life science facility for \$74 million, three medical office buildings for \$20 million and a senior housing operating portfolio (“SHOP”) facility for \$6 million and recognized total gain on sales of \$120 million.

In October 2016, we sold seven SH NNN facilities for \$88 million. As part of the sale transaction we provided a \$10 million mezzanine loan with a five year term which accrues interest at 9%. Concurrently, we modified the in-place NNN master lease to transition the operations of the remaining three properties to a new regional operator.

In October 2016, we entered into definitive agreements to sell 64 assets, currently under triple-net leases with Brookdale for \$1.125 billion to affiliates of Blackstone Real Estate Partners VIII L.P. The closing of this transaction is expected to occur in the first quarter of 2017 and remains subject to regulatory and third party approvals and other customary closing conditions. Additionally, in October 2016, we entered into definitive agreements for a multi-element transaction with Brookdale to: (i) sell or transition 25 assets currently triple-net leased to Brookdale, for which Brookdale will receive a \$10.5 million annualized rent reduction upon sale or transition, (ii) re-allocate annual rent of \$9.6 million from those 25 assets to the remaining Brookdale triple-net lease portfolio and (iii) transition eight triple-net leased assets into RIDEA structures. The closing of these transactions is expected to occur during the fourth quarter of 2016 and throughout 2017 and remain subject to regulatory and third party approvals and other customary closing conditions.

In June 2016 and September 2016, we entered into a definitive agreements to sell two SHOP facilities out of RIDEA III for \$22 million (sold in October 2016) and \$13 million, respectively. The remaining SHOP facility is expected to close in the fourth quarter of 2016.

In June 2016 and September 2016, we received \$51 million and \$16 million from the monetization of three senior housing development loans, recognizing \$15 million and \$4 million of incremental interest income, respectively, which represents our participation in the appreciation of the underlying real estate assets.

In July 2016, we entered into a definitive agreement to sell four life science facilities in Salt Lake City, Utah for \$76 million. This transaction is expected to close in the first quarter of 2017.

In May 2016, we entered into a master contribution agreement with Brookdale to contribute our ownership interest in RIDEA II to an unconsolidated JV owned by HCP and an investor group led by Columbia Pacific Advisors, LLC (“CPA”) (the “HCP/CPA JV”). The members have also agreed to recapitalize RIDEA II with an estimated \$630 million of debt, of which an estimated \$365 million will be provided by a third-party and an estimated \$265 million will be provided by HCP. In return, we will receive an estimated \$470 million in cash proceeds from the HCP/CPA JV and an estimated \$265 million in note receivables and retain an approximately 40% beneficial interest in RIDEA II (the note receivable and 40% beneficial interest are herein referred to as the “RIDEA II Investments”). This transaction, upon completion, would result in HCP deconsolidating the net assets of RIDEA II because it will not direct the activities that most significantly impact the venture. The closing of these transactions is expected to occur in the fourth quarter of 2016 and remains subject to regulatory and third-party approvals and other customary closing conditions.

In January 2016, we entered into a definitive agreement for purchase options that were exercised on eight life science facilities in South San Francisco, California, to be sold in two tranches for \$311 million and \$269 million, respectively. These transactions are expected to close in the fourth quarter of 2016 for the first tranche and 2018 for the second tranche.

Table of Contents

Financing Activities

In September 2016, we repaid \$400 million of maturing senior unsecured notes and assumed \$74 million of mortgage debt maturing in 2044 at a 4.0% interest rate.

In July 2016, we exercised a one-year extension option on our £137 million (\$178 million at September 30, 2016), four-year unsecured term loan that was entered into on July 30, 2012 (the “2012 Term Loan”). Based on our credit ratings at September 30, 2016, the 2012 Term Loan accrues interest at a rate of British pound sterling (“GBP”) LIBOR plus 1.40%.

In February 2016, we repaid \$500 million of maturing senior unsecured notes.

Dividends

On October 31, 2016, we announced that our Board of Directors declared a quarterly common stock cash dividend of \$0.37 per share. The common stock dividend will be paid on November 25, 2016 to stockholders of record as of the close of business on November 10, 2016.

Results of Operations

We evaluate our business and allocate resources among our reportable business segments: (i) senior housing triple-net (SH NNN), (ii) senior housing operating portfolio (SHOP), (iii) life science, (iv) medical office and (v) QCP. Under the medical office segment, we invest through the acquisition and development of medical office buildings (“MOBs”), which generally require a greater level of property management. Otherwise, we primarily invest, through the acquisition and development of real estate, in single tenant and operator properties. We have other non-reportable segments that are comprised primarily of our U.K. care homes, debt investments and hospitals. We evaluate performance based upon (i) property net operating income from continuing operations (“NOI”) and (ii) adjusted NOI (cash NOI) of the combined consolidated and unconsolidated investments in each segment.

Non-GAAP Financial Measures

Net Operating Income (“NOI”)

NOI and adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. We include properties from our consolidated portfolio, as well as our pro-rata share of properties owned by our unconsolidated joint ventures in our NOI and adjusted NOI. We believe providing this information assists investors and analysts in estimating the economic interest in our total portfolio of real estate. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of revenues and expenses included in NOI (see below) do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

The presentation of pro-rata information has limitations, which include, but are not limited to, the following (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro-rata financial information as a supplement.

Table of Contents

NOI is defined as rental and related revenues, including tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss) as presented in Note 13 to the Consolidated Financial Statements. Management believes NOI provides relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unleveraged basis. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, non-refundable entrance fees and lease termination fees (“non-cash adjustments”). Adjusted NOI is oftentimes referred to as “cash NOI.” We use NOI and adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our same property portfolio (“SPP”), as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Further, our definition of NOI may not be comparable to the definition used by other REITs or real estate companies, as they may use different methodologies for calculating NOI. For a reconciliation of NOI and Adjusted NOI to net income (loss) by segment, refer to Note 13 to the Consolidated Financial Statements.

Operating expenses generally relate to leased medical office and life science properties and senior housing RIDEA properties. We generally recover all or a portion of our leased medical office and life science property expenses through tenant recoveries. We present expenses as operating or general and administrative based on the underlying nature of the expense. Periodically, we review the classification of expenses between categories and make revisions based on changes in the underlying nature of the expenses.

Same Property Portfolio

SPP NOI and adjusted NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in our SPP NOI and adjusted NOI (see NOI above for further discussion regarding our use of pro-rata share information and its limitations). We identify our SPP as stabilized properties that remained in operations and were consistently reported as leased properties or RIDEA properties for the duration of the year-over-year comparison periods presented, excluding assets held for sale. Accordingly, it takes a stabilized property a minimum of 12 months in operations under a consistent reporting structure to be included in our SPP. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. SPP NOI excludes (i) certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis and (ii) entrance fees and related activity such as deferred expenses, reserves and management fees related to entrance fees. A property is removed from our SPP when it is sold, placed into redevelopment or changes its reporting structure. For a reconciliation of SPP to total portfolio adjusted NOI and other relevant disclosures by segment, refer to our Segment Analysis below.

Funds From Operations (“FFO”)

We believe FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.

FFO, as defined by the National Association of Real Estate Investment Trusts (“NAREIT”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other depreciation and amortization, and adjustments to compute our share of FFO and FFO as adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity

Table of Contents

by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of reconciling items included in FFO (see above) do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.

The presentation of pro-rata information has limitations which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting or allocating noncontrolling interests, and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses; and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro-rata financial information as a supplement. FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute FFO in accordance with the current NAREIT definition; however, other REITs may report FFO differently or have a different interpretation of the current NAREIT definition from ours.

In addition, we present FFO before the impact of non-comparable items including, but not limited to, severance-related charges, litigation settlement charges, preferred stock redemption charges, impairments (recoveries) of non-depreciable assets, prepayment costs (benefits) associated with early retirement or payment of debt, foreign currency remeasurement losses (gains) and transaction-related items (“FFO as adjusted”). Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Transaction-related items include acquisition and pursuit costs (e.g., due diligence and closing) and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Management believes that FFO as adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors and other interested parties in the evaluation of our performance as a REIT. At the same time that NAREIT created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes, in addition to adjustments made to arrive at the NAREIT defined measure of FFO, other adjustments to net income (loss). FFO as adjusted is used by management in analyzing our business and the performance of our properties, and we believe it is important that stockholders, potential investors and financial analysts understand this measure used by management. We use FFO as adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO

measure, and accordingly, our FFO as adjusted may not be comparable to those reported by other REITs. For a reconciliation of net income (loss) to FFO and FFO as adjusted and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.

Funds Available for Distribution (“FAD”)

FAD is defined as FFO as adjusted after excluding the impact of the following: (i) amortization of acquired market lease intangibles, net, (ii) amortization of deferred compensation expense, (iii) amortization of deferred financing costs, net, (iv) straight-line rents, (v) non-cash interest and depreciation related to DFLs and lease incentive amortization (reduction of straight-line rents) and (vi) deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their

Table of Contents

contractual rents. Also, FAD: (i) is computed after deducting recurring capital expenditures, including leasing costs and second generation tenant and capital improvements, and (ii) includes lease restructure payments and adjustments to compute our share of FAD from our unconsolidated joint ventures and those related to CCRC non-refundable entrance fees. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FAD for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FAD to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (see FFO above for further disclosure regarding our use of pro-rata share information and its limitations). Other REITs or real estate companies may use different methodologies for calculating FAD, and accordingly, our FAD may not be comparable to those reported by other REITs. Although our FAD computation may not be comparable to that of other REITs, management believes FAD provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. We believe FAD is an alternative run-rate earnings measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods and (iii) results among REITS more meaningful. FAD does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, (iv) severance-related expenses and (v) actual cash receipts from interest income recognized on loans receivable (in contrast to our FAD adjustment to exclude non-cash interest and depreciation related to our investments in direct financing leases). Furthermore, FAD is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. FAD is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP. For a reconciliation of net income (loss) to FAD and other relevant disclosure, refer to “Non-GAAP Financial Measures Reconciliations” below.

Comparison of the Three Months Ended September 30, 2016 to the Three Months Ended September 30, 2015 and the Nine Months Ended September 30, 2016 to the Nine Months Ended September 30, 2015

Overview

Three Months Ended September 30, 2016 and 2015

The following table summarizes results for the three months ended September 30, 2016 and 2015 (dollars in thousands except per share data):

| | Three Months Ended September 30, 2016 | | Three Months Ended September 30, 2015 | | Per Share Change |
|--|--|-----------|--|-----------|------------------------|
| | Amount | Per Share | Amount | Per Share | |
| Net income applicable to common shares | \$ 150,924 | \$ 0.32 | \$ 115,046 | \$ 0.25 | \$ 0.07 |
| FFO | 304,387 | 0.65 | 263,370 | 0.57 | 0.08 |

Edgar Filing: HCP, INC. - Form 10-Q

| | | | | | |
|-----------------|---------|------|---------|------|--------|
| FFO as adjusted | 336,513 | 0.72 | 365,800 | 0.79 | (0.07) |
| FAD | 317,540 | | 309,946 | | |

Earnings per share (“EPS”) and FFO increased \$0.07 and \$0.08 per share, respectively, primarily as a result of: (i) impairment charges during the third quarter of 2015 not repeated in the third quarter of 2016 and (ii) increased NOI from: (a) annual rent escalations, (b) our third and fourth quarter 2015 and year-to-date 2016 consolidated acquisitions and (c) developments placed in service. The increase in EPS was partially offset by: (i) a reduction in income from our HCRMC investments as a result of the sale of non-strategic assets during the second half of 2015 and the first half of 2016 and a change in income recognition to a cash basis method beginning in January 2016, (ii) increased acquisition and pursuit costs from the Spin-Off and (iii) severance-related charges primarily related to the departure of our former President and Chief Executive Officer.

FFO as adjusted decreased \$0.07 per share primarily as a result of a reduction in income from our HCRMC investments due to the sale of non-strategic assets during the second half of 2015 and the first half of 2016 and a change in income

Table of Contents

recognition to a cash basis method beginning in January 2016, partially offset by increased NOI from: (i) annual rent escalations, (ii) our third and fourth quarter 2015 and year-to-date 2016 consolidated acquisitions and (iii) developments placed in service.

FAD increased primarily as a result of increased adjusted NOI from: (i) annual rent escalations, (ii) our third and fourth quarter 2015 and year-to-date 2016 consolidated acquisitions and (iii) developments placed in service. The increase in FAD was partially offset by a reduction in lease restructure payments received from our 2014 transaction with Brookdale.

Nine Months Ended September 30, 2016 and 2015

The following table summarizes results for the nine months ended September 30, 2016 and 2015 (dollars in thousands except per share data):

| | Nine Months Ended September 30, 2016 | | Nine Months Ended September 30, 2015 | | Per Share Change |
|--|---|-----------|---|-----------|------------------------|
| | Amount | Per Share | Amount | Per Share | |
| Net income applicable to common shares | \$ 568,109 | \$ 1.22 | \$ 38,613 | \$ 0.08 | \$ 1.14 |
| FFO | 956,864 | 2.05 | 447,838 | 0.97 | 1.08 |
| FFO as adjusted | 1,006,166 | 2.15 | 1,095,234 | 2.36 | (0.21) |
| FAD | 964,437 | | 948,257 | | |

EPS increased \$1.14 per share primarily as a result of: (i) impairment charges during 2015 not repeated in 2016, (ii) increased NOI from: (a) annual rent escalations, (b) our 2015 and 2016 consolidated acquisitions, (c) developments placed in service, (iii) increased gains on sales of real estate due to a higher volume of disposition activities during 2016, (iv) a net termination fee recognized in 2015 not repeated in 2016 and (v) increased incremental interest income from the payoff of participating development loans. The increase in EPS was partially offset by the following: (i) a reduction in income from our HCRMC investments as a result of the HCRMC lease amendment effective April 1, 2015, the sale of non-strategic assets during the second half of 2015 and the first half of 2016, and a change in income recognition to a cash basis method beginning in January 2016, (ii) increased income tax expense related to our estimated exposure to state built-in gain tax, (iii) increased depreciation and amortization from our 2015 and 2016 acquisitions, (iv) a reduction in interest income from placing our Four Seasons senior notes ("Four Seasons Notes") on cost recovery status in the third quarter of 2015 (see Note 9 to the Consolidated Financial Statements) and loan repayments during 2015 and 2016, (v) increased severance-related charges during 2016 and (vi) a reduction of foreign currency remeasurement gains recognized as a result of effective hedges designated in September 2015 (see Note 19 to the Consolidated Financial Statements).

FFO increased \$1.08 per share primarily as a result of the aforementioned events impacting EPS plus increased depreciation and amortization, partially offset by gains on sales of real estate, both of which are adjustments from our

calculation of FFO.

FFO as adjusted decreased \$0.21 per share primarily as a result of: (i) a reduction in income from our HCRMC investments as a result of the HCRMC lease amendment effective April 1, 2015, the sale of non-strategic assets during the second half of 2015 and the first quarter of 2016, and a change in income recognition to a cash basis method beginning in January 2016 and (ii) a reduction in interest income from placing our Four Seasons Notes on cost recovery status in the third quarter of 2015 and loan repayments during 2015 and 2016. The decrease in FFO as adjusted was partially offset by: (i) increased NOI from: (a) annual rent escalations, (b) our 2015 and 2016 consolidated acquisitions and (c) developments placed in service and (ii) increased incremental interest income from the payoff of participating development loans.

FAD increased primarily as a result of: (i) increased NOI from: (a) annual rent escalations, (b) our 2015 and 2016 consolidated acquisitions and (c) developments placed in service and (ii) increased incremental interest income from the payoff of participating development loans. The increase in FAD was partially offset by: (i) decreased income from our HCRMC investments as a result of the HCRMC lease amendment effective April 1, 2015 and the sale of non-strategic assets during the second half of 2015 and the first half of 2016, (ii) decreased interest income from placing our Four Seasons Notes on cost recovery status in the third quarter of 2015 and loan repayments during 2015 and 2016 and (iii) increased leasing costs and second generation capital expenditures.

Table of Contents

Segment Analysis

The tables below provide selected operating information for our SPP and total property portfolio for each of our business segments. Our SPP for the three months ended September 30, 2016 consists of 1,149 properties representing properties acquired or placed in service and stabilized on or prior to July 1, 2015 and that remained in operation under a consistent reporting structure through September 30, 2016. Our SPP for the nine months ended September 30, 2016 consists of 1,063 properties representing properties acquired or placed in service and stabilized on or prior to January 1, 2015 and that remained in operation under a consistent reporting structure through September 30, 2016. Our total property portfolio consists of 1,198 and 1,209 properties at September 30, 2016 and 2015, respectively.

Senior Housing Triple-Net

The following table summarizes results as of and for the three months ended September 30, 2016 and 2015 (dollars in thousands except per unit data):

| | SPP | | | Total Portfolio | | |
|------------------------------|---------------------------------------|------------|----------|---------------------------------------|------------|------------|
| | Three Months Ended September 30, 2016 | 2015 | Change | Three Months Ended September 30, 2016 | 2015 | Change |
| Rental revenues(1) | \$ 102,040 | \$ 102,129 | \$ (89) | \$ 104,262 | \$ 105,405 | \$ (1,143) |
| Operating expenses | (604) | (384) | (220) | (1,794) | (871) | (923) |
| NOI | 101,436 | 101,745 | (309) | 102,468 | 104,534 | (2,066) |
| Non-cash adjustments to NOI | (1,014) | (2,358) | 1,344 | (1,003) | (2,312) | 1,309 |
| Adjusted NOI | \$ 100,422 | \$ 99,387 | \$ 1,035 | 101,465 | 102,222 | (757) |
| Non-SPP adjusted NOI | | | | (1,043) | (2,835) | 1,792 |
| SPP adjusted NOI | | | | \$ 100,422 | \$ 99,387 | \$ 1,035 |
| Adjusted NOI % change | | | 1.0 % | | | |
| Property count(2) | 287 | 287 | | 292 | 296 | |
| Average capacity (units)(3) | 27,681 | 27,691 | | 28,378 | 28,771 | |
| Average annual rent per unit | \$ 14,598 | \$ 14,412 | | \$ 14,555 | \$ 14,333 | |

(1) Represents rental and related revenues and income from DFLs.

(2) From our past presentation of SPP for the three months ended September 30, 2015, we removed eight senior housing properties from SPP that were sold or transitioned to a RIDEA structure.

(3) Represents average capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented.

SPP. SPP adjusted NOI increased primarily as a result of annual rent escalations.

Non-SPP. Non-SPP NOI and adjusted NOI decreased primarily as a result of two SH NNN facilities sold in 2016 and the transition of six SH NNN facilities to a RIDEA structure (reported in our SHOP segment).

Total Portfolio. NOI and adjusted NOI decreased as a result of SH NNN facilities sold or transitioned to a RIDEA structure, partially offset by annual rent escalations.

The following table summarizes results as of and for the nine months ended September 30, 2016 and 2015 (dollars in thousands except per unit data):

| | SPP | | | Total Portfolio | | |
|-----------------------------|---------------------------------|------------|--------|---------------------------------|------------|----------|
| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 308,759 | \$ 308,340 | \$ 419 | \$ 319,989 | \$ 317,532 | \$ 2,457 |
| Operating expenses | (1,973) | (1,177) | (796) | (5,521) | (2,655) | (2,866) |
| NOI | 306,786 | 307,163 | (377) | 314,468 | 314,877 | (409) |
| Non-cash adjustments to NOI | (8,640) | (10,008) | 1,368 | (8,464) | (8,853) | 389 |
| Adjusted NOI | \$ 298,146 | \$ 297,155 | \$ 991 | 306,004 | 306,024 | (20) |
| Non-SPP adjusted NOI | | | | (7,858) | (8,869) | 1,011 |
| SPP adjusted NOI | | | | \$ 298,146 | \$ 297,155 | \$ 991 |
| Adjusted NOI % change | | | 0.3 % | | | |

Table of Contents

| | | | | |
|------------------------------|-----------|-----------|-----------|-----------|
| Property count(2) | 287 | 287 | 292 | 296 |
| Average capacity (units)(3) | 27,681 | 27,691 | 28,863 | 28,795 |
| Average annual rent per unit | \$ 14,456 | \$ 14,365 | \$ 14,391 | \$ 14,293 |

- (1) Represents rental and related revenues and income from DFLs.
- (2) From our past presentation of SPP for the nine months ended September 30, 2015, we removed eight senior housing properties from SPP that were sold or transitioned to a RIDEA structure.
- (3) Represents average capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented.

SPP. SPP adjusted NOI increased primarily as a result of annual rent escalations.

Non-SPP. Non-SPP NOI and adjusted NOI decreased primarily as a result of: (i) two SH NNN facilities sold in 2016 and (ii) the transition of six SH NNN facilities to a RIDEA structure (reported in our SHOP segment), partially offset by six SH NNN facilities acquired in the first quarter of 2016.

Total Portfolio. NOI and adjusted NOI decreased as a result of SH NNN facilities sold or transitioned to a RIDEA structure, partially offset by annual rent escalations and six SH NNN facilities acquired in the first quarter of 2016.

Senior Housing Operating Portfolio

The following table summarizes results as of and for the three months ended September 30, 2016 and 2015 (dollars in thousands except per unit data):

| | SPP | | | Total Portfolio | | |
|--|---------------------------------------|------------|----------|---------------------------------------|------------|-----------|
| | Three Months Ended September 30, 2016 | 2015 | Change | Three Months Ended September 30, 2016 | 2015 | Change |
| Resident fees and services | \$ 157,417 | \$ 150,837 | \$ 6,580 | \$ 170,739 | \$ 155,472 | \$ 15,267 |
| HCP share of unconsolidated JV revenues | 45,939 | 44,488 | 1,451 | 50,973 | 45,891 | 5,082 |
| Operating expenses | (111,589) | (106,203) | (5,386) | (121,502) | (110,254) | (11,248) |
| HCP share of unconsolidated JV share of operating expenses | (39,929) | (38,954) | (975) | (42,463) | (39,226) | (3,237) |
| NOI | 51,838 | 50,168 | 1,670 | 57,747 | 51,883 | 5,864 |
| Non-cash adjustments to NOI | — | — | — | 4,608 | 6,984 | (2,376) |
| Adjusted NOI | \$ 51,838 | \$ 50,168 | \$ 1,670 | 62,355 | 58,867 | 3,488 |
| Non-SPP adjusted NOI | | | | (10,517) | (8,699) | (1,818) |
| SPP adjusted NOI | | | | \$ 51,838 | \$ 50,168 | \$ 1,670 |

Edgar Filing: HCP, INC. - Form 10-Q

| | | | | | | |
|---------------------------------|----------|----------|-----|---|----------|----------|
| Adjusted NOI % change | | | 3.3 | % | | |
| Property count | 120 | 120 | | | 143 | 126 |
| Average capacity (units) | 21,892 | 17,758 | | | 23,575 | 18,053 |
| Average annual rent per unit(1) | \$ 3,157 | \$ 3,767 | | | \$ 3,527 | \$ 4,348 |

(1) Average annual rent per unit for RIDEA properties is based on NOI.

SPP. SPP NOI and adjusted NOI increased primarily as a result of increased occupancy and rates for resident fees and services.

Non-SPP. Non-SPP NOI and adjusted NOI increased primarily as a result of fourth quarter 2015 acquisitions and the transition of six SH NNN facilities to a RIDEA structure in the third quarter of 2016.

Total Portfolio. NOI and adjusted NOI increased based on the combined increases to SPP and Non-SPP discussed above.

Table of Contents

The following table summarizes results as of and for the nine months ended September 30, 2016 and 2015 (dollars in thousands except per unit data):

| | SPP | | | Total Portfolio | | |
|--|---------------------------------|------------|-----------|---------------------------------|------------|------------|
| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Resident fees and services | \$ 330,133 | \$ 313,242 | \$ 16,891 | \$ 500,704 | \$ 360,002 | \$ 140,702 |
| HCP share of unconsolidated JV revenues | 130,261 | 125,078 | 5,183 | 152,424 | 134,047 | 18,377 |
| Operating expenses | (234,483) | (224,179) | (10,304) | (350,949) | (260,393) | (90,556) |
| HCP share of unconsolidated JV share of operating expenses | (113,333) | (108,324) | (5,009) | (125,244) | (112,395) | (12,849) |
| NOI | 112,578 | 105,817 | 6,761 | 176,935 | 121,261 | 55,674 |
| Non-cash adjustments to NOI | — | — | — | 15,175 | 26,620 | (11,445) |
| Adjusted NOI | \$ 112,578 | \$ 105,817 | \$ 6,761 | 192,110 | 147,881 | 44,229 |
| Non-SPP adjusted NOI | | | | (79,532) | (42,064) | (37,468) |
| SPP adjusted NOI | | | | \$ 112,578 | \$ 105,817 | \$ 6,761 |
| Adjusted NOI % change | | | 6.4 | % | | |
| Property count | 83 | 83 | | 143 | 126 | |
| Average capacity (units) | 16,905 | 16,808 | | 23,447 | 17,782 | |
| Average annual rent per unit(1) | \$ 8,879 | \$ 8,394 | | \$ 10,925 | \$ 11,089 | |

(1) Average annual rent per unit for RIDEA properties is based on NOI.

SPP. SPP NOI and adjusted NOI increased primarily as a result of increased occupancy and rates for resident fees and services.

Non-SPP. Non-SPP NOI and adjusted NOI increased as a result of 2015 acquisitions, primarily our RIDEA III acquisition (see Note 3 to the Consolidated Financial Statements).

Total Portfolio. NOI and adjusted NOI increased based on the combined increases to SPP and Non-SPP discussed above.

Table of Contents

Life Science

The following table summarizes results as of and for the three months ended September 30, 2016 and 2015 (dollars and square feet in thousands except per square foot data):

| | SPP | | | Total Portfolio | | |
|--|----------------------------------|-----------|----------|----------------------------------|-----------|----------|
| | Three Months Ended September 30, | | | Three Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 77,040 | \$ 74,288 | \$ 2,752 | \$ 90,847 | \$ 86,140 | \$ 4,707 |
| HCP share of unconsolidated JV revenues | 1,904 | 1,782 | 122 | 1,929 | 1,840 | 89 |
| Operating expenses | (15,077) | (14,922) | (155) | (18,487) | (17,785) | (702) |
| HCP share of unconsolidated JV share of operating expenses | (406) | (425) | 19 | (406) | (425) | 19 |
| NOI | 63,461 | 60,723 | 2,738 | 73,883 | 69,770 | 4,113 |
| Non-cash adjustments to NOI | 615 | (1,803) | 2,418 | (314) | (2,673) | 2,359 |
| Adjusted NOI | \$ 64,076 | \$ 58,920 | \$ 5,156 | 73,569 | 67,097 | 6,472 |
| Non-SPP adjusted NOI | | | | (9,493) | (8,177) | (1,316) |
| SPP adjusted NOI | | | | \$ 64,076 | \$ 58,920 | \$ 5,156 |
| Adjusted NOI % change | | | 8.8 % | | | |
| Property count(2) | 110 | 110 | | 118 | 116 | |
| Average occupancy | 97.6 % | 97.1 % | | 96.8 % | 97.4 % | |
| Average occupied square feet | 6,639 | 6,602 | | 7,675 | 7,456 | |
| Average annual total revenues per occupied square foot | \$ 48 | \$ 45 | | \$ 48 | \$ 46 | |
| Average annual base rent per occupied square foot | \$ 39 | \$ 37 | | \$ 40 | \$ 38 | |

(1) Represents rental and related revenues and tenant recoveries.

(2) From our past presentation of SPP for the three months ended September 30, 2015, we removed a life science facility that was sold and eight life science facilities that were classified as held for sale.

SPP. SPP NOI and adjusted NOI increased primarily as a result of mark-to-market lease renewals and new leasing activity. Additionally, SPP adjusted NOI increased as a result of annual rent escalations and a decline in rent abatements.

Non-SPP. Non-SPP NOI and adjusted NOI increased primarily as a result of life science acquisitions in 2015 and 2016 and increased occupancy in a development placed in operation in 2016, partially offset by a life science facility sold in 2016.

Total Portfolio. NOI and adjusted NOI increased based on the combined increases to SPP and Non-SPP discussed above.

During the three months ended September 30, 2016, 182,000 square feet of new and renewal leases commenced at an average annual base rent of \$42.06 per square foot, including 38,000 square feet related to a development placed in service at an average annual base rent of \$55.80 per square foot, compared to 233,000 square feet of expired leases with an average annual base rent of \$32.33 per square foot. During the three months ended September 30, 2016, we classified 324,000 square feet as real estate and related assets held for sale, net with an average annual base rent of \$18.81 per square foot and acquired properties with 61,000 occupied square feet with an average annual base rent of \$47.79 per square foot.

Table of Contents

The following table summarizes results as of and for the nine months ended September 30, 2016 and 2015 (dollars and square feet in thousands except per square foot data):

| | SPP | | | Total Portfolio | | |
|--|---------------------------------|------------|-----------|---------------------------------|------------|-----------|
| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 228,520 | \$ 220,194 | \$ 8,326 | \$ 269,994 | \$ 255,100 | \$ 14,894 |
| HCP share of unconsolidated JV revenues | 5,545 | 5,198 | 347 | 5,628 | 5,257 | 371 |
| Operating expenses | (43,239) | (43,334) | 95 | (53,191) | (51,718) | (1,473) |
| HCP share of unconsolidated JV share of operating expenses | (1,173) | (1,173) | — | (1,173) | (1,173) | — |
| NOI | 189,653 | 180,885 | 8,768 | 221,258 | 207,466 | 13,792 |
| Non-cash adjustments to NOI | 994 | (5,688) | 6,682 | (1,545) | (8,635) | 7,090 |
| Adjusted NOI | \$ 190,647 | \$ 175,197 | \$ 15,450 | 219,713 | 198,831 | 20,882 |
| Non-SPP adjusted NOI | | | | (29,066) | (23,634) | (5,432) |
| SPP adjusted NOI | | | | \$ 190,647 | \$ 175,197 | \$ 15,450 |
| Adjusted NOI % change | | | 8.8 | % | | |
| Property count(2) | 110 | 110 | | 118 | 116 | |
| Average occupancy | 97.8 | % 96.1 | % | 97.6 | % 96.4 | % |
| Average occupied square feet | 6,648 | 6,534 | | 7,651 | 7,384 | |
| Average annual total revenues per occupied square foot(1) | \$ 47 | \$ 45 | | \$ 48 | \$ 45 | |
| Average annual base rent per occupied square foot | \$ 39 | \$ 37 | | \$ 39 | \$ 38 | |

(1) Represents rental and related revenues and tenant recoveries.

(2) From our past presentation of SPP for the nine months ended September 30, 2015, we removed a life science facility that was sold and eight life science facilities that were classified as held for sale.

SPP. SPP NOI and adjusted NOI increased primarily as a result of mark-to-market lease renewals, new leasing activity and increased occupancy. Additionally, SPP adjusted NOI increased as a result of annual rent escalations and a decline in rent abatements.

Non-SPP. Non-SPP NOI and adjusted NOI increased primarily as a result of life science acquisitions in 2015 and 2016 and increased occupancy in a development placed in operation in 2016, partially offset by a life science facility sold in 2016.

Total Portfolio. NOI and adjusted NOI increased based on the combined increases to SPP and Non-SPP discussed above.

During the nine months ended September 30, 2016, 1.1 million square feet of new and renewal leases commenced at an average annual base rent of \$28.70 per square foot, including 38,000 square feet related to a development placed in service at an average annual base rent of \$55.80 per square foot, compared to 1.1 million square feet of expired and terminated leases with an average annual base rent of \$24.60 per square foot. During the nine months ended September 30, 2016, we classified 781,000 square feet as real estate and related assets held for sale, net with an average annual base rent of \$38.71 per square foot, acquired properties with 61,000 occupied square feet with an average annual base rent of \$47.79 per square foot and disposed of 78,000 square feet with an average annual base rent of \$57.18 per square foot.

Table of Contents

Medical Office

The following table summarizes results as of and for the three months ended September 30, 2016 and 2015 (dollars and square feet in thousands except per square foot data):

| | SPP | | | Total Portfolio | | |
|--|----------------------------------|------------|----------|----------------------------------|------------|----------|
| | Three Months Ended September 30, | | | Three Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 105,187 | \$ 103,398 | \$ 1,789 | \$ 113,653 | \$ 108,898 | \$ 4,755 |
| HCP share of unconsolidated JV revenues | 469 | 455 | 14 | 502 | 464 | 38 |
| Operating expenses | (40,087) | (39,063) | (1,024) | (44,738) | (43,008) | (1,730) |
| HCP share of unconsolidated JV share of operating expenses | (148) | (150) | 2 | (148) | (150) | 2 |
| NOI | 65,421 | 64,640 | 781 | 69,269 | 66,204 | 3,065 |
| Non-cash adjustments to NOI | 124 | (1,085) | 1,209 | (814) | (1,342) | 528 |
| Adjusted NOI | \$ 65,545 | \$ 63,555 | \$ 1,990 | 68,455 | 64,862 | 3,593 |
| Non-SPP adjusted NOI | | | | (2,910) | (1,307) | (1,603) |
| SPP adjusted NOI | | | | \$ 65,545 | \$ 63,555 | \$ 1,990 |
| Adjusted NOI % change | | | 3.1 | % | | |
| Property count(2) | 217 | 217 | | 226 | 226 | |
| Average occupancy | 92.0 | % 92.1 | % | 91.6 | % 91.1 | % |
| Average occupied square feet | 15,069 | 15,046 | | 15,817 | 15,572 | |
| Average annual total revenues per occupied square foot | \$ 28 | \$ 27 | | \$ 28 | \$ 27 | |
| Average annual base rent per occupied square foot | \$ 23 | \$ 23 | | \$ 24 | \$ 23 | |

(1) Represents rental and related revenues and tenant recoveries.

(2) From our past presentation of SPP for the three months ended September 30, 2015, we removed three MOB's that were sold and five MOB's that were placed into redevelopment.

SPP. SPP adjusted NOI increased primarily as a result of annual rent escalations.

Non-SPP. Non-SPP NOI and adjusted NOI increased primarily as a result of increased occupancy in former redevelopment and development properties that have been placed into service.

Total Portfolio. NOI and adjusted NOI increased based on the combined increases to SPP and Non-SPP discussed above.

During the three months ended September 30, 2016, 590,000 square feet of new and renewal leases commenced at an average annual base rent of \$23.03 per square foot, including 28,000 square feet related to redevelopments placed into service at an average annual base rent of \$21.35, compared to 577,000 square feet of expiring and terminated leases with an average annual base rent of \$23.56 per square foot. During the three months ended September 30, 2016, we disposed of 11,000 square feet with an average annual base rent of \$9.16 per square foot.

Table of Contents

The following table summarizes results as of and for the nine months ended September 30, 2016 and 2015 (dollars and square feet in thousands except per square foot data):

| | SPP | | | Total Portfolio | | |
|--|---------------------------------|------------|----------|---------------------------------|------------|-----------|
| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 286,157 | \$ 279,961 | \$ 6,196 | \$ 331,881 | \$ 307,881 | \$ 24,000 |
| HCP share of unconsolidated JV revenues | 1,406 | 1,368 | 38 | 1,503 | 1,395 | 108 |
| Operating expenses | (109,123) | (106,329) | (2,794) | (129,715) | (121,330) | (8,385) |
| HCP share of unconsolidated JV share of operating expenses | (452) | (467) | 15 | (452) | (467) | 15 |
| NOI | 177,988 | 174,533 | 3,455 | 203,217 | 187,479 | 15,738 |
| Non-cash adjustments to NOI | (76) | (2,437) | 2,361 | (2,361) | (4,326) | 1,965 |
| Adjusted NOI | \$ 177,912 | \$ 172,096 | \$ 5,816 | 200,856 | 183,153 | 17,703 |
| Non-SPP adjusted NOI | | | | (22,944) | (11,057) | (11,887) |
| SPP adjusted NOI | | | | \$ 177,912 | \$ 172,096 | \$ 5,816 |
| Adjusted NOI % change | | | 3.4 | % | | |
| Property count(2) | 204 | 204 | | 226 | 226 | |
| Average occupancy | 91.8 | % | 91.4 | % | 91.4 | % |
| Average occupied square feet | 13,259 | 13,169 | | 15,719 | 14,688 | |
| Average annual total revenues per occupied square foot | \$ 29 | \$ 28 | | \$ 28 | \$ 27 | |
| Average annual base rent per occupied square foot | \$ 24 | \$ 24 | | \$ 23 | \$ 23 | |

(1) Represents rental and related revenues and tenant recoveries.

(2) From our past presentation of SPP for the nine months ended September 30, 2015, we removed three MOBs that were sold and five MOBs that were placed into redevelopment.

SPP. SPP NOI and adjusted NOI increased primarily as a result of increased occupancy. Additionally, SPP adjusted NOI increased as a result of annual rent escalations.

Non-SPP. Non-SPP NOI and adjusted NOI increased primarily as a result of increased occupancy in former redevelopment and development properties that have been placed into service and additional NOI from our MOB acquisitions in 2015, partially offset by the sale of three MOBs.

Total Portfolio. NOI and adjusted NOI increased based on the combined increases to SPP and Non-SPP discussed above.

During the nine months ended September 30, 2016, 1.8 million square feet of new and renewal leases commenced at an average annual base rent of \$22.85 per square foot, including 192,000 square feet related to redevelopments placed into service at an average annual base rent of \$24.80, compared to 1.5 million square feet of expiring and terminated leases with an average annual base rent of \$23.28 per square foot. During the nine months ended September 30, 2016, we disposed of 82,000 square feet with an average annual base rent of \$23.94 per square foot.

Table of Contents

QCP

The following table summarizes results as of and for the three months ended September 30, 2016 and 2015 (dollars in thousands except per bed data):

| | SPP | | | Total Portfolio | | |
|-----------------------------|----------------------------------|------------|-------------|----------------------------------|------------|-------------|
| | Three Months Ended September 30, | | | Three Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 124,408 | \$ 143,495 | \$ (19,087) | \$ 123,716 | \$ 148,599 | \$ (24,883) |
| Operating expenses | (494) | (528) | 34 | (1,036) | (1,008) | (28) |
| NOI | 123,914 | 142,967 | (19,053) | 122,680 | 147,591 | (24,911) |
| Non-cash adjustments to NOI | 172 | (22,448) | 22,620 | 172 | (23,158) | 23,330 |
| Adjusted NOI | \$ 124,086 | \$ 120,519 | \$ 3,567 | 122,852 | 124,433 | (1,581) |
| Non-SPP adjusted NOI | | | | 1,234 | (3,914) | 5,148 |
| SPP adjusted NOI | | | | \$ 124,086 | \$ 120,519 | \$ 3,567 |
| Adjusted NOI % change | | | 3.0 | % | | |
| Property count(2) | 337 | 337 | | 338 | 360 | |
| Average capacity (beds)(3) | 39,624 | 38,535 | | 39,688 | 41,891 | |
| Average annual rent per bed | \$ 12,576 | \$ 12,565 | | \$ 12,486 | \$ 11,978 | |

(1) Represents rental and related revenues, tenant recoveries and income from DFLs.

(2) From our past presentation of SPP for the three months ended September 30, 2015, we removed 32 properties from SPP that were sold.

(3) Represents capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented. Certain operators in our hospital portfolio are not required under their respective leases to provide operational data.

SPP. SPP NOI decreased as a result of a change in income recognition to a cash basis method beginning in 2016 on our HCRMC DFL investments. SPP adjusted NOI increased primarily as a result of annual rent escalations.

Non-SPP. Non-SPP NOI and adjusted NOI decreased as a result of a reduction in income from our HCRMC DFL investments due to the sale of non-strategic assets during the second half of 2015 and first quarter of 2016.

Total Portfolio. NOI and adjusted NOI decreased primarily as a result of the non-strategic asset sales underlying our HCRMC DFL investments during the second half of 2015 and the first quarter of 2016.

Edgar Filing: HCP, INC. - Form 10-Q

The following table summarizes results as of and for the nine months ended September 30, 2016 and 2015 (dollars in thousands except per bed data):

| | SPP | | | Total Portfolio | | |
|-----------------------------|---------------------------------|------------|-------------|---------------------------------|------------|-------------|
| | Nine Months Ended September 30, | | | Nine Months Ended September 30, | | |
| | 2016 | 2015 | Change | 2016 | 2015 | Change |
| Rental revenues(1) | \$ 369,700 | \$ 437,628 | \$ (67,928) | \$ 367,714 | \$ 454,740 | \$ (87,026) |
| Operating expenses | (1,460) | (1,446) | (14) | (3,068) | (2,898) | (170) |
| NOI | 368,240 | 436,182 | (67,942) | 364,646 | 451,842 | (87,196) |
| Non-cash adjustments to NOI | 376 | (63,608) | 63,984 | 375 | (65,807) | 66,182 |
| Adjusted NOI | \$ 368,616 | \$ 372,574 | \$ (3,958) | 365,021 | 386,035 | (21,014) |
| Non-SPP adjusted NOI | | | | 3,595 | (13,461) | 17,056 |
| SPP adjusted NOI | | | | \$ 368,616 | \$ 372,574 | \$ (3,958) |
| Adjusted NOI % change | | | (1.1) % | | | |
| Property count(2) | 337 | 337 | | 338 | 360 | |
| Average capacity (beds)(3) | 39,572 | 38,535 | | 39,690 | 41,943 | |
| Average annual rent per bed | \$ 12,469 | \$ 12,941 | | \$ 12,365 | \$ 12,364 | |

(1) Represents rental and related revenues, tenant recoveries and income from DFLs.

(2) From our past presentation of SPP for the nine months ended September 30, 2015, we removed 32 properties from SPP that were sold.

(3) Represents capacity as reported by the respective tenants or operators for the 12-month period and a quarter in arrears from the periods presented. Certain operators in our hospital portfolio are not required under their respective leases to provide operational data.

Table of Contents

SPP. SPP NOI and adjusted NOI decreased primarily as a result of a reduction in income from our HCRMC DFL investments as a result of the HCRMC lease amendment effective April 1, 2015, partially offset by annual rent escalations. In addition, SPP NOI decreased as a result of a change in income recognition to a cash basis method beginning in 2016.

Non-SPP. Non-SPP NOI and adjusted NOI decreased as a result of a reduction in income from our HCRMC DFL investments due to the sale of non-strategic assets during the second half of 2015 and first quarter of 2016.

Total Portfolio. NOI and adjusted NOI decreased primarily as a result of the non-strategic asset sales underlying our HCRMC DFL investments during the second half of 2015 and the first quarter of 2016.

The Spin-Off, completed on October 31, 2016, resulted in us disposing of our entire QCP segment, including allocated goodwill. Beginning in the fourth quarter of 2016, the historical financial results of the QCP segment will be reflected in our consolidated financial statements as discontinued operations for all periods presented (see Note 1 to the Consolidated Financial Statements).

The following tables summarize HCRMC's consolidated financial information (in millions):

| | | | | |
|---|-----------------------|----------------------|-------------------------------------|------------------------------------|
| | September 30, 2016 | December 31, 2015 | | |
| Real estate and other property, net | \$ 2,554.1 | \$ 2,628.5 | | |
| Cash and cash equivalents | 163.7 | 125.0 | | |
| Goodwill, intangible and other assets, net | 4,537.5 | 4,598.3 | | |
| Total assets | \$ 7,255.3 | \$ 7,351.8 | | |
| Debt and financing obligations | \$ 5,767.2 | \$ 5,836.4 | | |
| Accounts payable, accrued liabilities and other | 1,028.3 | 982.9 | | |
| Redeemable preferred stock | 2.1 | 2.1 | | |
| Total equity | 457.7 | 530.4 | | |
| Total liabilities and equity | \$ 7,255.3 | \$ 7,351.8 | | |
| | | | Three Months Ended September 30, | Nine Months Ended September 30, |
| | | | 2016 | 2015 |
| Revenues | \$ 951.4 | \$ 1,009.6 | \$ 2,893.6 | \$ 3,091.1 |
| Operating, general and administrative expense | (838.8) | (885.7) | (2,527.4) | (2,667.8) |

Edgar Filing: HCP, INC. - Form 10-Q

| | | | | |
|---|-----------|-----------|-----------|-----------|
| Depreciation and amortization expense | (32.5) | (33.3) | (97.6) | (104.6) |
| Interest expense | (114.8) | (119.7) | (345.0) | (339.9) |
| Other income, net | 5.4 | 2.6 | 13.7 | 7.5 |
| Loss on disposal of assets | (10.0) | (76.0) | (12.6) | (76.0) |
| Impairment | — | — | (6.0) | — |
| Loss from continuing operations before income tax benefit | (39.3) | (102.5) | (81.3) | (89.7) |
| Income tax benefit | 0.6 | 13.3 | 8.8 | 7.7 |
| Loss from continuing operations | (38.7) | (89.2) | (72.5) | (82.0) |
| Income (loss) from discontinued operations, net of taxes | — | 2.0 | — | (4.0) |
| Net loss | \$ (38.7) | \$ (87.2) | \$ (72.5) | \$ (86.0) |

Other Income and Expense Items

Interest income

Interest income decreased \$18 million to \$71 million for the nine months ended September 30, 2016. The decrease was primarily the result of (i) a reduction in interest income from placing our Four Seasons Notes on cost recovery status in

Table of Contents

the third quarter of 2015 (see Note 9 to the Consolidated Financial Statements) and (ii) paydowns in our loan portfolio, partially offset by: (i) incremental interest income from the payoff of a participating development loan, (ii) additional interest income from the Four Seasons senior secured term loan purchased in the fourth quarter of 2015 and (iii) additional fundings in our loan portfolio (see Note 6 to the Consolidated Financial Statements).

Interest expense

Interest expense decreased \$4 million to \$118 million for the three months ended September 30, 2016. The decrease was primarily the result of mortgage debt that was repaid during 2015 and 2016, primarily in our SH NNN segment, partially offset by increased borrowings under our line of credit facility. The increased borrowings were used to refinance our debt maturities. The increase in interest expense from 2015 senior unsecured notes issuances was offset by the decrease in interest expense from 2015 and 2016 senior unsecured notes payoffs.

Interest expense increased \$4 million to \$361 million for the nine months ended September 30, 2016. The increase was primarily the result of: (i) \$2 billion of aggregate senior unsecured notes issuances during 2015, offset by \$1.3 billion of aggregate senior unsecured notes payoffs during 2015 and 2016 and (ii) increased borrowings under our line of credit facility, partially offset by mortgage debt repayments during 2015 and 2016, primarily from mortgage debt secured by properties in our SH NNN segment. The increased borrowings were used to fund our investment activities and to refinance our debt maturities.

The following table sets forth information with respect to our debt, excluding premiums and discounts (dollars in thousands):

| | As of September 30, (1) | | | |
|--|-------------------------|---|---------------|---|
| | 2016 | | 2015 | |
| Balance: | | | | |
| Fixed rate | \$ 9,343,587 | | \$ 10,081,236 | |
| Variable rate | 1,549,899 | | 1,000,824 | |
| Total | \$ 10,893,486 | | \$ 11,082,060 | |
| Percent of total debt: | | | | |
| Fixed rate | 85.8 | % | 91.0 | % |
| Variable rate | 14.2 | % | 9.0 | % |
| Total | 100.0 | % | 100.0 | % |
| Weighted average interest rate at end of period: | | | | |
| Fixed rate | 4.65 | % | 4.70 | % |
| Variable rate | 1.84 | % | 1.52 | % |
| Total | 4.25 | % | 4.41 | % |

(1) At September 30, 2016 and 2015, excludes \$94 million and \$95 million, respectively, of other debt that represents non-interest bearing life care bonds and occupancy fee deposits at certain of our senior housing facilities and

demand notes that have no scheduled maturities. At September 30, 2016 and 2015, principal balances of \$70 million and \$71 million, respectively, of variable-rate mortgages are presented as fixed-rate debt as the interest payments were swapped from variable to fixed (see Note 19 to the Consolidated Financial Statements). At September 30, 2016 and 2015, principal balances of £220 million (\$286 million) and £357 million (\$541 million) of term loans, respectively, are presented as fixed-rate debt as the interest payments were swapped from variable to fixed (see Note 19 to the Consolidated Financial Statements).

Our exposure to interest rate fluctuations related to our variable rate indebtedness is substantially mitigated by our interest rate swap contracts. For a more detailed discussion of our interest rate risk, see “Quantitative and Qualitative Disclosures About Market Risk” in Item 3 below.

Depreciation and amortization expense

Depreciation and amortization expense increased \$8 million to \$143 million for the three months ended September 30, 2016. The increase was primarily the result of the impact of acquisitions.

Depreciation and amortization expense increased \$56 million to \$426 million for the nine months ended September 30, 2016. The increase was primarily the result of the impact of acquisitions.

Table of Contents

General and administrative expenses

General and administrative expenses increased \$14 million to \$35 million for the three months ended September 30, 2016. The increase was primarily the result of \$14 million of severance-related charges primarily resulting from the departure of our former President and Chief Executive Officer in July 2016.

General and administrative expenses increased \$9 million to \$83 million for the nine months ended September 30, 2016. The increase was primarily the result of: (i) \$14 million of severance-related charges primarily resulting from the departure of our former President and Chief Executive Officer in July 2016 and (ii) higher professional fees in 2016, partially offset by a \$7 million severance-related charge resulting from the resignation of our former Executive Vice President and Chief Investment Officer in June 2015.

Acquisition and pursuit costs

Acquisition and pursuit costs increased \$16 million to \$18 million for the three months ended September 30, 2016. The increase was primarily a result of the Spin-Off (see Note 1 to the Consolidated Financial Statements).

Acquisition and pursuit costs increased \$11 million to \$35 million for the nine months ended September 30, 2016. The increase was primarily a result of the Spin-Off, partially offset by lower levels of transactional activity in 2016 compared to the same period in 2015.

We expect to incur total transaction costs relating to the Spin-Off of approximately \$155 million. Additionally, on November 1, 2016, we issued notices of redemption for \$500 million of 6.00% senior unsecured notes due 2017 and \$600 million of 6.70% senior unsecured notes due 2018 (see Note 10 to the Consolidated Financial Statements). We expect to incur total prepayment costs of \$47 million associated with early retirement of debt, including the aforementioned senior unsecured notes' redemptions.

Impairments

During the three months ended September 30, 2015, we recognized an impairment charge of \$70 million related to our investment in the Four Seasons Notes (see Note 9 to the Consolidated Financial Statements). There were no impairment charges recognized during the three months ended September 30, 2016.

During the nine months ended September 30, 2015, we recognized the following impairment charges: (i) \$478 million related to our DFL investments with HCRMC, (ii) \$112 million related to our investment in the Four Seasons Notes and (iii) \$3 million related to a MOB (see Notes 5 and 9 to the Consolidated Financial Statements). There were no impairment charges recognized during the nine months ended September 30, 2016.

Gain on sales of real estate

During the nine months ended September 30, 2016, we sold a portfolio of five facilities in one of our non-reportable segments and two SH NNN facilities for \$130 million, a life science facility for \$74 million, three MOBs for \$20 million and a SHOP facility for \$6 million, recognizing total gain on sales of \$120 million.

During the nine months ended September 30, 2015, we sold the following assets: (i) nine SH NNN facilities for \$60 million, resulting from Brookdale's exercise of its purchase option received as part of a transaction with Brookdale in 2014, (ii) a parcel of land in its life science segment for \$11 million and (iii) a MOB for \$400,000, recognizing total gain on sales of \$6 million.

Other income (expense), net

Other income (expense), net increased \$2 million to income of \$1 million for the three months ended September 30, 2016. The increase was primarily the result of a reduction of foreign currency remeasurement losses from remeasuring assets and liabilities denominated in GBP to USD as a result of effective hedges designated in September 2015 (see Note 19 to the Consolidated Financial Statements).

Table of Contents

Other income, net decreased \$8 million to \$5 million for the nine months ended September 30, 2016. The decrease was primarily the result of reduction of foreign currency remeasurement gains from remeasuring assets and liabilities denominated in GBP to USD as a result of effective hedges designated in September 2015 (see Note 19 to the Consolidated Financial Statements).

Income tax expense

Income tax expense increased \$55 million to \$49 million of expense for the nine months ended September 30, 2016. The increase was primarily the result of recognizing tax liabilities of \$53 million representing our estimated exposure to state built-in gain tax, of which \$47 million is related to our HCRMC DFL investments (see Note 5 to the Consolidated Financial Statements).

Equity (loss) income from unconsolidated joint ventures

During the three months ended September 30, 2016, we recognized equity loss from unconsolidated joint ventures of \$2 million compared to equity income from unconsolidated joint ventures of \$8 million for the three months ended September 30, 2015. The decrease was primarily the result of a change in income recognition on our HCRMC investments to a cash basis method beginning in 2016 within our QCP segment.

During the nine months ended September 30, 2016, we recognized equity loss from unconsolidated joint ventures of \$4 million compared to equity income from unconsolidated joint ventures of \$34 million for the nine months ended September 30, 2015. The decrease was primarily the result of a change in income recognition on our HCRMC investments to a cash basis method beginning in 2016 within our QCP segment.

Impairment of investments in unconsolidated joint ventures

During the three and nine months ended September 30, 2015, we recognized an impairment charge of \$27 million related to our equity investment in HCRMC within our QCP segment (see Note 7 to the Consolidated Financial Statements). There were no impairment charges recognized during the nine months ended September 30, 2016.

Liquidity and Capital Resources

We anticipate: (i) funding recurring operating expenses, (ii) meeting debt service requirements including principal payments and maturities, and (iii) satisfying our distributions to our stockholders and non-controlling interest members, for the next 12 months primarily by using cash flow from operations, available cash balances and cash from our various financing activities.

Our principal investing needs for the next 12 months are to:

- fund capital expenditures, including tenant improvements and leasing costs; and
- fund future acquisition, transactional and development activities.

We anticipate satisfying these future investing needs using one or more of the following:

- issuance of common or preferred stock;
- issuance of additional debt, including unsecured notes and mortgage debt;
- draws on our credit facilities; and/or
- sale or exchange of ownership interests in properties.

Access to capital markets impacts our cost of capital and ability to refinance maturing indebtedness, as well as our ability to fund future acquisitions and development through the issuance of additional securities or secured debt. Credit ratings impact our ability to access capital and directly impact our cost of capital as well. For example, as noted below, our revolving line of credit facility accrues interest at a rate per annum equal to LIBOR plus a margin that depends upon our credit ratings. We also pay a facility fee on the entire revolving commitment that depends upon our credit ratings. As of

Table of Contents

October 28, 2016, we had a credit rating of BBB from Fitch, Baa2 from Moody's and BBB from S&P Global on our senior unsecured debt securities. Additionally, in October 2016, Fitch revised our outlook to stable.

Cash Flow Summary

The following summary discussion of our cash flows is based on the consolidated statements of cash flows and is not meant to be an all-inclusive discussion of the changes in our cash flows for the periods presented below.

Cash and cash equivalents were \$133 million and \$347 million at September 30, 2016 and December 31, 2015, respectively, representing a decrease of \$214 million. The following table sets forth changes in cash flows (in thousands):

| | Nine Months Ended September 30, | | |
|---|---------------------------------|-------------|-------------|
| | 2016 | 2015 | Change |
| Net cash provided by operating activities | \$ 998,632 | \$ 867,660 | \$ 130,972 |
| Net cash used in investing activities | (314,159) | (1,685,585) | 1,371,426 |
| Net cash (used in) provided by financing activities | (897,328) | 755,880 | (1,653,208) |

The increase in operating cash flow is primarily the result of our 2015 and 2016 acquisitions, annual rent increases and increased working capital. Our cash flow from operations is dependent upon the occupancy levels of our buildings, rental rates on leases, our tenants' performance on their lease obligations, the level of operating expenses and other factors.

The following are significant investing and financing activities for the nine months ended September 30, 2016:

- made investments of \$766 million (development and acquisition of real estate, and investments in DFLs, unconsolidated joint ventures and loans) and received proceeds of \$433 million primarily from real estate and DFL sales;
- paid dividends on common stock of \$806 million, which were generally funded by cash provided by our operating activities and cash on hand; and
- raised proceeds of \$1.2 billion primarily from our net borrowings under our bank line of credit and repaid \$1.3 billion under our bank line of credit, senior unsecured notes and mortgage debt.

Debt

Bank Line of Credit and Term Loans

Our \$2.0 billion unsecured revolving line of credit facility (the “Facility”) matures on March 31, 2018 and contains a one-year extension option. Borrowings under the Facility accrue interest at LIBOR plus a margin that depends on our credit ratings. We pay a facility fee on the entire revolving commitment that depends on our credit ratings. Based on our credit ratings at October 28, 2016, the margin on the Facility was 1.05%, and the facility fee was 0.20%. The Facility also includes a feature that allows us to increase the borrowing capacity by an aggregate amount of up to \$500 million, subject to securing additional commitments from existing lenders or new lending institutions. At September 30, 2016, we had \$1.4 billion, including £275 million (\$357 million), outstanding under the Facility with a weighted average effective interest rate of 1.85%.

In July 2016, we exercised a one-year extension option on our 2012 Term Loan. Based on our credit ratings at July 29, 2016, the 2012 Term Loan accrues interest at a rate of GBP LIBOR plus 1.40%. We also have a £220 million (\$286 million at September 30, 2016) four-year unsecured term loan that accrues interest at a rate of GBP LIBOR plus 1.15%, subject to adjustments based on our credit ratings.

The Facility and term loans contain certain financial restrictions and other customary requirements, including cross-default provisions to other indebtedness. Among other things, these covenants, using terms defined in the agreements, (i) limit the ratio of Consolidated Total Indebtedness to Consolidated Total Asset Value to 60%, (ii) limit the ratio of Secured Debt to Consolidated Total Asset Value to 30%, (iii) limit the ratio of Unsecured Debt to Consolidated Unencumbered Asset Value to 60% and (iv) require a minimum Fixed Charge Coverage ratio of 1.5x. The Facility and term loans also require a

Table of Contents

Minimum Consolidated Tangible Net Worth of \$9.5 billion at September 30, 2016, which requirement was subsequently reduced, via an amendment to the Facility, to \$6.5 billion effective upon the completion of the Spin-Off of QCP on October 31, 2016. At September 30, 2016, we were in compliance with each of these restrictions and requirements.

Senior Unsecured Notes

At September 30, 2016, we had senior unsecured notes outstanding with an aggregate principal balance of \$8.3 billion. Effective interest rates on the notes ranged from 2.79% to 6.88% with a weighted average effective interest rate of 4.63% and a weighted average maturity of six years at September 30, 2016. The senior unsecured notes contain certain covenants including limitations on debt, maintenance of unencumbered assets, cross-acceleration provisions and other customary terms. We believe we were in compliance with these covenants at September 30, 2016.

Additionally, on November 1, 2016, we issued notices of redemption for \$500 million of 6.00% senior unsecured notes due 2017 and \$600 million of 6.70% senior unsecured notes due 2018 (see Note 10 to the Consolidated Financial Statements).

Mortgage Debt

At September 30, 2016, we had mortgage debt outstanding with an aggregate principal balance of \$758 million, which is secured by 46 healthcare facilities (including redevelopment properties) with a carrying value of \$1.1 billion. Effective interest rates on the mortgage debt ranged from 3.05% to 8.20% with a weighted average effective interest rate of 5.79% and a weighted average maturity of five years at September 30, 2016.

Mortgage debt generally requires monthly principal and interest payments, is collateralized by real estate assets and is generally non-recourse. Mortgage debt typically restricts transfer of the encumbered assets, prohibits additional liens, restricts prepayment, requires payment of real estate taxes, requires maintenance of the assets in good condition, requires maintenance of insurance on the assets, and includes conditions to obtain lender consent to enter into and terminate material leases. Some of the mortgage debt is also cross-collateralized by multiple assets and may require tenants or operators to maintain compliance with the applicable leases or operating agreements of such real estate assets.

Equity

At September 30, 2016, we had 468 million shares of common stock outstanding, equity totaled \$9.6 billion, and our equity securities had a market value of \$18.0 billion.

At September 30, 2016, non-managing members held an aggregate of 4 million units in five limited liability companies (“DownREITs”) for which we are the managing member. The DownREIT units are exchangeable for an amount of cash approximating the then-current market value of shares of our common stock or, at our option, shares of our common stock (subject to certain adjustments, such as stock splits and reclassifications).

At-The-Market Program

In June 2015, we established an At-The-Market Program, in connection with the renewal of our Shelf Registration Statement. Under this program, we may sell shares of our common stock from time to time having an aggregate gross sales price of up to \$750 million through a consortium of banks acting as sales agents or directly to the banks acting as principals. There was no activity during the nine months ended September 30, 2016 and, as of September 30, 2016, shares of our common stock having an aggregate gross sales price of \$676 million were available for sale under the At-The-Market Program. Actual future sales will depend upon a variety of factors, including but not limited to market conditions, the trading price of our common stock and our capital needs. We have no obligation to sell the remaining shares available for sale under our program.

Shelf Registration

We filed a prospectus with the SEC as part of a registration statement on Form S-3ASR, using a shelf registration process, which expires in June 2018. Under the “shelf” process, we may sell any combination of the securities described in the prospectus through one or more offerings. The securities described in the prospectus include common stock, preferred stock, depositary shares, debt securities and warrants.

Table of Contents

Capital Market Outlook

The capital markets have facilitated our continued growth, including our international expansion. For the 21 months ended September 30, 2016, we have raised \$2.0 billion in senior unsecured notes and originated a £220 million (\$333 million) four-year unsecured term loan. The capital raised, in combination with available cash and borrowing capacity under our Facility, supported \$2.8 billion of investments completed during the 21 months ended September 30, 2016. We believe our equity and debt investors, as well as our banking relationships, will provide additional capital as we pursue new investment opportunities.

Contractual Obligations

The following table summarizes our material contractual payment obligations and commitments at September 30, 2016 (in thousands):

| | Total(1) | Less than One Year | 2017-2018 | 2019-2020 | More than Five Years |
|-----------------------------------|----------------------|-----------------------|---------------------|---------------------|-------------------------|
| Bank line of credit(2) | \$ 1,372,032 | \$ — | \$ 1,372,032 | \$ — | \$ — |
| Term loans(3) | 463,493 | — | 177,867 | 285,626 | — |
| Senior unsecured notes | 8,300,000 | — | 1,350,000 | 1,250,000 | 5,700,000 |
| Mortgage debt | 757,961 | 30,626 | 591,831 | 7,746 | 127,758 |
| U.K. loan commitments(4) | 48,602 | 32,874 | 15,728 | — | — |
| Construction loan commitments(5) | 466 | 466 | — | — | — |
| Development commitments(6) | 101,535 | 52,078 | 47,297 | 2,160 | — |
| Ground and other operating leases | 397,587 | 1,857 | 13,654 | 13,235 | 368,841 |
| Interest(7) | 2,436,621 | 70,011 | 738,907 | 548,123 | 1,079,580 |
| Total | \$ 13,878,297 | \$ 187,912 | \$ 4,307,316 | \$ 2,106,890 | \$ 7,276,179 |

(1) Excludes \$94 million of other debt that represents Life Care Bonds and Demand Notes that have no scheduled maturities and \$100 million of Capital Addition Financing (as defined in the amended master lease with HCRMC) for which the timing and amount of payments are uncertain.

(2) Includes £275 million (\$357 million) translated to USD.

(3) Represents £357 million translated to USD.

(4) Represents £37 million translated to USD for commitments to fund our U.K. loan facilities.

(5) Represents commitments to finance development projects and related working capital financings.

(6) Represents construction and other commitments for developments in progress.

(7) Interest on variable-rate debt is calculated using rates in effect at September 30, 2016.

Off-Balance Sheet Arrangements

We own interests in certain unconsolidated joint ventures as described in Note 7 to the Consolidated Financial Statements. Except in limited circumstances, our risk of loss is limited to our investment in the joint venture and any outstanding loans receivable (see Note 16 to the Consolidated Financial Statements). In addition, we have certain properties which serve as collateral for debt that is owed by a previous owner of certain of our facilities. Our risk of loss for these certain properties is limited to the outstanding debt balance plus penalties, if any. We have no other material off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources except those described above under “Contractual Obligations.”

Inflation

Our leases often provide for either fixed increases in base rents or indexed escalators, based on the Consumer Price Index or other measures, and/or additional rent based on increases in the tenants’ operating revenues. Most of our MOB leases require the tenant to pay a share of property operating costs such as real estate taxes, insurance and utilities. Substantially all of our senior housing, life science, post-acute/skilled nursing and hospital leases require the tenant or operator to pay all of the property operating costs or reimburse us for all such costs. We believe that inflationary increases in expenses will be offset, in part, by the tenant or operator expense reimbursements and contractual rent increases described above.

Table of Contents

Non-GAAP Financial Measures Reconciliations

The following is a reconciliation from net income applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to FFO, FFO as adjusted and FAD (in thousands, except per share data):

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|----------------------------------|------------|---------------------------------|-----------|
| | 2016 | 2015 | 2016 | 2015 |
| Net income applicable to common shares | \$ 150,924 | \$ 115,046 | \$ 568,109 | \$ 38,613 |
| Depreciation and amortization | 142,874 | 134,704 | 425,582 | 369,629 |
| Other depreciation and amortization | 2,986 | 5,204 | 8,922 | 17,016 |
| Loss (gain) on sales of real estate | 9 | (52) | (119,605) | (6,377) |
| Taxes associated with real estate disposition | 257 | — | 53,434 | — |
| Impairment of real estate | — | — | — | 2,948 |
| Equity loss (income) from unconsolidated joint ventures | 2,053 | (8,314) | 4,028 | (33,916) |
| FFO from unconsolidated joint ventures | 10,554 | 20,530 | 32,104 | 69,322 |
| Noncontrolling interests' and participating securities' share in earnings | 3,115 | 2,908 | 10,517 | 9,586 |
| Noncontrolling interests' and participating securities' share | (8,385) | (6,656) | (26,227) | (18,983) |

Edgar Filing: HCP, INC. - Form 10-Q

| | | | | | |
|---|------------|------------|------------|--------------|--------------|
| in FFO FFO applicable to common shares | 304,387 | 263,370 | 956,864 | 447,838 | |
| Distributions on dilutive convertible units | 2,376 | 2,365 | 10,622 | — | |
| Diluted FFO applicable to common shares | \$ 306,763 | \$ 265,735 | \$ 967,486 | \$ 447,838 | |
| Diluted FFO per common share | \$ 0.65 | \$ 0.57 | \$ 2.05 | \$ 0.97 | |
| Weighted average shares used to calculate diluted FFO per common share | 471,994 | 467,772 | 473,011 | 462,302 | |
| Impact of adjustments to FFO: | | | | | |
| Other impairments(1) | | \$ — | \$ 96,856 | \$ — | \$ 617,207 |
| Transaction-related items | | 17,568 | 1,538 | 34,570 | 28,973 |
| Severance-related charges(2) | | 14,464 | — | 14,464 | 6,713 |
| Foreign currency remeasurement losses (gains) | | 94 | 4,036 | 268 | (5,497) |
| | | \$ 32,126 | \$ 102,430 | \$ 49,302 | \$ 647,396 |
| FFO as adjusted applicable to common shares | | \$ 336,513 | \$ 365,800 | \$ 1,006,166 | \$ 1,095,234 |
| Distributions on dilutive convertible units and other | | 3,467 | 3,443 | 10,549 | 10,198 |
| Diluted FFO as adjusted applicable to common shares | | \$ 339,980 | \$ 369,243 | \$ 1,016,715 | \$ 1,105,432 |
| Diluted FFO as adjusted per common share | | \$ 0.72 | \$ 0.79 | \$ 2.15 | \$ 2.36 |
| Weighted average shares used to calculate diluted FFO as adjusted per common share | | 473,692 | 469,590 | 473,011 | 468,320 |

Table of Contents

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|----------------------------------|------------|---------------------------------|--------------|
| | 2016 | 2015 | 2016 | 2015 |
| FFO as adjusted applicable to common shares | \$ 336,513 | \$ 365,800 | \$ 1,006,166 | \$ 1,095,234 |
| Amortization of market lease intangibles, net | (421) | (344) | (1,393) | (980) |
| Amortization of deferred compensation(3) | 3,389 | 5,344 | 12,894 | 18,174 |
| Amortization of deferred financing costs | 5,037 | 5,224 | 15,598 | 14,950 |
| Straight-line rents | (3,295) | (7,069) | (14,412) | (24,817) |
| DFL non-cash interest(4) | 637 | (22,662) | 1,967 | (64,176) |
| Other depreciation and amortization | (2,986) | (5,204) | (8,921) | (17,016) |
| Deferred revenues – tenant improvement related | (459) | (746) | (1,451) | (2,137) |
| Deferred revenues – additional rents | 240 | 254 | 424 | 641 |
| Leasing costs and tenant and capital improvements | (22,722) | (23,212) | (62,774) | (50,879) |
| Lease restructure payments | 1,868 | 6,067 | 14,480 | 16,368 |
| Joint venture adjustments – CCRC entrance fees | 7,201 | 8,386 | 22,424 | 22,048 |
| Joint venture and other FAD adjustments(4) | (7,462) | (21,892) | (20,565) | (59,153) |
| FAD applicable to common shares | \$ 317,540 | \$ 309,946 | \$ 964,437 | \$ 948,257 |
| Distributions on dilutive convertible units | 3,513 | 3,547 | 10,622 | 10,683 |
| Diluted FAD applicable to common shares | \$ 321,053 | \$ 313,493 | \$ 975,059 | \$ 958,940 |

Table of Contents

The following is a reconciliation, on a per share basis, from net income (loss) applicable to common shares, the most directly comparable financial measure calculated and presented in accordance with GAAP, to FFO and FFO as adjusted:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|----------------------------------|---------|---------------------------------|---------|
| | 2016 | 2015 | 2016 | 2015 |
| Net income applicable to common shares | \$ 0.32 | \$ 0.25 | \$ 1.22 | \$ 0.08 |
| Depreciation and amortization | 0.31 | 0.29 | 0.92 | 0.80 |
| Other depreciation and amortization | 0.01 | 0.01 | 0.02 | 0.04 |
| Taxes related to real estate disposition and gain on sales of real estate | — | — | (0.14) | (0.01) |
| Joint venture and participating securities FFO adjustments | 0.01 | 0.02 | 0.03 | 0.06 |
| Diluted FFO applicable to common shares | \$ 0.65 | \$ 0.57 | \$ 2.05 | \$ 0.97 |
| Other impairments(1) | — | 0.21 | — | 1.32 |
| Transaction-related items and other | 0.04 | — | 0.07 | 0.06 |
| Severance-related charges(2) | 0.03 | — | 0.03 | 0.02 |
| Foreign currency remeasurement losses (gains) | — | 0.01 | — | (0.01) |
| FFO as adjusted applicable to common shares | \$ 0.72 | \$ 0.79 | \$ 2.15 | \$ 2.36 |

- (1) For the three months ended September 30, 2015, other impairments include: (i) \$70 million related to our Four Seasons Notes and (ii) \$27 million related to our equity investment in HCRMC. For the nine months ended September 30, 2015, other impairments include: (i) \$478 million related to our DFL investments with HCRMC, (ii) \$112 million related to our Four Seasons Notes and (iii) \$27 million related to our equity investment in HCRMC.
- (2) For the three and nine months ended September 30, 2016, severance-related charges primarily relate to the departure of our former President and Chief Executive Officer. For the nine months ended September 30, 2015, severance-related charge relates to the resignation of our former Executive Vice President and Chief Investment Officer.
- (3) Excludes \$6 million related to the acceleration of deferred compensation for restricted stock units and stock options that vested upon the departure of our former President and Chief Executive Officer, which is included in the severance-related charges for the three and nine months ended September 30, 2016. Excludes \$3 million related to the acceleration of deferred compensation for restricted stock units and stock options that vested upon the resignation of our former Executive Vice President and Chief Investment Officer, which is included in the severance-related charge for the nine months ended September 30, 2015.
- (4) Our equity investment in HCRMC is accounted for using the equity method, which requires an elimination of DFL income that is proportional to our ownership in HCRMC. Further, our share of earnings from HCRMC (equity income) increases for the corresponding elimination of related lease expense recognized at the HCRMC entity level, which we present as a non-cash joint venture FAD adjustment. Beginning in January 2016, equity income is recognized only if cash distributions are received from HCRMC. As a result, we no longer eliminate our proportional ownership share of income from DFLs to equity income (loss) from unconsolidated joint ventures for our equity investment in HCRMC.

Critical Accounting Policies

The preparation of financial statements in conformity with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our consolidated financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. A summary of our critical accounting policies is included in our Annual Report on Form 10-K for the year ended December 31, 2015 in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2 to the Consolidated Financial Statements. Our critical accounting policies have not changed during 2016, except for the “Segment Reporting” update included in Note 2 to the Consolidated Financial Statements.

Table of Contents

Recent Accounting Pronouncements

See Note 2 to the Consolidated Financial Statements for the impact of new accounting standards.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign currency exchange rates, specifically the GBP. We use derivative financial instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. Derivatives are recorded on the consolidated balance sheets at fair value (see Note 19 to the Consolidated Financial Statements).

To illustrate the effect of movements in the interest rate and foreign currency markets, we performed a market sensitivity analysis on our hedging instruments. We applied various basis point spreads to the underlying interest rate curves and foreign currency exchange rates of the derivative portfolio in order to determine the change in fair value. Assuming a one percentage point change in the underlying interest rate curve and foreign currency exchange rates, the estimated change in fair value of each of the underlying derivative instruments would not exceed \$4 million (see Note 19 to the Consolidated Financial Statements).

Interest Rate Risk. At September 30, 2016, we are exposed to market risks related to fluctuations in interest rates primarily on variable rate debt, which has been predominately hedged through interest-rate swap contracts.

Interest rate fluctuations will generally not affect our future earnings or cash flows on our fixed rate debt and assets until their maturity or earlier prepayment and refinancing. If interest rates have risen at the time we seek to refinance our fixed rate debt, whether at maturity or otherwise, our future earnings and cash flows could adversely be affected by additional borrowing costs. Conversely, lower interest rates at the time of refinancing may reduce our overall borrowing costs. However, interest rate changes will affect the fair value of our fixed rate instruments. Conversely, changes in interest rates on variable rate debt and investments would change our future earnings and cash flows, but not significantly affect the fair value of those instruments. Assuming a one percentage point increase in the interest rate related to the variable-rate debt and variable-rate investments, and assuming no other changes in the outstanding balance as of September 30, 2016, our annual interest expense would increase by approximately \$14 million, or \$0.03 per common share on a diluted basis.

Foreign Currency Risk. At September 30, 2016, our exposure to foreign currencies primarily relates to U.K. investments in leased real estate, senior notes and related GBP denominated cash flows. Our foreign currency

exposure is partially mitigated through the use of GBP denominated borrowings and foreign currency swap contracts. Based solely on our operating results for the three months ended September 30, 2016, including the impact of existing hedging arrangements, if the value of the GBP relative to the USD were to increase or decrease by 10% compared to the average exchange rate during the quarter ended September 30, 2016, our cash flows would have decreased or increased, as applicable, by less than \$1 million.

Market Risk. We have investments in marketable debt securities classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are recorded at amortized cost and adjusted for the amortization of premiums and discounts through maturity. We consider a variety of factors in evaluating an other-than-temporary decline in value, such as: the length of time and the extent to which the market value has been less than our current adjusted carrying value; the issuer's financial condition, capital strength and near-term prospects; any recent events specific to that issuer and economic conditions of its industry; and our investment horizon in relationship to an anticipated near-term recovery in the market value, if any. At September 30, 2016, both the fair value and carrying value of marketable debt securities was \$82 million.

Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2016. Based upon that evaluation, our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2016.

Changes in Internal Control Over Financial Reporting. There were no changes in our internal control over financial reporting (as such term as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1A. Risk Factors

In addition to the information set forth in this Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A of our most recent Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results. The following updates the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015, as updated by Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2016:

We depend on one tenant and operator for a significant percentage of our revenues and net operating income. Adverse developments in Brookdale's business and affairs or financial condition could have a materially adverse effect on us.

We manage our facilities utilizing triple-net lease ("lease arrangements") and RIDEA structures. As of September 30, 2016, Brookdale leased or managed 282 senior housing facilities that we own and 15 CCRCs owned by our unconsolidated joint venture pursuant to long-term lease and management agreements. Under our lease arrangements, we generated 10% of our revenues from Brookdale during the nine months ended September 30, 2016. Giving pro forma effect to the Spin-Off as if it had occurred on January 1, 2016, Brookdale would have represented 12% of our revenues for the same period.

In addition to our lease arrangements with Brookdale, we generated 12% of our net operating income from properties managed by Brookdale under RIDEA structures during the nine months ended September 30, 2016, or 16% of our net operating income for the same period after giving pro forma effect to the Spin-Off as if it had occurred on January 1, 2016. Services provided by our tenants or operators in facilities managed under a RIDEA structure are primarily paid for by the residents directly or through private insurance and are less reliant on government reimbursement programs. We report the resident level fees and services revenues and corresponding operating expenses in our consolidated financial statements.

Although we have various rights as the property owner under our management agreements, we rely on Brookdale's personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment to manage our senior living operations efficiently and effectively. We also rely on Brookdale to set appropriate resident fees, to provide property-level financial results for our properties in a timely manner and to otherwise operate our senior housing communities in compliance with the terms of our management agreements and all applicable laws and regulations.

In its capacity as a manager, Brookdale does not lease our properties, and, therefore, we are not directly exposed to their credit risk in the same manner or to the same extent as a triple-net tenant. However, any adverse developments in Brookdale's business and affairs or financial condition could impair its ability to manage our properties efficiently and effectively and could have a materially adverse effect on us. Brookdale is also one of our triple-net tenants. If Brookdale experiences any significant financial, legal, accounting or regulatory difficulties due to a weak economy or otherwise, such difficulties could result in, among other adverse events, acceleration of its indebtedness, impairment of its continued access to capital, the enforcement of default remedies by its counterparties or the commencement of insolvency proceedings by or against it under the U.S. Bankruptcy Code, any one or a combination of which indirectly could have a materially adverse effect on us.

In addition, any failure by Brookdale to effectively conduct its operations or to maintain and improve our properties could adversely affect its business reputation and its ability to attract and retain patients and residents in our properties, which could have a materially adverse effect on our business, results of operations and financial condition. Furthermore, they face an increasingly competitive labor market for skilled management personnel and nurses, which can cause operating costs to increase. While Brookdale generally has also agreed to indemnify, defend and hold us harmless from and against various claims, litigation and liabilities arising in connection with their respective businesses, they may have insufficient assets, income, access to financing and/or insurance coverage to enable them to satisfy their indemnification obligations.

The inability or other failure of Brookdale under its lease agreements and RIDEA structures, to meet its obligations to us could materially reduce our cash flow, net operating income and results of operations, which could in turn reduce the

Table of Contents

amount of dividends we pay to our stockholders, cause our stock price to decline and have other materially adverse effects on our business, results of operations and financial condition.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

(a)

None.

(b)

None.

(c)

The following table sets forth information with respect to purchases of our common stock made by us or on our behalf or by any “affiliated purchaser,” as such term is defined in Rule 10b-18(a)(3) under the Exchange Act, during the three months ended September 30, 2016.

| Period Covered | Total Number Of Shares Purchased(1) | Average Price Paid Per Share | Total Number Of Shares (Or Units) Purchased As Part Of Publicly Announced Plans Or Programs | Maximum Number (Or Approximate Dollar Value) Of Shares (Or Units) That May Yet Be Purchased Under The Plans Or Programs |
|----------------------|---|---------------------------------------|---|--|
| July 1-31, 2016 | 117,098 | \$ 37.43 | — | — |
| August 1-31, 2016 | 5,443 | 38.44 | — | — |
| September 1-30, 2016 | 5,364 | 37.63 | — | — |
| Total | 127,905 | 37.48 | — | — |

- (1) Represents shares of our common stock withheld under our equity incentive plans to offset tax withholding obligations that occur upon vesting of restricted shares and restricted stock units. The value of the shares withheld is based on the closing price of our common stock on the last trading day prior to the date the relevant transaction occurs.

Item 6. Exhibits

- 2.1 Separation and Distribution Agreement, dated as of October 31, 2016, by and between the Company and Quality Care Properties, Inc. (incorporated by reference to the Company's Current Report on Form 8-K filed October 31, 2016).
- 4.1 Indenture, dated as of October 17, 2016, among QCP SNF West REIT, LLC, QCP SNF Central REIT, LLC, QCP SNF East REIT, LLC and QCP AL REIT, LLC, as issuers, and Wilmington Trust, National Association, as trustee and notes collateral agent (incorporated by reference to the Company's Current Report on Form 8-K filed October 18, 2016).
- 10.1 Separation and General Release Agreement, dated as of July 11, 2016, by and between the Company and Lauralee E. Martin (incorporated by reference to the Company's Current Report on Form 8-K filed July 11, 2016).†
- 10.2 Amendment No. 5 to Credit Agreement, dated September 27, 2016, by and among the Company, the lenders referred to therein, and Bank of America, N.A., as administrative agent (incorporated by reference to the Company's Current Report on Form 8-K filed September 28, 2016).
- 10.3 HCP, Inc. Executive Severance Plan (adopted as of May 6, 2016).*†

Table of Contents

| | |
|---------|---|
| 10.4 | HCP, Inc. Executive Change in Control Severance Plan (as Amended and Restated as of May 6, 2016).*† |
| 10.5 | Tax Matters Agreement, dated as of October 31, 2016, by and between the Company and Quality Care Properties, Inc. (incorporated by reference to the Company's Current Report on Form 8-K filed October 31, 2016). |
| 31.1 | Certification by Michael D. McKee, HCP's Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).* |
| 31.2 | Certification by Thomas M. Herzog, HCP's Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(a).* |
| 32.1 | Certification by Michael D. McKee, HCP's Principal Executive Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.** |
| 32.2 | Certification by Thomas M. Herzog, HCP's Principal Financial Officer, Pursuant to Securities Exchange Act Rule 13a-14(b) and 18 U.S.C. Section 1350.** |
| 101.INS | XBRL Instance Document.* |
| 101.SCH | XBRL Taxonomy Extension Schema Document.* |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document.* |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document.* |
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase Document.* |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document.* |

* Filed herewith.

** Furnished herewith.

† Management Contract or Compensatory Plan or Arrangement.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 1, 2016 HCP, Inc.

(Registrant)

/s/ MICHAEL D. MCKEE

Michael D. McKee
Chairman of the Board,

President and Chief Executive Officer
(Principal Executive Officer)

/s/ THOMAS M. HERZOG

Thomas M. Herzog
Executive Vice President and
Chief Financial Officer
(Principal Financial Officer)

/s/ SCOTT A. ANDERSON

Scott A. Anderson
Executive Vice President and
Chief Accounting Officer
(Principal Accounting Officer)